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Pelvic Inflammatory Disease (PID), the infection and inflammation of the female upper genital 
tract, can result in serious sequelae. Markers to predict sequelae following PID are greatly 
needed. The goal of this research is to explore the role of host genetic factors and delayed care 
seeking in the development of sequelae following clinically suspected PID. We studied the 
microbial correlates of delayed care and long-term outcomes among 298 women with 
histologically confirmed endometritis from the PID Evaluation and Clinical Health (PEACH) 
study. Mean days of pain prior to care were compared by microbial pathogen, with the longest 
times among women infected by Chlamydia trachomatis (CT) only (12.3±9.4 days) and 
Mycoplasma genitalium (MG) only (10.9±8.9 days), and the shortest among women infected by 
Neisseria gonorrhoeae (NG) only (4.6±5 days) or co-infection (5.6±5.1 days, p<0.001). 
Infertility, recurrent PID, and chronic pelvic pain were frequent (17%, 20%, and 36%), albeit 
non-significantly elevated after delayed care. PID patients infected with CT or MG were more 
likely to delay care, possibly increasing persistent inflammation which may permanently damage 
the reproductive tract before patients seek care. 
 Toll-like receptors (TLR) eliminate microbes through inflammatory responses. As 
genetic variations may increase TLR signaling, we determined if 18 tagging single nucleotide 
polymorphisms assayed in 4 TLR genes (TLR1, TLR2, TLR4, TLR6) and 2 adaptor molecules 
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(TIRAP, MyD88) were associated with CT, endometritis, or infertility among 205 African 
Americans with PID from the PEACH study. An empirical p-value <0.004 was significant. 
Logistic regression revealed that the TLR4 rs1927911 CC genotype was associated with CT 
(odds ratio (OR) 3.7, 95% confidence interval (CI) 1.6-8.8, p=0.0021). Further, the TLR1 
rs4833095 TT genotype displayed trends towards increased CT (OR 2.8, 95% CI 1.3-6.2, 
p=0.0084). Predicted carriers of the TLR4 GTC haplotype (p=0.006) and the TLR1 TGT 
haplotype (p=0.04) were more likely to be CT positive. Genetic variations in TLR genes may 
play a role in CT pathogenesis. 
 This dissertation yields public health significance by demonstrating the need for 
increased efforts for early identification and treatment of genital tract infections and providing a 
novel exploration into the role of genetic variants in CT pathogenesis. 
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1.0  INTRODUCTION 
1.1 SPECIFIC AIMS 
Pelvic Inflammatory Disease (PID) is the infection and inflammation of the female upper genital 
tract and can cause serious reproductive morbidity including infertility, ectopic pregnancy, 
recurrent PID, and chronic pelvic pain (1-5). PID has a multimicrobial etiology and is associated 
with Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, and bacterial 
vaginosis (5-8). There is a significant need for biomarkers to predict morbidity following an 
episode of PID. However, little is known about differences in morbidity by pathogen (1). One 
strong predictor of sequelae following PID may be delayed care (1). Further, the delayed care 
association may vary by microbial pathogen (9). However, these associations have not been 
replicated in a contemporary cohort and the distribution of microbes among women with PID 
appears to have changed over time. In addition, new microorganisms including M. genitalium 
have recently been identified, and the care seeking pattern and long term outcomes of M. 
genitalium upper genital tract infection is largely unknown. 
Chlamydia trachomatis is a f requent cause of PID and the most common bacterial 
sexually transmitted disease in the United States (10). There is great variability in the course and 
outcome of chlamydial infections. Further, the role of host genetic factors in chlamydial PID and 
post-PID sequelae development is not understood. The goal of the proposed research will be to 
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explore the relationships between host genetic factors and delayed care seeking in the 
development of reproductive sequelae following clinically suspected PID. Further, the role of 
host genetic factors in upper genital tract infection will be explored. As few studies have 
examined these associations, there is an opportunity to provide novel information regarding the 
pathogenesis of chlamydial PID and the development of post-PID sequelae. 
The following research aims and hypotheses will be used to achieve this goal: 
1. Determine the microbial correlates of time to treatment and the impact of delayed 
care for pelvic inflammatory disease (PID) on long term outcomes (infertility, 
chronic pelvic pain, and recurrent PID) among 298 women with histologically 
confirmed endometritis. We hypothesize that self-reported timing of treatment for 
a current PID episode will vary by microbial pathogen among women with 
clinically suspected PID. We hypothesize that women who have Chlamydia 
trachomatis or Mycoplasma genitalium monoinfection will have waited longer to 
seek treatment for PID symptoms than women with Neisseria gonorrhoeae 
monoinfection or co-infection with two or more pathogens. Women who delay 
care, defined as 14 or more days of pain before seeking treatment, will have an 
increased risk for reproductive morbidity. 
2. Determine if specific Toll-like receptor (TLR) and TLR adaptor molecule single 
nucleotide polymorphisms (SNPs) are associated with histologically confirmed 
endometritis or Chlamydia trachomatis among 290 women (205 black, 51 white, 
34 other) with clinically suspected PID. As variations in toll-like receptor genes 
are suggested to be associated with disease progression, we believe that TLRs 
and TLR adaptor molecule polymorphisms will be associated with histologically 
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confirmed endometritis or Chlamydia trachomatis among women with clinically 
suspected PID. 
3. Determine if specific Toll-like receptor (TLR) and TLR adaptor molecule single 
nucleotide polymorphisms (SNPs) are associated with infertility or reduced 
pregnancy following clinically suspected pelvic inflammatory disease (N = 290; 
205 black, 51 white, 34 other) We hypothesize that genetic variations in TLRs 
and TLR adaptor molecules will be associated with infertility following pelvic 
inflammatory disease. Variations in innate immune receptors may be responsible 
for inadequate or overt immune responses, possibly increasing the risk for 
reproductive morbidity. 
1.2 BACKGROUND 
1.2.1 Pelvic Inflammatory Disease 
Pelvic inflammatory disease (PID) is the infection and inflammation of the female upper genital 
tract including the tubes and ovaries (salpingitis) and the uterine lining (endometritis) (1), which 
can cause serious reproductive sequelae including infertility, chronic pelvic pain, recurrent PID 
and ectopic pregnancy (2, 3). PID generally occurs when microorganisms ascend from the lower 
genital tract to the upper genital tract, infecting the uterus, fallopian tubes, and ovaries. PID is a 
fairly common disease with an estimated 8% of American women developing PID at some time 
in their reproductive lives (4). It is estimated that 1 million women will be treated annually for 
PID in the United States (US) (5). However, diagnosis and treatment can be difficult, as 
 4 
symptoms of PID may be mild or absent. Thus, the condition may be unrecognized (6). Also 
challenging the diagnosis and management of PID is the multimicrobial etiology of the disease 
(5). Various organisms have been implicated in the etiology of PID including Neisseria 
gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, and anaerobic and aerobic 
bacteria commonly associated with bacterial vaginosis (BV) (5-8). Although C. trachomatis and 
N. gonorrhoeae have been studied more extensively, the etiology and pathogenesis of PID has 
not been fully delineated (5).  
1.2.2 Microbiological Etiology and Pathogenesis of PID 
1.2.2.1 Chlamydia trachomatis and PID 
Chlamydia trachomatis is the most common bacterial sexually transmitted infection in the 
United States (10). In women, C. trachomatis can ascend from the endocervix to the upper 
genital tract and cause PID and serious reproductive morbidity including infertility, ectopic 
pregnancy, and chronic pelvic pain (5, 10). Although C. trachomatis is a frequent pathogen 
associated with PID, and is isolated in 10-27% of PID patients, rates of progression vary widely 
between patients (10-12). Among high risk populations the progression to PID in asymptomatic 
C. trachomatis positive women is generally low, at 2-4.5% (10, 13-15). Hook et al, in an eight 
month prospective cross-over trial, found that within 14 days after testing positive for chlamydia, 
3.2% of those women developed PID (13).  Similarly, Geisler et al conducted a prospective study 
of 129 adults who screened positive for C. trachomatis (15). Among the study population, two 
women (2%) developed PID within the interval between screening and treatment (15). Further, a 
retrospective study among 67 w omen who came in for follow-up care following a positive 
chlamydia test, three (4.5%) had clinically diagnosed PID (14). Among a lower risk Swedish 
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population of 109 asymptomatic chlamydial positive adolescents, four (3.7%) reported 
salpingitis within a three month period (16). Studies have also been conducted among women 
with treated C. trachomatis infection. A prospective study of 1,170 w omen at high risk for 
sexually transmitted infections from five U.S. sites found that 23(19%) of 122 w omen whom 
tested positive for C. trachomatis at baseline developed PID within three years (17).  
Data on progression of C. trachomatis to reproductive sequelae is limited. C. trachomatis 
antibodies have been found to be more common among infertile women (10). However, there are 
few prospective studies linking chlamydia to infertility. Haggerty et al, found that among patients 
with clinically suspected PID, those with endometritis and/or upper genital tract chlamydial or 
gonococcal infection were no more likely to experience reduced pregnancy or elevated 
infertility, chronic pelvic pain, or recurrent PID compared to women without endometritis and/or 
upper genital tract chlamydial or gonococcal infection (1). Bias towards the null is possible as the 
cohort may have had prior chlamydial infections that resulted in tubal damage preceding the PID 
episode. In fact a study among this same cohort found that PID recurrence was higher (hazard 
ratio (HR) 2.48, 95% confidence interval (CI) 1.00-6.27) and pregnancy rates were significantly 
lower (HR 0.47, 95% CI 0.28-0.79) among women whose antibody titers to chlamydial 
elementary bodies (EB) collected at the end of the study were in the highest tertile (18). Other 
studies have found chlamydial infections to be associated with infertility among women 
diagnosed with PID (10, 19, 20). Brunham et al suggested that among women with PID, those 
with culture and/or serological evidence of chlamydial infection may have a poor fertility 
prognosis (19). The authors found that 7 of 13 women with non-gonococcal PID had an adverse 
reproductive outcome, compared with none out of 10 women with gonococcal PID (P=0.007) 
(19). Further, of the seven infertile women, four had tubal abscess, and three of the four had 
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evidence of chlamydial infection. A retrospective study of 51 women with PID found that those 
who were positive for C. trachomatis by culture were more likely to experience involuntary 
infertility compared to those who tested negative for chlamydia (relative risk (RR) 2.5, 95% CI 
1.0-6.2) (20).  
As not all women with chlamydial PID develop sequelae, host genetic factors or 
pathogen-specific virulence factors likely contribute to variability in outcomes. Immune 
responses to chlamydia specific proteins may be responsible for the progression of C. 
trachomatis infections. It has been hypothesized that immune reactions to chlamydia heat shock 
protein 60 ( cHSP60) may cause chronic inflammation or persistent infection, leading to the 
progression of disease (21, 22). Several retrospective studies have found cHSP60 to be linked 
with chlamydia-associated tubal infertility and pelvic inflammatory disease (23-28). For 
example, Dutta et al, found that among 52 women with PID and infertility, there were 
significantly higher antibody titers for cHSP60 and cHSP10 when compared to 107 patients with 
uncomplicated cervicitis at dilutions of 1 in 50, 1 in 250, 1 i n 1250 (P<0.001) and 1 i n 6250 
(P<0.01) (24). However, prospective data examining this relationship has been limited. One 
prospective study among 302 female sex workers in Nairobi, Kenya, found cHSP60 antibodies to 
be associated with PID (odds ratio (OR) 3.9, 95% CI 1.04-14.5; P=0.04) (29). However, this 
study did not examine reproductive sequelae following chlamydial PID. Ness et al, did examine 
cHSP60 and reproductive sequelae prospectively, but did not find cHSP60 antibody titers to be 
significantly associated with sequelae following clinically suspected PID (18). This suggests that 
the retrospective nature of the other studies may have caused them to measure surrogates for 
prior chlamydial exposure (18). Certain biases, such as diagnostic bias, were also suggested to 
overestimate the effect size (18). For example, diagnosis of clinically suspected PID based on 
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symptoms may have been influenced by the knowledge of a previous chlamydial exposure. If 
cHSP60 is a surrogate for that prior exposure then this would have biased the results away from 
the null.  
Other proteins have been examined in the pathogenesis of C. trachomatis. C-reactive 
protein (CRP) is an acute phase protein and is an indicator of inflammation (26). In a study of 55 
patients with PID, CRP >10 mg/1 had good sensitivity and specificity in the diagnosis of PID 
(30). den Hartog et al found the presence of elevated CRP (> 10 mg/1) to be significantly greater 
in women with distal tubal pathology than in controls without tubal pathology (50.8% vs. 15.0%; 
P<0.05) (26). Although CRP is a general marker of inflammation and is not pathogen or 
condition specific, this suggests that C. trachomatis is associated with an increased inflammatory 
resposnse which may lead to upper genital tract pathology.  
Host genetic factors may also play a role in the development of sequelae following PID. 
It has been hypothesized that human leukocyte antigen (HLA) molecules may control the 
balance in Th1 (pro-inflammatory) and Th2 (anti-inflammatory) immune response to C. 
trachomatis (31). Studies have also shown a link between HLA class II alleles and tubal factor 
infertility (TFI) following chlamydial infection. A case control study of 52 w omen with TFI 
attending an in vitro fertilization lab found that HLA DQA*0102 and HLA DQB*0602 together 
with the interleukin (IL)-10-1082 AA genotype were significantly more frequent in the TFI 
patients than 61 Finnish controls (0.18 and 0.02; p=.005) (31). Similarly, results from the PID 
Evaluation and Clinical Health (PEACH) Study show that HLA DQA*0301 is associated with 
chlamydial/gonococcal cervicitis, endometritis and reduced fertility (32). In contrast, a 
prospective study which followed 113 female sex workers to determine incident C. trachomatis 
infection and PID found that HLA DQA1*0401 and DQB1*0402 alleles were significantly 
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associated with an increase in Chsp60 antibody (33). However, they did not find any significant 
associations with microimmunofluorescent antibody titers (MIF) to chlamydia elementrary 
bodies (33). Further, these alleles did not significantly alter the risk for chlamydial PID (OR 0.84, 
95% CI 0.15-4.60; P=0.84). The authors contributed this finding to their small sample size, 
suggesting that further studies are needed to delineate this relationship (33). The authors note 
that in mice, cHSP60 antibody is influenced by genes (33). Therefore, HLA genes may indeed be 
correlated with response to cHSP60. However, the contrasting results over associations with PID 
may be due to genetic differences in study populations as well as differences in the comparison 
groups used in the studies. As little is known about the natural history and pathogenesis of 
untreated chlamydial infections, future studies should continue to examine the role of host 
genetic influences in the progression of C. trachomatis. 
1.2.2.2 Other Organisms and PID 
C. trachomatis and N. gonorrhoeae are the two most common reportable diseases in the United 
States (US), and chlamydial infection often accompanies 20% to 40% of gonococcal infections 
(34). In the US there was a steady decline in the number of reportable cases of N. gonorrhoeae 
between 1975 a nd 1997 (34). Since then, the rates have begun to plateau (34). Still, N. 
gonorrhoeae is considered a prevalent sexually transmitted infection and can lead to serious 
reproductive morbidity. N. gonorrhoeae has been isolated from the cervix, endometrium and 
fallopian tubes of women with PID (35-37). Women with N. gonorrhoeae and PID tend to have 
onset of pain in the first part of the menstrual cycle, suggesting that loss of the cervical mucus 
plug may promote ascension into the upper genital tract (36). Approximately 10-19% of women 
with N. gonorrhoeae isolated in the cervix have signs of clinical PID (36).  Further, among PID 
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cases with positive lower genital tract N. gonorrhoeae culture, approximately 42% will have N. 
gonorrhoeae isolated from the Fallopian tubes (36).  
While serological studies suggest a role for chlamydial PID in the development of 
sequelae, fewer studies have addressed the importance of other microorganisms such as N. 
gonorrhoeae. Although, serological testing exists for N. gonorrhoeae this method is not widely 
used. It is suggested that long term sequelae occurs more frequently among those with non-
gonococcal PID, as those with N. gonorrhoeae present with more overt symptoms and acute 
inflammation and are possibly treated earlier (36, 38). In a study of 82 w omen with 
laparoscopically confirmed salpingitis N. gonorrhoeae in the upper genital tract appeared to be 
isolated more frequently in women with patent tubes (21/39; 54%) compared to women with 
tubal occlusion (4/14; 29%) (39). However, no statistically significant associations were found 
between N. gonorrhoeae and tubal disease severity. The authors report that low statistical power 
may have limited their ability to detect differences between groups. The study did find that 
women with gonorrhea were more likely to have free exudate compared to no exudate or exudate 
limited to the tubes (P=0.04) (39). Severity of tubal damage was negatively associated with the 
presence of free pelvic-abdominal exudate (39). Further, women with free exudate tended to 
present earlier after the onset of symptoms and presented with signs of peritonitis and elevated 
white blood cell (WBC) count, suggesting an earlier stage of acute infection (39). Still, N. 
gonorrhoeae has been isolated from women with infertility. Miettinen et al reported that among 
76 women with tubal factor infertility, 14% tested positive for N. gonorrhoeae and 46% tested 
positive for C. trachomatis (40). Among these women, 26% of gonococcal positive women and 
58% of chlamydial positive women reported a history of PID (40). In a Nigerian study, N. 
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gonorrhoeae was isolated in 17.4% of infertile women compared with 10.5% of pregnant women 
(P<0.05) (41).  
Like C. trachomatis, host immune responses and bacterial virulence factors may play a 
role in the progression of N. gonorrhoeae infection. N. gonorrhoeae is considered to be versatile 
and can undergo a great degree of antigenic and phase variation (42). The mechanisms 
responsible for the progression of N. gonorrhoeae to PID and subsequent sequelae have not been 
completely delineated. It is known that in the Fallopian tubes ciliary activity is significantly 
decreased after exposure to gonococcal supernatant (36). Further, gonococcal infection can 
induce cell death in the fallopian tubes through necrosis, which then will trigger an inflammatory 
response and apoptosis (43). Aggressive inflammatory responses in the fallopian tubes are also 
produced when host antibodies bind to gonococcal lipooligosaccharide and petidoglycan (44). 
This may in part explain why women with gonococcal PID have more overt symptoms and acute 
inflammation, compared to those with C. trachomatis associated-PID who have less severe 
symptoms and longstanding low level inflammation (36).  
Gonococcal proteins have been examined to determine their role in PID and subsequent 
sequelae. In a cohort of 243 s ex workers from Nairobi, Kenya, antibodies to opacity proteins 
(Opa) were found to significantly decrease the risk of gonococcal salpingitis (OR 0.35, 95% CI 
0.17-0.76) (45). However, the reduction in risk was only statistically significant for two Opa 
variants (1B-5 and 1A-6) (45). The authors also found the risk of salpingitis to be dramatically 
reduced in women with seropositivity to all nine Opa variants compared to women with antibody 
to less than one (RR 0.13, 95% CI 0.02-0.96, p <0.01) (45).  In a separate study, Plummer et al 
reported that antibody response to outer membrane protein 3 ( Rmp) was associated with an 
increased risk of gonococcal salpingitis (OR 3.4, 95% CI 1.1-10.4, P < 0.05), although this was 
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of borderline significance (46). Antibodies to gonococcal pili have also been examined in PID. 
One study of 35 women with PID and 115 normal controls found no difference in antibody 
response (IgM, IgG, and IgA) to gonococcal pili between groups (47). Despite the potential role 
for several N. gonorrhoeae proteins in virulence, management of the disease through vaccine 
development has been unsuccessful (48). Further investigation into both bacterial virulence 
factors and host immune response to N. gonorrhoeae infection is needed.  
Chlamydia and gonorrhea are identified in approximately a third to a half of cases of PID. 
Thus, up to 70% of PID can be non-gonococcal and non-chlamydial in nature (5). Bacterial 
vaginosis (BV) is characterized by an imbalance in vaginal microflora, and occurs when 
hydrogen producing lactobacilli decrease in concentration and are replaced by anaerobic and 
facultative aerobic bacteria including Gardnerella vaginalis and Mycoplasma organisms (49). 
BV can be diagnosed in several ways. Amsel’s criteria requires three of the following four 
criterion: 1) homogenous, thin, white discharge that smoothly coats vaginal walls; 2) presence of 
clue cells on microscopic examination (> 20 percent of epithelial cells with adherent bacteria); 3) 
pH >4.5; and 4) upon s lide preparation a positive whiff test (production of a fishy odor when 
10% potassium hydroxide is added) (6). Gram stain can also be interpreted using Nugent’s 
criteria to determine the relative concentration of lactobacilli, Gram-negative and Gram-variable 
rods and cocci (G. vaginalis, Prevotella, Porphyromonas, and peptostreptococci) and curved 
Gram-negative rods (Mobiluncus) (6). However, this method cannot detect organisms such as 
ureaplasmas and mycoplasmas (50). Recently, cultivation independent studies using 16S rDNA 
sequences, polymerase chain reaction (PCR) amplified from vaginal DNA have found a range of 
novel bacteria associated with BV including Atopobium vaginae, Leptotrichia sanguinegens, 
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Leptotrichia amnionii, and three new species called Bacteria Vaginosis Associated Bacteria 
(BVAB) 1, 2, and 3 (50-52).  
BV diagnosed by Nugent’s criteria has been associated with clinically suspected PID (5, 
53-55). Haggerty et al, found the association between BV and acute endometritis to be 
independent of C. trachomatis and N. gonorrhoeae (OR 2.4, 95% CI 1.3-4.3) (7). Further this 
study found significant associations between endometrial diptheriods, black-pigmented gram-
negative rods, anaerobic gram-positive cocci, and acute endometritis independent of N. 
gonorrhoeae and C. trachomatis (7). BV is frequent among women with N. gonorrhoeae and C. 
trachomatis infections (56), but it is unclear whether anaerobes and facultative bacteria cause 
PID or if they ascend as a consequence of N. gonorrhoeae or C. trachomatis infection (57, 58). 
In a prospective study of 1,179 women from the Gynecologic Infection Follow-Through (GIFT) 
study, Ness et al reported no increase in the risk of developing incident PID over a three year 
period among women with BV diagnosed by Nugent criteria after adjustment for C. trachomatis 
and N. gonorrhoeae infection (HR 0.89, 95 % CI 0.55-1.45) (57).  However, acute carriage of 
pigmented, anaerobic gram negative rods was associated with PID (57). Further analysis in this 
cohort found that women with the highest growth of a cluster of BV-associated microorganisms 
(Lactobacillus, Gardnerella vaginalis, Mycoplasma hominis, pigmented and non-pigmented 
anaerobic gram negative rods, and Ureaplasma urealyticum) were significantly more likely to 
develop PID (RR 2.03, 95% CI 1.16-3.53) (58).   
BV is a polymicrobial condition and it ma y be optimal to examine the relationships 
between individual BV-associated bacteria and PID. A pilot study among the PEACH 
population, found that women with clinically suspected PID infected with fastidious bacteria L. 
sanguinegens/amnionii, A. vaginae, and BVAV1 were more likely than women testing negative 
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by PCR to have BV (50). As these bacteria were not associated with vaginal discharge, cases of 
BV caused by these organisms may go undetected (50). This could leave women untreated 
possibly increasing their risk of PID. Further, not all PID treatment provides coverage against 
BV-associated bacteria. The Centers for Disease Control (CDC) does recommend an optional 
treatment of metronidazole for coverage against a broader spectrum of microorganisms (6). 
However, if BV goes undiagnosed among women with PID and metronidazole is not 
administered, treatment may be suboptimal for a number of women.  
The pathogenesis of BV is not well understood and to date no single host factor has been 
found to increase susceptibility. The course and outcome of BV varies widely. It has been 
suggested that BV may increase the susceptibility of the upper genital tract to bacterial invasion 
through production of enzymes and cytokines (36, 59). In a clinical trial of 102 w omen 
randomized to either oral or vaginal metronidazole for BV, cervical levels of IL-1beta, IL-6, and 
IL-8 were significantly decreased after treatment among 72 women cured of BV (P<0.001, 
P=0.001, and P=0.2) (60). This study suggests a link between BV and elevated cytokine levels. 
In fact, Sturm-Ramirez et al found that cytokine levels, such as tumor necrosis factor-alpha 
(TNF-α) and IL-1β were significantly associated with BV (OR 4.17, 95% CI 1.69-10.30) among 
196 women (61). Cauci et al, examining 51 w omen with BV and 60 healthy controls found 
similar results. Vaginal IL-1β concentrations were significantly higher in BV positive women 
(P<0.001) (62). However, there was no difference in IL-8 concentrations between BV positive 
women and healthy controls (P=0.189) (62). The authors suggested that this finding may explain 
the low inflammation seen in many BV positive women as low levels of IL-8 may be responsible 
for low counts of leukocytes (62). Further, the decrease in recruitment of neutrophils found in 
this study may impair the defense system of the vaginal mucosa (62). Collectively these studies 
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and others may suggest a role for host immune response in the development and progression of 
BV. However, the mechanisms leading to these observed responses need to be further 
investigated.  
Mycoplasma genitalium is a sexually transmitted bacterial pathogen that is associated 
with non-gonococcal chlamydia-negative urethritis, mucopurulent cervicitis, endometritis, PID, 
and tubal factor infertility in humans (5, 63-69). M. genitalium was first isolated from the 
urethral discharge from men with non-gonococcal urethritis (66, 68).  As M. genitalium is 
difficult to culture, it wasn’t until recently when PCR became available that researchers began to 
examine this microorganism in women. A study of 170 w omen presenting with genital 
symptoms (abnormal vaginal discharge, dysuria, or pelvic pain) and attending a sexually 
transmitted disease clinic in France detected M. genitalium by PCR in 38% of women (68). M. 
genitalium has also been associated with cervicitis (66, 69), and PID (63-67). While M. 
genitalium has been detected frequently in women with gynecological conditions, it was found to 
be absent in healthy pregnant and non-pregnant women as well as women without endometritis 
(65, 68, 69). Work by Simms et al, suggests that the association between M. genitalium and PID 
is independent of chlamydial infection (64). Using PCR, the authors found that 13% (6/45) of 
women with PID had evidence of M. genitalium compared to none (0/37) of the controls (64). 
Further 27% (12/45) had C. trachomatis detected in the endocervix compared to none of the 
controls, and 16% of cases and 5% of controls had serological evidence of C. trachomatis 
infection (64). A study of 115 w omen in Nairobi, Kenya detected M. genitalium, N. 
gonorrhoeae, or C. trachomatis in the cervix, endometrium, or both in nine (16%), nine (16%), 
and four (7%) of 58 women with histologically confirmed endometritis and in one (2%), four 
(7%), and two (4%) of 57 women without endometritis (P=0.02 for M. genitalium) (65).  Further 
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analysis from this group found among 126 women with acute salpingitis, M. genitalium was 
detected in 7% (9/126) of women, while N. gonorrhoeae was detected in 16% (21/126) and C. 
trachomatis in 6% (8/126) (63). A pilot study using data from the PEACH study detected M. 
genitalium in 14% (7/50) of women with clinically suspected PID (67). A more recent study 
from this group of 682 women found that M. genitalium was associated with baseline 
endometritis (OR 2.6, 95% CI 1.5-4.6) (8). After adjustments for age, race, N. gonorrhoeae, and 
C. trachomatis, results were similar (OR 2.0, 95% CI 1.0-4.2) (8). In addition, the authors 
reported that those whom tested positive for M. genitalium had an increased risk for short term 
treatment failure, defined as the presence of both endometritis and pelvic pain 30 days following 
treatment for PID, compared to those whom tested negative (RR 4.6, 95% CI 1.1-20.1) (8). 
Further, 44% of women with baseline endometrial positive specimens tested positive at 30 days 
post-treatment (8). Interestingly, among these women with mild to moderate PID, those with M. 
genitalium monoinfection had significantly less pelvic pain than women with N. gonorrhoeae 
(58.0±21.9 vs. 72.3±23.9; P=0.01), but not C. trachomatis (P=0.05).  
It is unclear what the risk of sequelae is following M. genitalium-associated PID. Clausen 
et al examining 308 women with tubal factor infertility undergoing invitro fertilization (IVF), 
reported that 22% (29/132) displayed seropositivity to the major adhensin protein, MgPa, of M. 
genitalium compared to 6.3% of women with normal tubes (70). Among this same group, a 
prospective study examining 212 couples attending infertility clinics found that 17% of women 
with tubal factor infertility were seropositive to M. genitalium compared to 4% of women with 
normal tubes (71). Among these women 14%, who were seropositive for M. genitalium, reported 
a history of PID. However, detecting M. genitalium by serology can be difficult due to its cross-
reactivity with M. pneumoniae (72). Using PCR, in the PEACH study, rates of sequelae were 
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higher among those testing positive for M. genitalium; 22% infertility, 31% recurrent PID, 42% 
chronic pelvic pain (8). Although there were increasing trends towards these sequelae they were 
non-significant; infertility (RR 1.4, 95% CI 0.6-2.9), recurrent PID (RR 1.6, 95% CI 0.8-3.1, and 
chronic pelvic pain (RR 1.6, 95% CI 0.3-1.3) (8).  However, all women in this study had signs 
and symptoms of PID and all may have been at increased risk for reproductive sequelae biasing 
the results towards the null.  
Few studies have examined the pathogenesis of M. genitalium. However, it is known that 
M. genitalium has the ability to produce pathological changes although it generally takes a more 
chronic course. M. genitalium has several adhesion proteins which are clustered in a tip structure 
(73). Among these proteins MgPa and P110 are considered to be immunogenic and are needed 
for adherence to host cells (72). These proteins are located on the cell surface and are potential 
targets for host antibodies. However, M. genitalium has been shown to be able to persist for long 
lengths of time in an infected individual (72, 74).  Thus, M. genitalium is thought to be able to 
evade the host immune response through antigenic variation (72, 74).  Less is known about the 
role of host response to M. genitalium in the course and outcome of infection. In the case of M. 
pneumoniae, it has been suggested that much of the tissue damage may actually be due to the 
host cell response (75). Further, M. pneumoniae lipids have been found to adhere to surface 
protein D (76), which is part of the innate immune system and may enable the organism to use 
the host defense mechanism for pathogenesis (77). As M. genitalium is genetically similar to M. 
pneumoniae, it ma y have similar functions (77). It is imperative that research continue to 
investigate the role of host immunity in M. genitalium upper genital tract infection, as these 
relationships have not been completely elucidated.   
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1.2.3 Diagnosis of PID 
Diagnosis of PID is often difficult as signs and symptoms vary, may be mild or absent, and are 
generally based on clinical findings (5, 6).  The CDC recommends that empiric treatment of PID 
be initiated in women at risk for sexually transmitted infections if they have pelvic or lower 
abdominal pain, and one or more of the following are present; cervical motion tenderness, 
uterine tenderness, or adnexal tenderness (6). To enhance the specificity the following criteria 
can be used; oral temperature > 1 01°F, abnormal cervical or vaginal mucopurulent discharge, 
presence of white blood cells, elevated erythrocyte sedimentation rate (ESR), elevated C-reactive 
protein and laboratory documentation of cervical infection with N. gonorrhoeae or C. 
trachomatis (6).  These guidelines aim to diagnose with a high sensitivity at the expense of low 
specificity, in order to treat women early and prevent sequelae. These criteria have a positive 
predictive value to detect salpingitis of 65%-90% compared with laparoscopy (6). The PEACH 
study has shown that adnexal tenderness has a sensitivity of 96% for the detection of 
endometritis (77). In a recent study by Yudin et al, vaginal neutrophils had a sensitivity of 90.9% 
and a negative predictive value of 94.5% in the diagnosis of upper genital tract infection (78).  
However, this method had a low specificity of 26.3% and a low positive predictive value of 
17.1% (78). 
The most specific methods for the diagnosis of PID include the following; endometrial 
biopsy with histopathologic evidence of endometritis, transvaginal sonography, magnetic 
resonance imaging, or laparoscopy (6). Laparoscopy is considered to be the gold standard; 
however this method is invasive and not widely used in the United States (6). Further, 
laparoscopy is not standardized, is subjective, and will not detect endometritis or possibly even 
subtle inflammation in the Fallopian tubes (6). Laparoscopy was also found to have low 
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sensitivity for the diagnosis of PID (25-50%) when compared to fimbrial minibiopsy (79, 80). A 
good alternative for laparoscopy is histologically confirmed endometritis. Endometrial biopsy 
has been found to have a sensitivity of 70-89% and a s pecificity of 67-92% compared to 
laparoscopy (81-83). Due to the difficulties of diagnosis of PID, new methods have been 
developed. Transvaginal Doppler ultrasound which detects hyperaemia associated with fallopian 
tube inflammation is reported to have a high sensitivity and specificity (100% and 80%) 
compared to laparoscopy (84). Although it is not widely available, magnetic resonance imaging 
(MRI) can also be used as an alternative diagnosis of PID. Compared to laparoscopy, MRI is 
estimated to have a sensitivity of 95% and specificity of 89% for the diagnosis of PID (85). 
Endovaginal sonography is another minimally invasive procedure that may improve diagnosis of 
PID, although it has a lower sensitivity (32-81%) when compared to laparoscopy (86). 
1.2.4 Treatment of PID 
It is recommended that PID treatment provide a broad spectrum of coverage against C. 
trachomatis, N. gonorrhoeae, mycoplasmas and anaerobic and aerobic bacteria (6). Most PID 
patients are treated as outpatients. Findings from the PEACH study demonstrated that among 
women with mild to moderate PID, there is no difference in clinical and microbiological cure 
rates or rates of long term outcomes between inpatient and outpatient treatment of PID (87). 
However, the CDC recommends hospitalization for certain women, such as those with surgical 
emergencies (not excluding appendicitis), pregnant patients, those who do not respond clinically 
to oral antimicrobial therapy, those who cannot tolerate oral outpatient regimens, patients who 
have severe illness, nausea, or vomiting, and those with tubo-ovarian abscess (6). For inpatient 
treatment, the CDC recommends regimens of cefotetan (2g IV every 12 hours), cefoxitin (2g IV 
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every 6 hours) plus doxycycline (100mg orally or IV every 12 hours), or clindamycin (900mg IV 
every 8 hou rs) plus gentamicin (2mg/kg of body weight loading dose IV or IM followed by 
1.5mg/kg maintenance does every 8 hours or 3-5mg/kg single daily dose). Gentamicin can also 
be given as a single daily dose, although there are no trials of once daily gentamicin dosing in 
PID (6). However, the regimen of clindamycin plus gentamicin has better coverage for anaerobic 
infections and facultative Gram-negative rods (88). Some studies have examined the efficacy of 
inpatient treatment trials, although most have focused on outpatient treatment. One study among 
103 patients with PID randomized to ampicillin-subactam or cefoxitin (2g every 6 hours) plus 
doxycycline (100mg every 12 hours), found that the clinical cure/improvement rates were similar 
(85.5% and 89.6%) (89). In another study of 84 women with PID, IV meropenem had similar 
clinical cure rates (88% vs. 90%) and microbiological cure rates (88% vs. 86%) compared to 
clindamycin plus gentamicin (90).  
For outpatient therapy, the CDC recommends several regimens including levofloxacin 
(500mg orally 1/day for 14 da ys), ofloxacin (400mg orally 2/day for 14 da ys), ceftriaxone 
(250mg IM single dose) plus doxycycline (100mg orally 2/day for 14 days), cefoxitin (2g IM 
single dose and probenecid 1g orally single dose) plus doxycycline (100mg oral 2/day for 14 
days), or parenteral third generation cephalosporins plus doxycycline (100mg oral 2/day for 14 
days) (6). The CDC provides the option that all recommended regimens can be given with 
metronidazole (500mg orally 2/day for 14 days) to provide coverage against anaerobes (6). In a 
meta-analysis, cefoxitin and doxycycline used in the PEACH study and the treatment 
recommended by CDC, was found to have a clinical cure of 93% and a microbiological cure of 
98% for C. trachomatis and N. gonorrhoeae (91). In this same meta-analysis the clinical cure 
and microbiological cure rates for clindamycin and aminoglycoside, cefotetan and doxycycline, 
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and ciprofloxacin were 92% and 97%, 94% and 100%, and 94% and 96%.  In general many trials 
have focused on ofloxacin due to its in vitro activity against C. trachomatis, N. gonorrhoeae, and 
anaerobic and aerobic bacteria (5). In one randomized clinical trial, oral ofloxacin was compared 
with cefoxitin followed by doxycycline among 295 women with clinically suspected PID and 
reported high rates of clinical cure (95% vs. 93%) and 100% N. gonorrhoeae eradication (92).  
Ofloxacin was associated with a higher microbiological cure rate for C. trachomatis (100% vs. 
88%) and lower prevalence of side effects (7% vs. 14%). Ofloxacin has also been found to 
eradicate a range of anaerobic and aerobic pathogens (93). The CDC suggests that levofloxacin 
can be substituted for ofloxacin. In a pilot study, levofloxacin plus metronidazole, administered 
to 40 women with uncomplicated PID, has a 37% clinical cure rate and 100% microbiological 
cure (94). At follow-up 100% of patients were clinically cured and side effects were minimal. 
This study suggested that levofloxacin was well tolerated and effective for treatment of PID.  
The multimicrobial nature of PID makes it difficult to successfully treat PID. Although 
about a third to a half of PID cases are caused by chlamydia or gonorrhea (5, 36), many cases are 
non-gonococcal and non-chlamydial in nature. For example BV, anaerobic bacteria, and 
mycoplasmas have been implicated in the etiology of PID (5, 7, 8, 36). Further, the 
microbiological etiology of many cases of PID is unknown. Metronidazole can optionally be 
added to all CDC recommended regimens to provide coverage against anaerobes (6). This is 
recommended as studies have found that BV-associated microorganisms are associated with PID 
and endometritis (5, 7, 54, 56, 58). However, in the same meta-analysis mentioned previously, a 
regimen consisting of metronidazole and doxycycline was found to have low efficacy, with a 
clinical cure rate of 75% and a microbiological cure rate of 71% (91). Studies conducted after the 
meta-analyses have also examined the efficacy of metronidazole. In one study, combined therapy 
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of doxycycline and metronidazole also exhibited a l ow clinical cure rate (35%) and clinical 
improvement rate (50%) among 40 women with laparoscopically diagnosed salpingitis (95). In a 
study of 135 w omen with PID from the United Kingdom (UK), the clinical cure rate of 
doxycycline and metronidazole was only 55%, although the addition of ceftriaxone increased the 
cure rate to 72% (96). The combination of doxycycline and metronidazole does not provide 
sufficient coverage for N. gonorrhoeae, as doxycycline itself is less effective without the 
addition of other drugs including cefoxitin. In a more recent analysis among women with 
uncomplicated PID, the cure rate for doxycycline (100mg 2/day) and metronidazole (400mg 
3/day for 14 days) plus one single dose of 500mg ciprofloxacin was  higher at 98% 2-14 days 
post therapy and 93.8% 21-35 days post therapy (97). However, the microbiological cure rate 
was only 88.2%, 2-14 days post therapy, with 95.5% C. trachomatis eradication and 91.7% N. 
gonorrhoeae eradication. In another randomized trial, women who received ofloxacin (14mg 
2/day) plus metronidazole (400mg 1/day) for 14 days had a clinical resolution rate of 90.7% 5-24 
days post therapy (98). During follow-up (28-42 days post therapy) the resolution rate was 
87.9% and microbiological cure rate was 82.1% (98). Specifically the cure rates against C. 
trachomatis and N. gonorrhoeae was 85.7% and 81.8%.  
 Data from the National Hospital Ambulatory Medical Care Survey reported in 2004 that 
the compliance rate with the CDC PID treatment regimens is only 35% among women attending 
emergency departments (99). This is of great concern, especially for teenagers and young adults 
as they are at an increased risk for sexually transmitted diseases and PID. Therefore, short term 
monotherapies may be important for those with low compliance, such as teenagers and women 
of low socio-economic status (SES) (5). Some studies have examined single or short-term 
therapies for treatment of PID. In a randomized clinical trial of 165 Indian women with clinically 
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suspected PID, a regimen of fluconazole (1 tablet 150mg), azithromycin (1 tablet 1g) and 
secnidazole (2 tablets 2g) had a clinical cure rate of 94% (100). This was similar to a group who 
was treated with 500mg of ciprofloxacin and 600mg of tinidazole for 7 days (96%), and better 
than a group treated with 100mg of doxycycline (2/day) and 200mg of metronidazole (3/day) for 
7 days (91%) (100). A study among 309 p atients with clinically suspected PID (75% with 
laparoscopically confirmed PID) from the United Kingdom, compared azithromycin 
monotherapy (500mg IV single dose followed by 250mg oral dose for 6 days), and azithromycin 
in combination with metronidazole, with standard regimens (101). This study found similar rates 
of clinical success among the azithromycin monotherapy group (97%) compared to azithromycin 
and metronidazole (98%) and the comparator regime consisting of metronidazole, doxycycline, 
cefoxitin, and probenecid or doxycycline and amoxicillin and clavulanate (75%). Azithromycin 
is also suggested to be effective for treatment of anaerobes. In a study of 106 women with mild 
PID who received intramuscular injection of 250mg of ceftriaxone, azithromycin was found to 
have a better clinical cure rate (98.2% vs. 85.7%) compared to doxycycline (102). 
There is numerous data on clinical and microbiologic cure following a variety of PID 
treatments with various regimens. However, data on the efficacy of PID treatment regimens in 
the prevention of sequelae is limited, as few studies have examined reproductive morbidity after 
PID treatment. Data from the PEACH study shows that among women treated with cefoxitin and 
doxycycline, endometritis and upper genital tract infection with chlamydia or gonorrhea was not 
associated with reproductive morbidity (1). This may suggest that current PID treatments are 
effective for the prevention of reproductive sequelae (1, 5). However, this study may have been 
biased as women could have had previous infections or PID that resulted in tubal damage prior to 
enrollment (1). Heinonen et al, found that among women treated for salpingitis with a regimen of 
 23 
doxycycline plus metronidazole 28% had recurrent PID at follow-up (103). However, 89% of 
these women reported conception, which again may suggest the PID treatment is effective. It 
should be noted that the average time to pregnancy was 38 months, with greater times among 
women with severe salpingitis. Infertility is defined as lack of conception within 12 m onths; 
therefore many of these women would have been considered infertile (5). Further, high 
conception rates could be attributed to fertility treatments (5). Therefore, it is  suggested that 
women with PID (chlamydial, gonococcal, or non-chlamydial/gonococcal), despite treatment 
may be at higher risk for reproductive morbidity than women without PID (5). There may also be 
subgroups of women who are more likely to have sequelae following PID. Those with non-
gonococcal PID were more likely to experience sequelae in PEACH (infertility rates: N. 
gonorrhoeae 13%, C. trachomatis 19%, anaerobic bacteria 22%, U. urealyticum 27%, M. 
hominis 17%) (5). Similar results by Brunham et al., reported that 54% of women with non-
gonococcal infections suffered adverse reproductive sequelae (19). Further, in the Heinonen 
study, among those with recurrent PID at follow-up, two had C. trachomatis, two had N. 
gonorrhoeae, and seven had unknown etiology (103). This suggests that among women with 
non-gonococcal PID, standard PID treatment may not be effective in the prevention of long term 
sequelae. 
The current recommended therapies for PID may not provide sufficient coverage against 
all PID-associated pathogens. Haggerty et al, reported that among women treated with cefoxitin 
and doxycycline, women who tested positive for M. genitalium had an increased risk for short 
term treatment failure compared to those whom tested negative for M. genitalium (RR 4.6, 95% 
CI 1.1-20.1) (8). Studies among men with non-gonococcal urethritis found the M. genitalium can 
persist after treatment with levofloxacin (96, 102) and tetracyclines (104, 105).  It has been 
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reported that in vitro M. genitalium is susceptible to azithromycin but not doxycycline or 
ciprofloxacin (106). However, in a study among 120 m ales and females infected with M. 
genitalium and treated with azithromycin, M. genitalium was reported to be eradicated in 84% 
and persisted in 16%, although 8% of those with persistent infection may have been at risk from 
untreated or doxycycline treated partners (107). Among those with persistent infection, 
moxifloxacin was effective in eradicating M. genitalium completely. Moxifloxacin has been 
studied in women with PID. Moxifloxacin monotherapy (400mg 1/day for 14 days) was found to 
have similar clinical resolution rates 5-24 days post treatment (90.2% vs. 90.7%) and similar 
clinical resolution rates 28-42 days post treatment (85.8% vs. 87.9%) compared to oral ofloxacin 
(400mg 2/day) plus metronidazole (500mg 2/day) (99). Microbiological cure rates were slightly 
higher for the moxifloxacin group (87.5% vs. 82.1%). In another study moxifloxacin also had 
similar clinical cure rates (96.6% vs. 98.0%) and microbiological cure rates (92.5% vs. 88.2%) 
compared to women treated with doxycycline and metronidazole (98).  
1.2.4.1 Delayed Treatment of PID 
Women who delay seeking treatment for PID may be at increased risk for adverse sequelae. For 
example, those who delay care could have chronic low level inflammation which may 
permanently damage the reproductive tract prior to receiving treatment. Among women with 
PID, pelvic pain may be mild or absent (55), and PID symptoms vary by microbial etiology (36, 
108-110). Therefore, PID may go undetected in many women. Chlamydial infections are known 
to elude detection because they produce few or no symptoms or because the symptoms are non-
specific (111). Further, in chlamydial salpingitis, clinical manifestations are often mild but 
associated with severe tubal damage (36, 111). This is in contrast to gonococcal salpingitis which 
produces more overt and severe acute inflammation and symptoms but leads to less damage to 
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the fallopian tubes (36). In fact, C. trachomatis has been found to increase the odds of subclinical 
“silent” PID six-fold (OR 6.1, 95% CI 1.8-2.1) compared to a four-fold increase among women 
with N. gonorrhoeae (OR 3.9, 95% CI 1.7-8.9) (108). Studies have reported similar symptoms 
between C. trachomatis and M. genitalium (109, 110). This may indicate that among women 
with PID, those infected with N. gonorrhoeae present with more overt and severe symptoms, 
leading to earlier treatment than women with C. trachomatis or M. genitalium (36). In fact, Hillis 
et al reported that delayed treatment for more than 3 days increases the risk of impaired fertility 
following an episode of PID (9). In this case-control study nested within a Scandinavian cohort 
conducted between the 1960s and early 1980s (3), delayed care was associated with a three-fold 
increase in infertility or ectopic pregnancy among 443 women with one known episode of 
clinical or laparoscopically confirmed PID (9). Further, the association was strongest among 114 
women infected with C. trachomatis, with 17.8% of C. trachomatis positive women who delayed 
seeking care experiencing impaired fertility compared to 0% who sought care promptly (9). 
However, these associations have not been replicated in a contemporary cohort, and the 
distribution of microbes among women with PID appears to have changed over time. Therefore, 
the microbial correlates of time to treatment and long term outcomes among PID patients should 
continue to be examined.  
1.2.5 Morbidity following PID 
PID can cause serious reproductive sequelae such as infertility, chronic pelvic pain, and ectopic 
pregnancy (3, 5). These complications can result from damage to the cilia lining of the Fallopian 
tubes, Fallopian tube blockage, or adhesion formation among pelvic organs (5). A landmark 
Scandinavian cohort study among 2500 women with clinically suspected PID, found that 16% of 
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women with laparoscopically verified salpingitis versus 2.7% of controls became infertile (3). In 
addition, 20% and 25% developed recurrent PID and chronic pelvic pain respectively (2).  Tubal 
factor infertility was also found to double with each PID episode and reached an estimated 40% 
after three or more episodes (3). Results from the PEACH study found that the mean physical 
and mental health composite scores progressively lowered as the grade of chronic pelvic pain 
increased (112). This highlights chronic pelvic pain as an important post-PID morbidity (5). 
Among patients with clinically suspected PID from the PEACH study, those with 
endometritis were no m ore likely than those without endometritis to experience reduced 
pregnancy (OR 0.8, 95% CI 0.6-1.2), infertility (OR 1.0, 95% CI 0.6-1.6), or chronic pelvic pain 
(OR 0.6, 95%  CI 0.6-1.6) (1). Although salpingitis has been found to be associated with 
morbidity, and endometritis is an accepted alternative to laparoscopically diagnosed salpingitis, 
this study suggests that endometritis may not be a good predictor of morbidity following PID. 
These findings may partially be a result of the study population. The PEACH population is likely 
a different patient population than the Scandinavian women recruited a generation ago. In 
addition, endometrial histology was used to confirm PID in PEACH, whereas 1,844 patients in 
the Westrom study had laparoscopically confirmed salpingitis and not all women with 
endometritis have salpingitis (1). Salpingitis may indicate more severe disease and lead to tissue 
damage, while endometritis may have lesser effects on tubal pathology (1). Further, the PEACH 
study treatment covered a broader range of microbes than did those used in the 1960-1980’s.  
Differences in findings between the two studies may also be explained by the comparison group 
in the PEACH study. Women in PEACH had clinically suspected PID and studies have 
suggested that some women with clinically suspected PID may actually have ovarian cysts, 
pelvic adhesions, or endometriosis all of which may be associated with infertility (81). As these 
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women would be more likely to be in the comparison group and may have had infertility or 
chronic pelvic pain prior to enrollment, the results may have been biased towards the null. 
Attempts were made to reduce this bias by excluding women with greater than 30 days of pain, 
as these women could have had chronic pelvic pain caused by other conditions (1). Although 
endometritis was not associated with morbidity in the PEACH study, rates of sequelae were high 
(17% infertility, 20% recurrent PID, and 36% chronic pelvic pain). Therefore, despite treatment, 
women with PID may still be at high risk for reproductive morbidity.  
Obstruction of the fallopian tubes following PID is a preventable cause of infertility and 
ectopic pregnancy. The role of individual microbes in the development of sequelae following 
PID is not well understood. Studies have shown that C. trachomatis, N. gonorrhoeae, M. 
genitalium, and M. hominis antibodies have been identified in women with tubal factor infertility 
or tubal occlusion (26, 39, 70, 113-116). Chlamydial antibodies have been found to be 
significantly more common among patients experiencing ectopic pregnancy as compared to 
controls with normal pregnancies (OR 3.1, 95% CI 2.2-4.3) (117). Low et al, in a study of 43,715 
women from the general population, found that C. trachomatis, diagnosed by culture or PCR, 
was associated with infertility (HR 1.31, 95 % CI 1.09-1.57) and ectopic pregnancy (HR 1.26, 
95% CI 0.94-1.67) (118).  Chlamydia is a l eading cause of permanent tubal damage (36), and 
therefore antibody testing has been used in the evaluation of infertility (119, 120).  
1.2.6 Toll-like Receptors, the Reproductive Tract, and PID  
Interaction between the immune system and the reproductive tract is important for fertility and 
reproductive health. The innate immune system serves as the first line of defense after exposure 
to pathogens and depends on pa ttern recognition receptors (PRRs) for microbial recognition 
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(121-123). The understanding of the innate immune system has increased due to the discovery of 
a highly conserved family of PRRs call the Toll-like receptor (TLR) family (122). TLRs are 
characterized by an evolutionary conserved cytoplasmic Toll/interleukin-1 receptor homology 
(TIR) signaling domain, as well as an external antigen recognition domain which is comprised of 
19-25 tandem leucine-rich repeat (LRR) motifs (123). TLRs are able to detect microorganisms 
by recognizing non-specific pathogen-associated molecular patterns (PAMPs). These ligands can 
include lipopolysaccharide (LPS), mannans, flagellins, carbohydrates, peptides, nucleic acid 
structures, and several others (122, 123). Thus, TLRs play a critical role in the recognition of 
pathogens and are responsible for direct microbial elimination through induction of pro-
inflammatory cytokines, adaptive immunity, and resolution of inflammation through apoptosis. 
However, the exact mechanism of activity and function of TLRs in relation to fertility and 
reproductive health are unknown.  
Ten different TLRs (TLRs 1-10) have been identified in humans and the overlap between 
them allows recognition of a diverse range of pathogens (121-123).  TLRs 1, 2, 4 -6, and 10 are 
expressed on the cell surface of a number of immune effector cells, while TLRs 3, and 7-9 are 
expressed inside of the cell in endosomes or endoplasmic reticulum (123-126). Lipids and 
lipoproteins can act as ligands for TLRs 1, 2, 4,  and 6; proteins can act as ligands for TLR5 and 
nucleic acid for TLRs 3 and 7-9 (123, 124, 127, 128). There is no known ligand for TLR10. In 
addition to be able to identify lipids and lipoproteins, TLR2 can form noncovalent hetrodimers 
with TLR1 or TLR6, enabling TLR2 to recognize a diverse range of pathogens (127).  
After ligand binding, TLRs can recruit other TIR domain containing molecules to the 
site. These are called adaptor molecules and they include myeloid differentiation primary 
response protein 88 ( MyD88), TIR domain-containing adaptor protein (TIRAP or MAL), TIR 
 29 
domain-containing adaptor protein interferon-beta (IFN)-β (TRIF), and TRIF-related adaptor 
molecule (TRAM) (123, 127). TIRAP and TRAM are needed to recruit either MyD88 or TRIF to 
the site and therefore are called bridging adaptor molecules. Almost all TLRs signal via MyD88, 
with the exception of TLR3. Therefore, variations in MyD88 genes and other adaptor molecules 
may also play a role in disease pathogenesis.  
After MyD88 is recruited to the complex it w ill initiate a cascade of signaling events, 
which will eventually dissociate nuclear factor κ-B (NF-κB) from its inhibitor, translocating it 
into the nucleus, releasing proinflammatory cytokines and chemokines. Specifically, upon ligand 
binding MyD88 is joined by IL-1 associated protein kinase 1 (IRAK-1), IRAK-4, and TNF-
associated factor 6 (TRAF-6) (129). IRAK-1 and TRAF-6 will then dissociate from the complex 
and activate transforming growth factor-β-activated kinase (TAK-1), which in turn activates IκB 
kinase kinase (IKK) complex (129). This complex is modulated by the transcription factor NF-
κB essential modulator (NEMO) (129). IKK-mediated phosphorylation of IκB eventually leads 
to the translocation of NF-κB into the nucleus, activating cytokine genes (129).  
As TLRs are expressed throughout the female reproductive tract (121,125,126), there is a 
possible role for TLRs in gynecological disease and fertility. TLRs 1-3, 5 and 6 are expressed in 
vaginal and cervical epithelial cells, further TLRs 1-3, and 6 are expressed by primary 
endocervical epithelial cells (121, 130-133). TLR4 has been reported to be present in the 
endocervix, endometrium, and Fallopian tubes (121, 130-133). TLRs 7-10 have been identified 
in the endometrial epithelia and stroma (134).  
TLR2 and TLR4 are suggested to have differential expression, with low expression in the 
lower genital tract and higher expression in the upper genital tract (131). Studies have also 
shown variability in expression of TLRs during the menstrual cycle (133, 134). For example, 
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during the menstrual phase there is an increase in TLR expression possibly as a defense 
mechanism (133). In contrast, during the periovulatory phase there is a decrease in expression 
that may prevent unfavorable inflammation (133). However, Aflatoonian et al reported that 
TLRs 2-6, 9, and 10 have higher expression during the secretory phase compared to other phases 
of the menstrual cycle (134). These contrasting results may have been due to differences in study 
methodology. Overall, the variability in expression may suggest that TLRs hold different 
functions in different parts of the genital tract.  
1.2.6.1 Toll-like Receptors and Chlamydia trachomatis 
To our knowledge, no studies have examined the role of TLRs in PID. However, limited studies 
have examined the role of TLRs in infection with PID-associated pathogens (C. trachomatis, N. 
gonorrhoeae, M. genitalium), BV, and tubal factor infertility. It is known that Chlamydia sp. can 
infect epithelial cells causing them to secret proinflammatory cytokines (135-137). Researchers 
have suggested that this inflammatory response may be responsible for disease progression 
(137), especially among those with chronic or persistent infections. As TLRs are expressed in the 
genital tract and can stimulate proinflammatory genes after binding to a bacterial ligand, it is  
possible that they may play a role in chlamydial pathogenesis.  
TLRs have been examined in chlamydial infections, although most have focused on 
TLR2 and TLR4. Studies have shown that TLRs can bind to several possible chlamydial ligands. 
TLR4 have been suggested to recognize LPS and HSP60 (138). TLR2 can respond to a variety of 
ligands such as lipoproteins and lipopeptides, lipoarabinomannan, lipoteichoic acid, and bacterial 
prion (139-143). Further, TLR2 can dimerize with TLRs 1 and 6, possibly to recognize a more 
diverse range of ligands (144). Interestingly, one study found that LPS from the 
lymphogranuloma venereum (LGV)-1 strain of C. trachomatis activated the NF-kB pathway via 
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TLR2 (145). Therefore, C. trachomatis may be able to express a variety of ligands for TLR 
recognition.  
It is known that inflammatory responses are necessary for the elimination of primary C. 
trachomatis infections, although inflammation leads to long-term damage in chlamydial genital 
tract infections (146, 147). Several studies have examined TLR pathways in chlamydial 
infections and have suggested a role for TLR2 in cytokine production. For example, Derbigny et 
al found that cloned murine epithelial cells infected with C. muridarum secreted cytokines IL-6 
and GM-CSF in a MyD88-dependent fashion (148). Similarly, O’Connell et al found that TLR2 
was required for chlamydial induced IL-8 expression, while TLR4/MD-2 had minimal effects on 
cytokine production (149). Further, TLR2 and MyD88 both localized to chlamydial inclusions 
during active infection (149). This study suggested that both TLR2 and its downstream adaptor, 
MyD88 are required for cellular activation.  However, this response did not occur with irradiated 
bacteria or bacteria treated with antibiotics.  
While TLRs are necessary for a healthy immune response, TLRs may also be involved in 
overt immune responses that could lead to tissue damage. Animal models have been able to 
provide us with some information regarding the role of TLRs in the progression of C. 
trachomatis infections. For example, Darville et al found that TLR2 knockout (KO) mice had 
significantly lower levels of inflammatory mediators in genital tract secretions during the first 
week of chlamydial infection, as well as a significant reduction in oviduct and mesosalpinx 
pathology at late time points compared with mice with the TLR2 gene (150). This essentially 
caused a reduction in reproductive sequelae caused by chlamydial infection. Further studies from 
the same group found that mutant plasmid deficient C. muridarum strains (CM972 and CM3.1) 
infected the murine genital tract but did not cause disease because of a failure to stimulate TLR2-
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dependent cytokine production in mice (151). Darville et al, concluded that TLR2 signaling is 
essential for the development of oviduct pathology. In chlamydial genital tract infection, plasmid 
deficient strains fail to stimulate TLR2 and do not induce oviduct pathology, and mice primarily 
infected with plasmid-deficient strains are protected against oviduct pathology upon c hallenge 
with virulent C. muridarum (150, 151). In contrast, TLR4 KO mice had similar pathology 
compared to infected controls with TLR4 genes (150). Further, a similar in vivo cytokine 
response was observed in TLR4 KO mice and controls and reflected similar outcomes of 
infection. Therefore, these data do not suggest a direct role for chlamydial HSP60-induced TLR4 
mediated tissue damage in genital tract infection (150). Interestingly, data from the PEACH 
study shows that chlamydial HSP60 is not associated with sequelae among women with 
clinically suspected PID (18). Therefore, if TLR2 stimulation is associated with chlamydial-
induced tissue damage and TLR4 is not, this could suggest that HSP60 is not a major player in 
chlamydial-induced disease pathogenesis.  
Although animal studies may not completely translate into human in vivo situations, they 
can certainly give insight into the biology and pathogenesis of chlamydial infection. 
Unfortunately, there are only a limited number of epidemiological studies examining the role of 
TLRs in C. trachomatis infection. There is a role for genetic variations in immunologically 
important host genes in the pathogenesis of disease (152). Single nucleotide polymorphisms 
(SNPs) are a type of variation, in which one nucleotide has been substituted, inserted or deleted 
and variations exist in the number of repetitive DNA sequences. Carrying a specific SNP may 
have direct or indirect biological consequences for the host. It has been suggested that TLR4 
homozygote (A>G) and Thr399I1e SNPs affect LPS receptor function, whereas heterozygous 
carriage had no effect (153). Morre et al examined 35 Dutch women with tubal pathology and 49 
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Dutch women without tubal pathology and found that the TLR4 Asp299Gyl polymorphism was 
not associated with tubal infertility (P>0.5) (Allele frequency: 7.1% vs. 10.2%) (154). In a cohort 
of 227 subfertile women, among C. trachomatis positive women there was an increasing risk for 
tubal pathology (64% risk for normal genotype vs. 83% risk for heterozygous SNP carrier), 
although this did not reach statistical significance (154). Read et al examined this polymorphism 
in meningococcal disease (gram-negative bacteria) and did not find an association with the TLR4 
polymorphism (155). The study results were not what the authors expected. However, the lack of 
associations in these studies may be explained by Erridge et al, who found that TLR4 
heterozygote mutations do not affect recognition of chlamydial LPS (153). As the rare 
homozygotes may be less responsive to LPS, they may be more likely to experience adverse 
effects. The lack of association may have been due to the fact that almost all carriers of the 
common TLR4+896 A>G SNP were heterozygous. Thus, the authors simply did not have 
enough genotypic diversity to detect any significant results. The protein CD14 is a co-receptor 
for TLR4 and confers responsiveness to LPS leading to the activation of NF-κB associated 
immune response (156). Polymorphisms in this co-receptor may lead to sequelae following 
infection. Outburg et al, compared 253 Dutch women with subfertility to 170 fertile women to 
examine the CD14 functional polymorphism -260C>T (156). However, this study found no 
association between this polymorphism and subfertility following chlamydial infection (156).  
Fewer studies have examined polymorphisms in C. trachomatis infections. In one study 
examining TLR4 polymorphisms, no a ssociations were found between TLR4 SNPs and C. 
trachomatis infection among a Dutch population (157). However, women with tubal pathology 
who were C. trachomatis Ig positive were twice as likely to be carriers of the TLR4 +896 G 
allele compared to women without tubal pathology (157). Karimi et al examined the role of 
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several TLR2 SNPs in 468 Dutch women (158). This study found no associations with any SNP 
genotypes and susceptibility to C. trachomatis infections (158). However, a haplotype formed by 
-16934 T>A and +2477 G>A SNPs was significantly associated with protection against tubal 
disease following C. trachomatis infection (P=0.015) (158). Further, this haplotype was 
associated with a decrease in severity of C. trachomatis infection (P=0.021), suggesting that this 
haplotype has a possible protective function (158). Results from theres studies need to be 
replicated. These limited studies among Dutch Caucasian populations have been unable to show 
any significant associations between innate immune receptor functional polymorphisms and 
tubal factor infertility. These studies have been limited by small sample sizes and low power. 
Further, the homogeneous population used in these studies is likely not generalizable to women 
with sexually transmitted diseases and PID in the US. Further studies should examine a full panel 
of candidate TLR genes in C. trachomatis infection and disease progression in different racial 
groups. 
1.2.6.2 Toll-like Receptors and Other PID Organisms 
Fewer studies have been conducted to examine the association between TLRs and other PID 
associated pathogens. Using real time PCR, Muenzner et al found that N. gonorrhoeae activated 
NF-κB possibly via TLR4 or TLR2 (159). However, the authors did not allow for determination 
of levels of expression (159).  A study that did examine the expression found that response to N. 
gonorrhoeae at the mucosal surface is independent of TLR4 (160). Pridmore et al found that 
lipooligosaccharide (LOS) from different strains of Neisseria, including gonococcal strains, 
induced TLR4/MD2 signaling (161). However, the level of signaling differed significantly 
depending on t he strain of Neisseria (P<0.01). Further, the level of TNF was significantly 
associated with the level of TLR signaling (161).  
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TLR2 may be important in producing an inflammatory response during gonococcal 
infection. Fisette et al suggested that TLR2 cooperates with TLR1 and/or TLR6 to respond to 
lipoproteins (162). However, they found that the Lip lipoprotein signals through TLR2 with 
TLR1 but not TLR6, suggesting that this lipoprotein induced inflammation in a TLR2 dependent 
manner (162). Continued investigation of the interactions between TLRs and N. gonorrhoeae are 
needed.  
Stimulation of cells and release of certain proinflammatory cytokines or alterations in the 
response by TLRs may mediate the adverse effects caused by BV. Genc et al reported that 
women with the TLR4 4795A>G polymorphisms who were homozygotes had increasing levels 
of IL-1β and IL-1ra (163). In addition, those who were carriers for the TLR4 4795 G allele had 
higher concentrations of G. vaginalis, although no significant associations were found with BV 
(163). This may suggest that the G allele increases susceptibility to BV. The small numbers in 
this study did not allow them to find significant differences in allele frequencies between races, 
although there appeared to be a g reater percentage of blacks who had the G allele (14%) 
compared to whites (8.5%) (163). Allelic variation by race may explain the higher incidence of 
BV among black women, but it has not been studied widely.  In a study of 885 predominantly 
African American women, the TLR4 4795A>G polymorphism was not associated with BV 
(164). The authors did find a slight protective effect with the TLR4 5095C>T polymorphism, 
however after controlling for ethnicity the association was no longer significant (164).  In a study 
of 144 C aucasian women, no s ignificant associations were found with TLR4A>G and 
Gardnerella vaginalis or Atopobium vaginae (165). Further, this study found no s ignificant 
associations between several other SNPs in TLR2 (-15607A>G, 1350T>C, 2258G>A, 
2029C>T), TLR4 (-2026A>G, 5095C>T), or TLR6 (-502T>C, 745C>T, 1083C>G, 1280T>C) 
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(165). The authors did find a significant association between A. vaginae, during the first half of 
pregnancy, and the TLR1 743A>G (P=0.038) polymorphism, as well as the TLR1 -720A>G 
(p=0.062) polymorphism. However, the authors did not find any significant associations between 
BV and any of the TLR SNPs. BV is not a condition of a single pathogen and the 
microorganisms which cause BV may differ between women. This may make it difficult to find 
associations between TLRs and BV.  
M. genitalium has a large amount of lipoproteins on the cell membrane, some of which 
can interact with TLRs leading to inflammatory cytokine production (166). Although the 
possibility exists that TLRs may be associated with the pathogenesis of M. genitalium, few 
studies have examined these associations. McGowin et al found that the C-terminal portion of 
the antigenic protein encoded by MG309 activates NF-κB via TLR2 and 6, resulting in cytokine 
secretion from genital epithelial cells (166). However, the authors report that although NF-κB 
activation was observed via TLR2 alone, results were not significant and were only observed at 
the highest concentrations of M. genitalium, suggesting TLR2 homodimers are not sufficient to 
recognize the microbe (166). Further, another experimental study found that the activation of 
NF-κB by M. genitalium lipoprotein MG149 was inhibited by a dominant negative construct of 
TLR1 and TLR2 but not TLR6, thus suggesting that NF-κB is activated through TLRs 1 and 2 
(167). To date no s tudies have examined TLRs, M. genitalium and PID or subsequent 
development of sequelae 
1.2.6.3 Toll-like Receptor Polymorphisms 
Variations in TLR genes or their adaptor molecules may lead to overt or inadequate immune 
responses, possibly influencing disease progression. For the proposed research study, several 
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SNPs from four TLR genes and two adaptor molecule genes will be examined. These SNPs 
include three from TLR1 (rs5743618, rs5743817, rs4833095), three from TLR2 (rs3804099, 
rs11938228, rs1898830), three from TLR6 (rs1039559, rs5743810, rs3775073), four from TLR4 
(rs5030728, rs4986790, rs11536889, rs1927911), two from MyD88 (rs7744, rs4988457) and 
three from TIRAP or MAL (rs3802813, rs7932976, rs8177374). The exact function of these 
SNPs in reproductive health is unknown and none of these SNPs have been studied in women 
with PID. Further, very few studies have examined these SNPs to determine their role in sexually 
transmitted diseases or infertility. Although the exact function of TLR SNPs in reproductive 
health has yet to be completely elucidated, it is important to take into consideration recent 
research exploring these SNPs in other disease states in order to gain insight into the 
development and progression of gynecological diseases.  
TLR2 can recognize a variety of ligands and is considered an inducer of proinflammatory 
signaling (144). Further, TLR2 was found to increase murine oviduct pathology following 
chlamydial infection (150 151). Human studies examining TLR2 variants in PID or PID-
associated pathogens are limited. However, several TLR2 SNPs including SNP rs3804099 
(Asn199Asn) have been studied in a variety of other diseases.  Asn199Asn so far has not been 
found to be associated with atopic asthma (168), rheumatoid arthritis (169), pulmonary 
tuberculosis (TB) (170), normal tension glaucoma (171), or allergic rhinitis (172). On the other 
hand Asn199Asn has been found to be associated with the occurrence of leprosy reversal 
reaction among Ethiopian patients (173). In particular, the T allele displayed a protective effect 
under the dominant model (OR 0.34, 95%  CI 0.17-0.68; P=0.002) (173). Reversal reaction 
occurs when there is a shift in the immune system leading to increased cell mediated response 
that can eventually lead to severe tissue damage (173). In a study of 410 Chinese patients with 
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major trauma, the Asn199Asn C allele was associated with increased production of IL-10 
(P=0.002), IL-8 (P=0.004), and TNF-α (P=0.005) compared to the wild T allele (174). In 
addition, the C allele was also associated with higher sepsis morbidity rates compared to the T 
allele (P=0.004; dominant model) (174). Not surprisingly, the wild-type haplotype ATT 
(1898830A 3804099T 7656411T), which includes the T allele for Asn199Asn, was significantly 
associated with lower production of cytokines (174). This SNP was also found to be associated 
with sepsis in preterm infants using transmission disequilibrium test (175). However, when 
individual alleles were examined no s ignificant associations with sepsis were found. It was 
unclear in this study if race was considered in the allelic analyses. Further, power may have 
limited in this study. The CC genotype of this SNP has been found to be associated with 
tuberculosis meningitis among a Vietnamese population (176). This association was increased 
when the C allele interacted with TIRAP SNP 558T (OR 5.4, 95% CI 1.34-21.77; P=0.008). A 
subsequent study from this same group which examined interactions between host genotypes and 
Mycobacterium tuberculosis genotypes, reported that those who carried the C allele were more 
likely to have tuberculosis meningitis caused by the East-Asia/Beijing genotype (OR 1.57, 95% 
CI 1.15-2.15) (177). No associations were found between the development of bronchiolitis 
obliterans following lung transplantation and Asn199Asn (178). Overall the function of this SNP 
is not well understood. As this SNP is located in the exon and induces synonymous variation 
(174), it is possible that it is in linkage disequilibrium with another functional SNP.  
Fewer studies have examined the other two TLR2 polymorphisms. Rs1898830 is located 
in intron 1 a nd has no known function. No associations have been found with this SNP and 
atopic asthma (168) or normal tension glaucoma (171). Chen et al, did find an association 
between the rs1898830 G allele and increased cytokine production (IL-10; P=0.013, IL-8; 
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P=0.014, and TNF-α; P=0.018) among a Chinese population (174). However, there were no 
associations found with sepsis morbidity rates or multiple organ dysfunction scores following 
major trauma (174). The authors report that low statistical power may have limited their analysis. 
Ryckman et al examined 97 Caucasian women in their first trimester of pregnancy and reported 
the rs1898830 G allele was associated with increased IL1-α, IL-10, and IP10 (179). However, 
theses associations did not remain significant after correction for multiple comparisons. Again, 
power may have contributed to these findings. In another study among 144 pregnant Caucasian 
women, the AA genotype was not associated with Atopobium vaginae (165). In contrast, a study 
among 110 D utch lung transplant patients found that homozygotes for the major A allele for 
rs1898830 had an increased risk of bronchiolitis obliterans compared to carriers of the minor G 
allele (178). Less is known about SNP rs11938228, which is located in the intron. The function 
is unknown and only two studies have examined this SNP. In these studies no s ignificant 
associations were found with either normal tension glaucoma (171) or Behcet’s disease (180).  
TLR1 and TLR6 can both form a heterodimer with TLR2, to recognize a range of 
pathogens and activate inflammatory responses. TLR1, TLR2, TLR6, and TLR10 are all located 
on chromosome 4, w hile TLR1/TLR6/TL10 form a gene cluster that is located on the P arm 
(181). TLR1 and TLR6 are suggested to have evolved from the same orthologous gene, as they 
share 69% of their amino acid sequence (181). TLR1 SNPs have been associated with several 
diseases, while the role of TLR6 and TLR10 is less clear. 
TLR1 SNP rs5743618 (Ser602Ile), is non-synonymous and results in an amino acid 
change. The G allele has been reported to be associated with deficient TLR signaling in 
comparison to the T allele (182-185). Johnson et al, reported that the G allele displayed 
significantly lower levels of TNF-a (P<0.05) in response to a synthetic triacylated lipopeptide, 
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TLR1/TLR2 agonist Pam3CSK4 (182). Further, these authors report that among 57 Caucasians 
with leprosy and 90 asymptomatic controls, homozygous carriers of the G allele had a decreased 
incidence of leprosy (P=0.017). Similarly, the G allele was also found to be protective against 
leprosy in an Indian population consisting of 258 leprosy cases and 300 controls (OR 0.31, 95% 
CI 0.20-0.48) (186). The G allele was also protective against leprosy reversal reaction in 1171 
patients from Nepal (184). Hawn et al, reported that the T allele expressed significantly greater 
NF-κB signaling in transfected HEK293 cells compared to the G allele (183). In a subsequent 
study from this group among 638 Caucasian women, the TT genotype was found to be protective 
against pyelonephritis (OR 0.53, 95% CI 0.29-0.96) (187). In another study among patients with 
sepsis, the T allele was found to be associated with higher mortality (OR 1.79, 95%  CI 1.02-
3.13; P=0.042) (185). However, the authors suggest the T allele does not affect phenotype 
independently, as Ser602Ile is in linkage disequilibrium with TLR1 SNP rs5743551 (r2=0.76), 
which showed a much stronger association with organ dysfunction and death. This SNP was not 
found to be associated with rheumatoid arthritis (169) or invasive aspergillosis (188).  
TLR1 SNP rs4833095 (Asn248Ser), is non-synonymous and results in an amino acid 
change. Like the Ser602Ile variant, Asn248Ser may alter TLR signaling increasing the risk of 
infection. Compared to the wild-type, the A allele was found to impair TLR response to 
Pam3CSK4 (P<0.05) (189). Several diseases have been found to be associated with this variant 
(181, 182, 188, 190 -193). A study among 302 p rimiparous women from Ghana, reported that 
heterozygotes had increased risk of placental P. falciparum infection (OR 2.01, 95% CI 1.01-4.0) 
compared to carries of the wild-type, although no associations were found with low birth weight 
or preterm delivery (191). Homozygotes in this population were too few for analysis. In a 
population based case control study among 1312 tuberculosis patients and controls, the G allele 
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significantly increased risk of tuberculosis in African Americans (P=0.009) (181). Further, the 
authors found that the G allele was more frequently transmitted in diseased children compared to 
the A allele during a transmission disequilibrium test (61 vs. 38 t imes; P=0.021). In a study of 
842 leprosy patients and 543 controls from Bangladesh, the GG genotype significantly increase 
leprosy (OR 0.78, 95% CI 1.06-1.70), while the heterozygotes had a decreased leprosy risk (OR 
0.78, 95% CI 0.63-0.96) (190). However, the AA genotype was not significantly associated with 
leprosy (OR 1.01, 95% CI 0.79-1.29). Neither the A nor G allele alone significantly altered risk. 
It should be mentioned that Asn248Ser and Ser602Ile are reported to be in strong linkage 
disequilibrium with each other as well as with TLR1 SNP rs5743551, which was found to be 
associated with poor sepsis outcomes (185). These SNPs may be measuring the same 
association. Haplotypes containing these SNPs may also be responsible for the significant 
associations (185). In fact, Pino-Yanes et al, reported that the 248Ser-602Ile haplotype was 
associated with circulatory dysfunction among 218 sepsis patients (P<0.022), decreased IL-10 
(P<0.047), and increased CRP (P<0.036) (194). TLR1 SNP rs5743817 is another SNP that 
results in an amino acid change. However, the function of this SNP is unknown and no studies 
have examined it for disease associations.  
Little is known about the function of TLR6 SNP rs1039559, and so far three studies have 
failed to find any significant associations with non-Hodgkin’s lymphoma (195), Atopobium 
vaginae (165) or bronchiolitis obliterans (178). TLR6 SNP rs5743810, also known as Ser249Pro, 
is non-synonymous and results in an amino acid change. There is no association between this 
SNP and rheumatoid arthritis (169) or Atopobium vaginae (165). However, Sales et al examined 
443 hypertensive Brazilian subjects and found that the TT genotype of Ser249Pro was associated 
with reduced posterior wall thickness (P=0.02), reduced intreventricular septum thickness 
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(P=0.03), and reduced left ventricle wall thickness (P=0.02) (196). In addition the authors found 
that monocytes from hypertensive women with the TT genotype had reduced IL-6 and TNF-α 
release compared to sex matched cells carrying the C allele (P<0.05). These results were not 
observed in hypertensive men. Similarly in a study among 100 subjects from South Africa, the T 
allele of Ser249Pro was associated with decreased NF-κB signaling activity (197). The authors 
also suggested this SNP may be associated with reduced IL-6 levels in response to lipopeptide. 
However, they were unable to reproduce their results to confirm their findings (197). Tantisira et 
al, reported that the T allele decreased the risk of asthma in African Americans (OR 0.38, 95% 
CI 0.16-0.84; P=0.01), however this was not observed for European Americans (OR 0.72, 95% 
CI 0.48-1.09) (198). A study among 1,872 Germans reported that the minor allele was associated 
with an increase in atopic childhood asthma (OR 1.79, 95% CI 1.24-2.58) under the dominant 
model (168). Lastly, an American study found that at least one copy of the T allele in 
combination with at least one copy of the minor allele for TLR1 SNP Asn248Ser increased 
susceptibility to invasive aspergillosis (OR 1.30, 95%  CI 1.13-1.50) (188). This study did not 
indicate if race was considered in their analysis.  
There is no evidence that TLR6 SNP rs3775073 is associated with any disease. However, 
two studies have examined the possible functional role of this SNP. One study found that the 
rs3775073 G allele was associated with differential responses to tri-acylated lipopeptide 
Pam3CSK4, mediating a decreased effect on IL-6 (185). In contrast, Shey et al did not find this 
variant to be associated with differential response to Pam3CSK4 (197). The contradicting results 
were suggested to be a result of different methodologies and patient populations (197). One 
population was recruited from Seattle, WA (185) and the other from South Africa (197).  
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TLR4 has been one of the most studied TLR genes, recognizing a wide range of 
pathogens and playing a role in the activation of inflammatory genes. However, not all TLR4 
polymorphisms have been studied extensively. The function of TLR4 SNP rs5030728 is not well 
known and very few studies have examined this SNP to determine associations with disease. In 
one study Cheng et al examined 506 men with prostate cancer and 506 controls from hospitals in 
Cleveland, OH and found that those who carried the AA genotype for rs5030728 had a 
significantly decreased risk of prostate cancer (OR 0.60, 95% CI 0.37-0.97) compared to those 
who carried the GG genotype (199). Similarly, little is known about the function or clinical 
relevance of SNP rs11536889, which is located in the 3’UTR of the TLR4 gene. The C allele for 
this variant has been found to increase the risk of severe gastric atrophy in Japanese patients 
(200). Further, the G/C genotype was found to be associated with moderate or severe 
periodontitis (201). However, no a ssociations have been found with this variant and prostate 
cancer (199), autoimmune pancreatitis (202), or liver fibrosis (203). The minor T allele of SNP 
rs1927911, which is located in the intron, has been found to decrease the risk of myocardial 
infarction (OR 0.88, 95% CI 0.77-0.99) among 1,216 cases and 2,682 controls from Washington 
state (204). In contrast, those who carried the TT genotype were found to have increased odds of 
bronchiolitis obliterans (BOS) (OR 4.20, 95%  CI 1.43-12.35; p=0.005) among 110 l ung 
transplantation patients from the Netherlands (178). In this study the authors noted that acute 
rejection is a risk factor for BOS and reduced frequency of rejection has been shown to be linked 
to an increase in pro-inflammatory cytokines and chemokines (178). In this study, heterozygous 
carriers of the G allele for TLR4 SNP Asp299Gly had reduced risk of rejection and others have 
noted that the G allele is associated with reduced BOS (178). The G allele of Asp299Gly was 
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reported to be completely linked to the C allele of rs1927911 (D’=1). Further, carriers of the C 
allele for rs1927911 had reduced risk of BOS.   
Much more is known about TLR4 SNP rs4986790 (Asp299Gly). Asp299Gly is a 
missense mutation and it has been reported that the AG genotype decreases responsiveness to 
inhaled LPS in humans, while the wild type (AA) is capable of secreting cytokines in response to 
LPS (205). This may lower cytokine production for heterozygotes. In fact, Genc et al reported 
that women who carried the AA genotype and were colonized with G. vaginalis or gram negative 
rods had significantly higher levels of IL-1β, compared with women who carried the AG or GG 
genotypes (163). Further, a study among 115 S weedish children reported a decrease in LPS-
induced IL-12 and IL-10 among heterozygous carriers (206). An Austrian study reported no 
significant differences in early cytokine release for wild type or those with the mutant G allele 
(207). However, carriers of the G allele had significantly lower IL-6 concentrations at 6 hours, 
and lower CRP and IL-1β at 24 hours, suggesting a possible role in chronic but not acute disease 
(207). Studies have challenged the effects of Asp299Gly on LPS signaling. In a study among 80 
Scottish subjects, Erridge et al reports that heterozygotes do not exhibit reduced recognition of 
LPS after challenge from E. coli, N. meningitides, B. fragilis, Y. pestis, C. trachomatis, P. 
gingivalis, or P. aeruginosa (153). The contrasting results could be due to a possible difference 
in response by human airways vs. human monocytes (153). Further, the LPS used in the first 
study was commercial bought and may have been contaminated (153). Thus, Erridge et al 
suggested that the blunting effect was caused by another TLR4 ligand and not LPS. However in 
study among 22 Dutch subjects, van der Graaf et al reports that Asp299Gly does not influence 
the production of TNF or IL-10 when human blood cells are stimulated with a variety of 
exogenous and endogenous TLR4 ligands (208). This study had a very small number of 
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volunteers, including only one who was homozygous. In another study among 160 G erman 
subjects, von Aulock et al also reported that heterozygotes did not differ significantly from the 
wild-type for any cytokines (TNF-α, IL-1β, IL-6, INF-γ, G-CSF) (209). However, heterozygous 
subjects produced less anti-inflammatory IL-10 (P=0.002), although this was only at the highest 
concentrations.  
Similar to the controversy over the function of Asp299Gly, reports of associations with 
various diseases have also been conflicting. The Asp299Gly G allele has been found to be 
associated with increased vaginal Ph (p=0.05) and G. vaginalis (p<0.0001) among 238 pregnant 
women (163). Similar trends were observed for anaerobic Gram-negative rods, Prevotella, 
Bacteroides, and Porphyromonas, although these did not reach statistical significance (p=0.08) 
(163). In addition, an American study reported that the G allele was present in 23.8% (67/282) 
premature infants and 15.9% (55/345) term infants (p=0.024) (210). A higher frequency either 
the GG or AG genotype was also observed in singleton preterm infants (p=0.028) compared to 
term infants. The G allele was also identified in 24.2% (15/62) of mothers with a preterm infant 
and 15.0% (3/20) of mothers with a term infant, although results were not significantly different. 
In a South American study also examining fetal genotype, Asp299Gly was not associated with 
preterm birth (OR 0.99, 95%  CI 0.6-1.7) (211). However, significant associations were found 
between heterozygous carriers and premature rupture of membranes (PROM) among severely 
premature infants (< 33 weeks gestation) (OR 4.6, 95% CI 1.2-16.6; p=0.032). In contrast, there 
was no association between the G allele and PROM among 131 African American premature 
infants (< 37 weeks gestation) and 246 controls (212). Severe premature birth was not examined 
in that study. Further, none of the 3 s tudies examined associations with maternal genotype. 
Among 115 S wedish children, this variant was associated with asthma (OR 4.5, 95%  CI 1.1-
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17.4) (206). Associations have also been found with septic shock and gram negative infections 
(213), as well as an increased risk of gram negative infections in critically ill patients (p=0.004) 
(214). In a Dutch study, Asp299Gly was not associated with susceptibility to C. trachomatis 
(157). However, subfertile women with tubal infertility who were positive for C. trachomatis 
immunoglobulin (Ig) G were twice as likely to be carriers for the mutant Asp299Gly allele. 
These results were not statistically significant. No significant associations have been found 
between this variant and rheumatoid arthritis (169, 215, 216) , systemic lupus erythematosus 
(216), meningococcal disease (155), aspergillosis (188), or atopic dermatitis (217).  
TLR adaptor molecules such as TIRAP and MyD88 are critical for innate immune 
response. Variations in these receptors may also affect TLR signaling. Unfortunately, little is 
known about the function and clinical relevance of most of these SNPs. In 187 rheumatoid 
arthritis patients from the United Kingdom, the MyD88 SNP rs7744 G allele was associated with 
response to anti-TNF treatment (218). Specifically, the GG genotype was associated with greater 
improvement (OR 1.5, 95% CI 1.1-2.3; p=0.020) (218). However, as this was an exploratory 
analysis no correction for multiple testing was made. The rs7744 SNP is located in the 3’UTR 
and was suggested to influence mRNA stability (218). On the other hand, this SNP is also in LD 
with rs156265, which may influence gene expression (218). MyD88 SNP rs4988457 was not 
found to be associated with Hodgkin’s lymphoma (219). No other studies to our knowledge have 
examined either rs7744 or rs4988457. Two SNPs in the TIRAP gene, rs3802813 and rs7932976 
also have no supporting studies to determine possible function or clinical relevance.  However, 
rs7932976 is a missense mutation that results in an amino acid change (Val197Ile). Therefore, 
Val197Ile may be a functional variant. TIRAP SNP rs8177374, also known as Ser180Leu, has 
been studied more extensively. This variant is thought to attenuate TLR2 signal transduction and 
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suggested that homozygotes have an over-active response, resulting in more severe outcomes 
(220). Heterozygous carriers of this variant were found to have a reduced risk of invasive 
pneumococcal disease (OR 0.59, 95%  CI 0.42-0.83, p=0.003) bacteraemia (OR 0.40, 95%  CI 
0.21-0.77, p=0.003), malaria (OR 0.47, 95% CI 0.28-0.76, p=0.002), and tuberculosis (OR 0.23, 
95% CI 0.07-0.73, p=0.008) among 6,106 subjects from Gambia, Kenya, the United Kingdom, 
and Vietnam (220). The T allele was also found to be protective against systemic lupus 
erythematosus (SLE) (OR 0.29, 95% CI 0.14-0.61; p=0.0002) and TB (OR 0.53, 95% CI 0.29-
0.97; p=0.04) in a case-control study among 1325 Columbians (221). Genotype analysis show 
that the CT genotype was protective against SLE (OR 0.27, 95% CI 0.13-0.57; p=0.0002) and 
TB (OR 0.50, 95% CI 0.27-0.94; p=0.03) compared to the CC genotype. The T allele was shown 
to have significantly increased cytokine production (TNF, IFN-y, and IL-6), indicating a 
protective effect against infection (222).  
As the function and clinical relevance of many of these polymorphisms remains unknown 
it is imperative the research continue to examine TLR and adaptor molecule SNPs in disease 
progression and inflammatory response. Contrasting findings in some of these association studies 
is likely a result of different patient populations, differences in gender or ethnicity, differences in 
doses, differences in heterogeneity, population stratification, population admixture, and/or 
chance findings. SNPs which result in an amino acid change may alter the function of TLR 
signaling and downstream cytokine responses. Those that do not result in an amino acid change 
may still be responsible for disease pathogenesis. However, it is possible that some of these 
SNPs are in linkage disequilibrium with a disease variant. Research should continue to delineate 
whether these SNPs are in proximity of a d isease variant or have their own functional 
consequences.  
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1.2.7 Summary 
Organisms such as Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium and 
anaerobic bacteria associated with bacterial vaginosis are prevalent and can lead to PID, and in 
turn major reproductive morbidity such as infertility, ectopic pregnancy, and chronic pelvic pain. 
The role of individual microbes in the development of sequelae following PID is not well 
understood. C. trachomatis is often asymptomatic and chlamydial salpingitis clinical 
manifestations are reported to be mild but associated with severe tubal damage. In contrast, 
gonococcal salpingitis may produce more overt and severe symptoms but leads to milder tubal 
damage. Studies have consistently reported similar symptoms between C. trachomatis and M. 
genitalium. Therefore, many women with C. trachomatis or M. genitalium may have chronic low 
level inflammation which could permanently damage the reproductive tract before treatment is 
initiated. In fact, delayed care has been implicated as a predictor of impaired fertility following 
PID, with the strongest association among women with C. trachomatis. However, these 
associations have not been replicated in a contemporary cohort and the distribution of microbes 
appears to have changed over time.  
Variability exists in the course and outcome of C. trachomatis. For example, 80% or 
more of women with chlamydia do not develop PID and not all women with chlamydial PID go 
on to develop reproductive morbidity. It is suggested that differences in C. trachomatis 
progression may be explained by variations in host genetic genes. Further, chlamydial 
pathogenesis has been suggested to be immunologically driven. However, the role of host 
immunity in the pathogenesis of C. trachomatis has not been extensively studied. Gaps in our 
knowledge of the natural history of C. trachomatis have made management and control a 
challenge. Examining the role of innate immune genes is important to further understand the 
 49 
pathogenesis of C. trachomatis and may bring researcher closer to developing a safe and 
effective vaccine. The proposed specific aims were designed to examine the role of innate 
immune receptor genes in endometritis, C. trachomatis, and infertility among women with PID. 
Further, the role of delayed care seeking in a contemporary cohort of women with clinically 
suspected PID will be examined.  
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2.1 ABSTRACT 
Objective: We studied the microbial correlates of time to care and long term outcomes among 
pelvic inflammatory disease (PID) patients, as delayed care may increase the risk for 
reproductive sequelae. 
Methods: Mean days of pain prior to care were compared by microbial pathogen (Chlamydia 
trachomatis only, Neisseria gonorrhoeae only, Mycoplasma genitalium only, co-infection with 
two or more pathogens, or no pathogens) among 298 w omen with histologically confirmed 
endometritis from the PID Evaluation and Clinical Health (PEACH) study. Times to pregnancy 
and recurrent PID were assessed over a mean of 84 months and compared between women who 
delayed care (≥14 days) and women who sought early care, in the entire cohort and in subsets 
defined by microbial infection. Analyses were adjusted for age and race, additionally time to 
pregnancy was adjusted for self-reported baseline infertility.  
Results: Patients waited a mean of 7 days before seeking care for symptoms. Time to care was 
longest among women infected by C. trachomatis only (12.3±9.4 days) and M. genitalium only 
(10.9±8.9 days) and the shortest among women infected by N. gonorrhoeae only (4.6±5 days) or 
co-infection (5.6±5.1 days, p<0.001). Rates of infertility, recurrent PID, and chronic pelvic pain 
were frequent overall (17%, 20%, and 36%) and tended to be higher, albeit non-significantly, 
after delayed care. 
Conclusions: Among women with clinically suspected PID, time to care was generally high. C. 
trachomatis and M. genitalium positive women had the longest times to care. Although 
reproductive morbidity was high in this cohort, associations with delayed care were non-
significant. 
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2.2 INTRODUCTION 
Pelvic Inflammatory Disease (PID), infection and inflammation of the female upper genital tract 
(1), is a common condition affecting an estimated 8% to 11% of American women at some time 
in their reproductive lives (4). Approximately 1 million women will be treated annually for PID 
in the United States (5). Various organisms have been implicated in the etiology of PID 
including Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium and 
anaerobic bacteria associated with bacterial vaginosis (5).  
PID is a d isease that can cause serious reproductive morbidity. In a landmark 
Scandinavian cohort study conducted between 1960 and 1984 (2, 3), of 2500 w omen with 
clinically suspected PID, 16% with laparoscopically verified salpingitis versus 2.7% of controls 
became infertile (2, 3). In addition, 20% and 25% with salpingitis developed recurrent PID and 
chronic pelvic pain respectively (2, 3).  
  Hillis et al reported that one strong predictor of sequelae following PID is delayed care 
(9). In this case-control study nested within the Scandinavian cohort (2), delayed care was 
associated with a three-fold increase in infertility or ectopic pregnancy among 714 women with 
one known episode of PID (9). Further, the association was strongest among 114 women infected 
with C. trachomatis, with 17.8% of C. trachomatis positive women who delayed seeking care 
experiencing impaired fertility compared to 0% who sought care promptly (9). As these 
associations have not been replicated in a contemporary cohort, and since the distribution of 
microbes among women with PID appears to have changed over time, our objective was to 
examine the microbial correlates of time to treatment and long term outcomes among PID 
patients. 
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2.3 METHODS 
This study utilized data from the PID Evaluation and Clinical Health (PEACH) study. This was 
the first randomized clinical trial to compare inpatient and outpatient treatment in preventing 
long-term complications among 831 women with mild to moderate PID. The methods of subject 
recruitment, data collection, and follow-up have been reported elsewhere (87). Briefly, between 
March 1996 a nd February 1999 w omen aged 14-37 years were recruited from emergency 
departments, obstetrics and gynecology clinics, sexually transmitted disease clinics, and private 
practices at 7 primary and 6 secondary sites throughout the eastern, southern, and central regions 
of the United States. Women who had suspected PID and gave informed consent were eligible 
for the PEACH study. Eligible women had a history of pelvic discomfort for less than 30 days, 
findings of pelvic organ tenderness (uterine or adnexal) on b imanual examination, and 
leukorrhea and/or mucopurulent cervicitis and/or untreated but documented gonococcal or 
chlamydial cervicitis. The University of Pittsburgh Institutional Review Board approved the 
study. 
 A total of 2941 women were screened for study entry, of those 346 (11.8%) did not meet 
the clinical inclusion criteria for randomization. Women were additionally excluded if they were 
pregnant (n = 141, 4.8%); had taken antimicrobials within the past 7 days (n = 248, 8.4%); had a 
history of hysterectomy or bilateral salpingectomy (n = 248, 8.4%); had an abortion, delivery, or 
gynecologic surgery within the past 14 da ys (n = 51, 1.7% ); had a suspected tubo-ovarian 
abscess or other condition requiring surgery (n = 191, 6.5% ); had an allergy to the study 
medications (n = 163, 5.5%); were homeless (n = 29, 1% ); or had vomiting after a trial of 
antiemetic treatment (n = 11, 0.4%).  A total of 831 women were enrolled in the PEACH study. 
Our analyses are among 298 w omen with histologically confirmed endometritis and complete 
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time to treatment data. These women did not differ on i mportant demographic, clinical, and 
behavioral characteristics compared to women without complete data. Among our cohort, 251 
had N. gonorrhoeae culture, 271 had C. trachomatis polymerase chain reaction (PCR) and 240 
had M. genitalium PCR results available for analysis. 
 Women were randomized to either inpatient treatment of intravenous cefoxitin every 6 
hours and doxycycline orally twice a day for 14 days; or outpatient treatment consisting of a 
single intramuscular injection of cefoxitin and oral doxycycline twice a day for 14 days. Because 
the treatment modality was not associated with reproductive morbidities in the PEACH study 
(87), we do not include them as a covariate in these analyses. Participants were followed-up with 
in-person visits at 5 and 30 days after treatment. At the 30-day follow-up the gynecological exam 
was repeated. Telephone follow-ups were conducted by the study nurses every 3 months during 
the first year after enrollment and then every 4 months until June 2004. At that point information 
was obtained by self-report for 69.1% of the cohort, with a mean follow-up of 84 months.  
 A pelvic examination and interview were conducted at the baseline visit. The interview 
collected information on r eason for visit, brief pain history, demographics, history of 
PID/sexually transmitted diseases (STDs), sexual and contraceptive history, reproductive 
decisions, douching history, pregnancy history, medical and gynecological history and lifestyle 
habits. Baseline demographic and clinical characteristics used in this analysis included age, race, 
marriage, education, insurance utilization, microbiological etiology, clinical findings (abnormal 
vaginal discharge, elevated temperature (>100.4oF), elevated white blood cell count (WBC) (> 
10,000mm3), and bilateral adnexal tenderness), smoking, drug use, history of PID, history of 
bacterial vaginosis, history of C. trachomatis, history of N. gonorrhoeae, and history of pelvic 
surgery. Data on prior M. genitalium infection was not available. Follow-up interviews collected 
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self-reported information on pe lvic pain, pregnancy and births, signs and symptoms of PID, 
STDs, contraceptive use, pattern of sexual intercourse, and health care utilization.   
Gynecological examinations were performed at baseline and 5 and 30 days post 
treatment. Vaginal smears were gram stained for bacterial vaginosis in a cen tral laboratory by 
standardized methods described by Nugent et al (223). Endometrial biopsy specimens were 
obtained for histological examination including, chlamydial PCR and gonococcal culture. PCR 
and cultures were performed at a central reference laboratory. For the patients with endometrial 
biopsies, two reference pathologists separately evaluated at least one section stained with 
hematoxylin and eosin and at least one stained with methyl green pyronine. Disagreements about 
the presence or absences of neutrophils and plasma cells were settled by both pathologists 
reading the slides together and coming to an agreement. Histological endometritis was based on 
a modification of the criteria proposed by Kiviat et al (224). Endometritis was defined as the 
presence of at least five neutrophils in the endometrial surface epithelium in the absence of 
menstrual endometrium and/or at least two plasma cells in the endometrial stroma. Cervical and 
endometrial specimens were stored and later used to test for M. genitalium (8), using a 
microwell-plate-based PCR assay (MgPa-IMW) targeting the MgPa gene (225). 
In the current paper, the main outcome variable is delayed care. Sensitivity analyses were 
conducted to define delayed care in our cohort. Participants were considered to have delayed 
care if they reported that treatment was sought after having pain between14 and 30 days (n = 70), 
as women with over 30 days of pain were not included in PEACH. Participants who sought 
treatment before experiencing 14 da ys of pain were considered to have sought early care (n = 
228). The variable was categorized by using the 75th percentile of the distribution of the days 
until treatment reported during the baseline questionnaire.   
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 Reproductive outcomes included pregnancy, infertility, live birth, recurrent PID, and 
chronic pelvic pain. Self-reported pregnancy was determined by a positive urine/blood test or 
physician’s diagnosis. Pregnancy was determined among women reporting no bi rth control or 
methods considered being unreliable, including withdrawal, rhythm method, vasectomy, or using 
the following methods rarely or occasionally – diaphragm, condoms, spermicidal 
foam/cream/jelly/suppositories, or cervical cap. Infertility was defined by lack of conception 
(positive urine test or blood test or doctor’s diagnosis of pregnancy) despite sexual activity with 
rare or never use of methods of contraception considered reliable during 12 or more months of 
follow-up. Frequency of sexual activity did not differ significantly between groups (P = 0.6180). 
Live birth was determined by self-report, and recurrent PID was self-reported and verified 
whenever medical records were available (45% of cohort). Recurrent PID was confirmed in 76% 
of medical records. Chronic pelvic pain was defined by two or more consecutive reports of 
pelvic pain during follow-up. Data from at least 2 follow-up visits were required to determine 
chronic pelvic pain. 
 Frequencies of baseline characteristics including age, race, marriage, education, 
insurance, microbiological etiology, vaginal discharge, temperature, elevated WBC, bilateral 
adnexal tenderness, smoking, drug use, and gynecological history were compared between 
patients seeking delayed care or early care, using the X2 test of proportions. 
Delayed care was compared among the following groups; women with C. trachomatis 
identified in the cervix and/or endometrium who had test results that were negative for both N. 
gonorrhoeae and M. genitalium, women with N. gonorrhoeae identified in the cervix and/or 
endometrium who had test results that were negative for both C. trachomatis and M. genitalium, 
women with M. genitalium identified in the cervix and/or endometrium who had test results that 
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were negative for both C. trachomatis and N. gonorrhoeae, and women with co-infection with 
two or more of these organisms. A total of 188 women had complete data on all three organisms. 
Important demographic, behavioral, and clinical characteristics of these women did not differ 
from women without complete data on all three organisms. Kruskal Wallis test was used to 
compare the mean time to treatment between microbial pathogens. Cox regression models were 
used to compare times to pregnancy and times to recurrent PID between groups among the entire 
cohort and by groups defined by microbial pathogen. All models were adjusted for race and age, 
and models predicting infertility, pregnancy, and live birth were additionally adjusted for self-
reported infertility at baseline.  All analyses were conducted using SAS Version 9.2 (Cary, NC).  
2.4 RESULTS 
Treatment group, age, education, marriage, insurance, vaginal discharge, elevated temperature, 
history of PID, history of bacterial vaginosis, history of C. trachomatis, history of N. 
gonorrhoeae, history of pelvic surgery, and behavioral characteristics did not differ significantly 
between groups (Table 1).  Women with delayed care (n = 70) compared to women with early 
care (n = 228) were significantly less likely to be black (68.6% vs. 82%; p = 0.016), less likely to 
have an elevated WBC count (26.3% vs. 43.9%; p =  0.017), and less likely to have bilateral 
adnexal tenderness (74.3% vs. 85.1%; p = 0.037).  
Time to care varied within our cohort, ranging from 1 to 30 days. Overall, women waited 
a mean of 7 days before seeking care for symptoms. The mean time to treatment differed 
significantly between microbial pathogen (p<0.0001), with those who had C. trachomatis 
monoinfection exhibiting the longest time to treatment (12.3 days) followed by patients with M. 
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genitalium monoinfection(10.86 days), co-infection patients (5.56 days), and patients with N. 
gonorrhoeae monoinfection (4.56 days; Table 2). Women who tested negative for all three 
pathogens delayed care for 8.83 da ys. While these women tested negative for all three of our 
pathogens, we cannot rule out that they aren’t infected with other pathogens which were not 
tested for or tested negative due to a small pathogen load. Pairwise comparisons revealed that 
time to care among patients with C. trachomatis monoinfection significantly differed from N. 
gonorrhoeae monoinfection and co-infection (p<0.05), but not M. genitalium monoinfection. 
Similarly, M. genitalium monoinfection significantly differed from N. gonorrhoeae 
monoinfection and co-infection (p<0.05), but not C. trachomatis monoinfection. 
Among women with co-infection, those infected with both C. trachomatis and M. 
genitalium, but not N. gonorrhoeae, had the longest times to treatment (6.8±5.7 days), followed 
by infection with both C. trachomatis and N. gonorrhoeae, but not M. genitalium, (5.8±5.6 
days), infection with both N. gonorrhoeae and M. genitalium, but not C. trachomatis, (4.7±3.7 
days), and co-infection with all three pathogens (2.7±1.7 days). Results were non-significant 
(p=0.6638). Pairwise comparisons revealed similar but non-significant results. 
Microbial correlates of participants presenting for care differed significantly between 
groups (p = 0.006; Table 3). Compared to women with prompt care those who delayed care were 
more likely to have C. trachomatis (23.8% vs. 8.9%) or M. genitalium (7.1% vs. 2.7%) 
monoinfection. In contrast, women with delayed care were less likely to be infected with N. 
gonorrhoeae alone (9.5% vs. 28.8%) or to be co-infected with two or more pathogens (19.1% vs. 
28.8%).   
Although infertility, recurrent PID, and chronic pelvic pain were frequent overall (17%, 
20%, & 36%), rates did not significantly differ between women with delayed care and early care. 
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In the entire cohort, there was a non-significant decrease in pregnancy rates (adjusted hazards 
ratio (AHR) 0.79, 95% CI 0.55-1.13) and increase in recurrent PID (AHR 1.46, 95% CI 0.83-
2.58) among women who delayed care. Among C. trachomatis patients there was a 6-fold 
increase in recurrent PID among those who delayed care (AHR 6.11, 95% CI 0.21-187.41), 
although this was non-significance. A non-significant increase in recurrent PID was also 
observed among M. genitalium (AHR 1.59, 95% CI 0.02-125.52) and N. gonorrhoeae (AHR 
1.23, 95% CI 0.15-10.05) patients who delayed care. However, the sample size was small for 
monoinfections, limiting our power and resulting in large confidence intervals.  
2.5 DISCUSSION 
In this cohort of women with mild to moderate PID, times to care varied by pathogen, with the 
longest times among women with C. trachomatis monoinfection, followed by M. genitalium 
monoinfection, and the shortest times among women with N. gonorrhoeae monoinfection and 
co-infection with two or more pathogens. Overall, rates of infertility, recurrent PID, and chronic 
pelvic pain were high in our cohort.  
Our findings demonstrate that women infected with C. trachomatis monoinfection had 
the longest times to care following the onset of pelvic pain. This is similar to Hillis et al. who 
reported that C. trachomatis was associated with delayed care (OR 2.1, 95% CI 1.0-4.1) (9). Our 
results indicate trends towards decreased pregnancy rates and increased recurrent PID. This is 
similar to Hillis et al, who found that delayed care was associated with impaired fertility (OR 
2.8, 95% CI 1.3-6.1) (9). In contrast to Hillis et al. our results were non-significant.  
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There are several possible explanations for these not entirely concordant results. Our 
sample size limited the power of our analysis. Further, our population of women is likely a 
different patient population than the Scandinavian women recruited a generation ago. In addition, 
endometrial histology was used to confirm PID in our study, whereas 1,844 patients in the 
Westrom study had laparoscopically confirmed salpingitis (2). Although, the use of 
histologically confirmed endometritis to diagnose PID is an appropriate alternative to 
laparoscopy (5), not all women with endometritis have salpingitis (1). Salpingitis may indicate 
more severe disease and lead to tissue damage, while endometritis may have lesser effects on 
tubal pathology (1). In fact, endometritis was previously reported to not be associated with 
reproductive morbidity in the PEACH study (1).  
Lastly, our studies differed in our definition of delayed care. Hillis et al. defined delayed 
care as 3 or more days of pain before seeking treatment. This cut-point was not appropriate for 
our population as 76% of patients delayed care for 3 days or more and waited a mean of 7 days 
before seeking treatment. We ran several sensitivity analyses and using a definition of 3 or more 
days of pain before seeking care did not change our results.   
Our finding that patients with chlamydial or M. genitalium-associated PID were more 
likely to delay care was not surprising. Among women with PID, pelvic pain may be mild or 
absent (55), and PID symptoms vary by microbial etiology (108, 36, 109, 110). Chlamydial 
infections are known to elude detection because they produce few or no symptoms or because 
the symptoms are non-specific (111). Further, in chlamydial salpingitis, clinical manifestations 
are often mild but associated with severe tubal damage (36). This is in contrast to gonococcal 
salpingitis which produces more overt and severe inflammation and symptoms but leads to 
milder disease (36).  
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We found that the time to treatment for M. genitalium was similar to that of C. trachomatis. This 
finding is consistent with other studies reporting similar symptoms between C. trachomatis and 
M. genitalium (109, 110). This may indicate that among women with PID, those infected with N. 
gonorrhoeae or co-infection present with more overt and severe symptoms, leading to earlier 
treatment than women with C. trachomatis or M. genitalium. Indeed we found that the clinical 
characteristics such as elevated temperature, elevated WBC count, and bilateral adnexal 
tenderness were lower among women who delayed care compared to those who presented with 
prompt care. 
The role of individual microbes in the development of sequelae following PID is not well 
understood.  In the PEACH study, approximately 6% of participants had N. gonorrhoeae or C. 
trachomatis and 45.9% had persistent endometritis at the 30-day follow-up following baseline 
treatment with cefoxitin and doxycycline (87). Despite demonstrated efficacy of this Centers for 
Disease Control recommended regimen (6), there may be several reasons for long term sequelae 
in some patients. First, as patients with chlamydial or M. genitalium infection were more likely 
to delay care, persistent, low level inflammation may have caused permanent damage to the 
reproductive tract prior to enrollment. Further M. genitalium is resistant to tetracycline and lacks 
the cell wall target of cefoxitin (8). Not surprisingly, PEACH study patients with endometrial M. 
genitalium were previously reported to suffer treatment failure (8). Although the effect of delayed 
care on sequelae among microbial subgroups was non-significant, rates of sequelae were high. 
Our study has several strengths. First, data were obtained from a large, multicentre, 
prospective randomized clinical trial, with comprehensive demographic, clinical, and obstetric 
measurements. Further, our findings are generalizable to patients treated for clinically suspected 
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PID.  We recognize that timing of treatment was based on self-reported data and that 
misclassification bias is possible.  
Our study demonstrates that among patients with clinically suspected PID, those infected 
with C. trachomatis and M. genitalium were more likely to delay care compared to those with 
gonococcal infection, possibly increasing the likelihood that persistent, low level inflammation 
may permanently damage the reproductive tract before patients seek care.  Our findings could be 
translated to a population with uncomplicated sexually transmitted infections, where those 
infected with C. trachomatis and M. genitalium may be more likely to delay or not seek 
treatment, putting them at higher risk for PID and its sequelae. Thus continued efforts aimed at 
early identifications and treatment of asymptomatic, mildly symptomatic, and symptomatic 
lower genital tract infections are needed for the prevention and progression to PID and its 
associated long term morbidities.  
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2.6 TABLES 
 
Table 1. Baseline characteristics of participants presenting for care 
 
Characteristics Delayed Care ( ≥ 14 days) 
N = 70 
n (%) 
Early Care ( < 14 days  
N = 228 
n (%) 
*p-value 
Treatment Groups 
Inpatient 
Outpatient 
31 (44.3) 
39 (55.7) 
121 (53.1) 
107 (46.9) 
0.198 
Demographics    
Age 
<25 years 
25+ years 
 
52 (74.3) 
18 (25.7) 
 
158 (69.3) 
70 (30.7) 
 
0.423 
Race/Ethnicity 
African American 
White/Hispanic/Other 
 
48 (68.6) 
22 (31.4) 
 
187 (82) 
141 (18) 
 
0.016 
Married 7 (11.3) 14 (6.7) 0.231 
Education 
Less than high school 
High school or greater 
 
30 (72.7) 
40 (57.1) 
 
103 (45.2) 
125 (54.8) 
 
0.732 
Uninsured 36 (58.5) 114 (54.3) 0.599 
Clinical Findings    
Abnormal vaginal discharge 
Temperature (>100.4 F) 
47 (24.4) 
3 (4.7) 
23 (21.9) 
26 (11.9) 
0.634 
0.095 
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WBC (> 10,000 mm3) 
Bilateral adnexal tenderness 
15 (26.3) 
52 (74.3) 
86 (43.9) 
194 (85.1) 
0.017 
0.037 
Gynecological History 
History of PID 
**History of BV 
History of C. trachomatis 
History of N. gonorrhoeae 
§History of pelvic surgery 
16 (23.5) 
15 (21.7) 
22 (31.9) 
24 (34.3) 
14 (20.0) 
53 (23.8) 
43 (19.5) 
100 (45.1) 
60 (26.8) 
51 (22.4) 
0.968 
0.679 
0.053 
0.225 
0.650 
Behavioral 
Current smoker 
Drug use 
33 (47.1) 
21 (30) 
113 (49.8) 
67 (29.5) 
0.699 
0.938 
*Chi-square was used to derive the p-value 
**History of bacterial vaginosis (BV) 
§Self-reported prior pelvic surgeries including but not limited to: Appendix, Bartho cyst, tubal, ovarian, 
uterine, fiscular, hernia, and colopscopy. 
 
 
 
 
 
 
 
 
 
Table 1. continued 
 65 
Table 2. Mean time to treatment by organism 
 
Organism Days of pain 
Mean±SD 
*p-value 
C. trachomatis Only  (N=23) 12.3±9.35 <.0001 
M.  genitalium Only  (N=7) 10.86±8.90 
N. gonorrhoeae Only (N=45) 4.56±4.97 
**Co-Infection  (N=50) 5.56±5.11 
None  (N=63) 8.83±8.95 
*Kruskal Wallis test was used to derive the p-value. 
* *Co-infection – participants with any combination of two or more of the following pathogens: C. 
trachomatis, N. gonorrhoeae, or M. genitalium 
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Table 3. Microbial correlates of participants presenting for care ≥14 days 
 
Organism Delayed Care ( ≥14 days) 
*N=42 
n (%) 
Early Care ( < 14 days) 
*N=146 
n (%) 
**p-value 
C. trachomatis Only  (N=23) 10 (23.8) 13 (8.9) 0.0186 
M.  genitalium Only  (N=7) 3 (7.1) 4 (2.7) 0.1551 
N. gonorrhoeae Only (N=45) 4 (9.5) 41 (28.8) 0.0122 
§Co-Infection  (N=50) 8 (19.1) 42 (28.8) 0.2090 
None  (N=63) 17 (40.5) 46 (31.5) 0.4613 
*A total of 188 women had data on C. trachomatis, M. genitalium, and N. gonorrhoeae combined.  
**Chi-square was used to derive the p-value  
§Co-infection – participants with any combination of two or more of the following pathogens: C. 
trachomatis, N. gonorrhoeae, or M. genitalium 
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3.1 ABSTRACT 
Background: Toll-like receptors (TLR) initiate microbial elimination through induction of 
inflammatory responses. As genetic variations may alter TLR signaling, we explored the role of 
TLR variants in Chlamydia trachomatis (CT) and endometritis among women with pelvic 
inflammatory disease (PID).  
Methods: We determined if 18 tagging single nucleotide polymorphisms (tagSNP) assayed in 4 
TLR genes (TLR1, TLR2, TLR4, TLR6) and 2 adaptor molecules (TIRAP, MyD88) were 
associated with CT or endometritis, among 205 African Americans with clinically suspected PID 
from the PID Evaluation and Clinical Health Study. Logistic regression was used to calculate 
odds ratios (OR) and 95% confidence intervals (CI). An empirical p-value of <0.004 was 
considered significant. Haplotype analyses were performed in SAS/Genetics v9.1.3. 
Results: Women with PID who carried the TLR4 rs1927911 CC genotype had increased odds of 
CT (case:control frequency = 36:14; OR 3.7, 95% CI 1.6-8.8; p=0.002). The TLR1 rs5743618 
TT genotype was also associated with CT (84:65; OR 2.8, 95%  CI 1.3-6.2), but not after 
permutations (p=0.008). Haplotype analysis revealed that the TLR4 GAC haplotype was more 
frequent in CT negative women (0.59:0.43; p=0.012). In contrast, the TLR4 GAT haplotype and 
the TLR1 TGT haplotype (0.15:0.07; p=0.04) were more frequent in CT positive women 
(0.19:0.10; p=0.04). No significant associations were found between any TLR or adaptor 
molecule SNP and endometritis.  
Conclusions: Among African American women with PID, variants in the TLR1 and TLR4 genes 
were associated with increased CT. Genetic variations in these TLR genes may increase 
signaling, possibly leading to upper genital tract inflammation. 
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3.2 INTRODUCTION 
Chlamydia trachomatis is the most common bacterial sexually transmitted infection in the 
United States (10), and can lead to serious complications such as pelvic inflammatory disease 
(PID) and its subsequent sequelae including ectopic pregnancy, infertility, and chronic pelvic 
pain (2, 3). C. trachomatis can be asymptomatic in up to 80% of women, making diagnosis and 
management a challenge (226). Further, rates of progression from C. trachomatis infection to 
PID vary widely, and can range from 2-4.5% in asymptomatic populations (10, 13-15). As the 
mechanisms underlying the pathogenesis of C. trachomatis have yet to be completely elucidated, 
the reasons for this variability are unknown. It is widely thought that chlamydial pathogenesis is 
driven by inflammatory responses (36, 137), especially among those with chronic or persistent 
infections. Thus, variations in host innate immune receptor genes may not only play a role in 
chlamydia pathogenesis but may explain the wide variability in the course and outcome of 
infection.  
The innate immune system serves as the first line of defense after exposure to pathogens 
and depends on pa ttern recognition receptors (PRRs) for microbial recognition (121-123). A 
conserved family of PRRs called the Toll-like receptor (TLR) family (122) is responsible for 
microbial elimination through induction of inflammatory cytokine and chemokine genes, as well 
as the priming of the adaptive immune system. Ten different TLRs (TLRs 1-10) have been 
identified in humans and the overlap between them allows identification of a diverse range of 
pathogens through ligand binding (121-123). Adaptor molecules including myeloid 
differentiation primary response protein 88 (MyD88) and TIR domain-containing adaptor protein 
(TIRAP or MAL) help to mediate TLR signaling (123, 127). However, as important as TLRs and 
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their adaptor molecules are for a healthy immune response, variations in these genes may lead to 
an overt or inadequate inflammatory response, possibly playing a role in disease progression. 
Studies have shown that TLRs 2 and 4 can bind to several possible chlamydial ligands 
(138-143), thus making them likely candidates for C. trachomatis recognition. TLR4 may be 
able to bind to Lipopolysaccharide (LPS) and chlamydia heat shock protein 60 (cHSP60) (138). 
TLR2 can dimerize with TLRs 1 a nd 6, t o recognize a more diverse range of ligands (144) 
including lipoproteins, lipopeptides, lipoteichoic acid, and bacterial prion (139-143). Still, the 
exact function of TLRs in C. trachomatis infection is unclear. O’Connell et al, using an 
experimental model to examine the role of TLRs in early infection, found that TLR2 was 
required for IL-8 expression, while TLR4/MD-2 had minimal effects on cytokine production 
(149). Further, TLR2 and MyD88 both localized within chlamydia inclusions during active 
infection (149). Darville et al, using a murine model, found that TLR2 signaling is necessary for 
the development of oviduct pathology and excessive cytokine production following chlamydial 
genital infection, while TLR4 has similar outcomes in TLR4 knockout mice (150). These studies 
may suggest that TLR2 is primarily responsible for signaling following C. trachomatis infection.  
Several TLR SNPs have been found to be associated with inflammatory and infectious 
diseases (163, 173, 176,  186, 199) . However, very few epidemiologic studies have examined 
TLRs in C. trachomatis pathogenesis. One group of researchers that conducted several limited 
studies among Dutch Caucasian populations has been unable to show any significant associations 
between innate immune receptor functional single nucleotide polymorphisms (SNPs) and C. 
trachomatis (154, 157, 158). One study among 48 women who were positive for C. trachomatis 
IG antibodies, found no significant associations between TLR4 SNP Asp299Gly (rs4986790) 
and tubal factor infertility (154). Similarly, in another study from this group Asp299Gly was not 
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associated with C. trachomatis susceptibility or subsequent pathology among 614 s exually 
transmitted disease (STD) patients (157). Karimi et al, examined the role of two TLR2 SNPs 
(rs5743708 and rs4696480) in 468 D utch women (158), and found no a ssociations with C. 
trachomatis infection (158). These homogenous Dutch populations may not be generalizable to 
more diverse populations of women with STDs in the United States.  
Our objective was to explore the role of TLR1, TLR2, TLR4, TLR6, MyD88, and TIRAP 
gene polymorphisms in C. trachomatis among African American women with clinically 
suspected PID. Further, to explore SNP associations with upper genital tract inflammation, we 
also used histologically confirmed endometritis as an outcome. As few studies have examined 
these associations, there is an opportunity to provide novel information regarding the 
pathogenesis of C. trachomatis. 
3.3 METHODS 
This study utilized data from the PID Evaluation and Clinical Health (PEACH) study. This was 
the first randomized clinical trial to compare inpatient and outpatient treatment in preventing 
long-term complications among 831 women with mild to moderate PID. The methods of subject 
recruitment, data collection, and follow-up have been reported elsewhere (87). Briefly, between 
March 1996 a nd February 1999 w omen aged 14-37 years were recruited from emergency 
departments, obstetrics and gynecology clinics, sexually transmitted disease clinics, and private 
practices at 7 primary and 6 secondary sites throughout the eastern, southern, and central regions 
of the United States. Women who had suspected PID and gave informed consent were eligible 
for the PEACH study. Eligible women had a history of pelvic discomfort for less than 30 days, 
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findings of pelvic organ tenderness (uterine or adnexal) on b imanual examination, and 
leukorrhea and/or mucopurulent cervicitis and/or untreated but documented gonococcal or 
chlamydial cervicitis. The University of Pittsburgh Institutional Review Board approved the 
study. 
A total of 2941 women were screened for study entry, of those 346 (11.8%) did not meet 
the clinical inclusion criteria for randomization. Women were additionally excluded if they were 
pregnant (n = 141, 4.8%); had taken antimicrobials within the past 7 days (n = 248, 8.4%); had a 
history of hysterectomy or bilateral salpingectomy (n = 248, 8.4%); had an abortion, delivery, or 
gynecologic surgery within the past 14 da ys (n = 51, 1.7% ); had a suspected tubo-ovarian 
abscess or other condition requiring surgery (n = 191, 6.5% ); had an allergy to the study 
medications (n = 163, 5.5%); were homeless (n = 29, 1% ); or had vomiting after a trial of 
antiemetic treatment (n = 11, 0.4%).  A total of 290 women (205 non-Hispanic black race, 51 
non-Hispanic white race, 34 ot her race) with previously stored buffy coats (n=237) or serum 
samples (n=50) were genotyped for TLR and adaptor molecule SNPs in this study. There were 
no significant differences in the genotype frequencies between women genotyped with buffy 
coats or serum samples. Because the sample size for white race and other races was small they 
were excluded from this analysis. A total of 205 African American women were included in this 
analysis.   
Women were randomized to either inpatient treatment of intravenous cefoxitin every 6 
hours and doxycycline orally twice a day for 14 days; or outpatient treatment consisting of a 
single intramuscular injection of cefoxitin and oral doxycycline twice a day for 14 days. Because 
the treatment modality was not associated with reproductive morbidities in the PEACH study 
(87), we do not include them as a covariate in this analysis. Participants were followed-up with 
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in-person visits at 5 and 30 days after treatment. At the 30-day follow-up the gynecological exam 
was repeated. Telephone follow-ups were conducted by the study nurses every 3 months during 
the first year after enrollment and then every 4 months until June 2004. At that point information 
was obtained by self-report for 69.1% of the cohort, with a mean follow-up of 84 months.  
A pelvic examination and interview were conducted at the baseline visit. The interview 
collected information on r eason for visit, brief pain history, demographics, history of 
PID/sexually transmitted diseases, sexual and contraceptive history, reproductive decisions, 
douching history, pregnancy history, medical and gynecological history and lifestyle habits. 
Follow-up interviews collected self-reported information on pe lvic pain, pregnancy and births, 
signs and symptoms of PID, STDs, contraceptive use, pattern of sexual intercourse, and health 
care utilization.   
Gynecological examinations were performed at baseline and 5 and 30 days post 
treatment. Vaginal smears were gram stained for bacterial vaginosis in a cen tral laboratory by 
standardized methods described by Nugent et al (223). Endometrial biopsy specimens were 
obtained for histological examination including, chlamydial polymerase chain reaction (PCR) 
and gonococcal culture. PCR and cultures were performed at a central reference laboratory. For 
the patients with endometrial biopsies, two reference pathologists separately evaluated at least 
one section stained with hematoxylin and eosin and at least one stained with methyl green 
pyronine. Disagreements about the presence or absences of neutrophils and plasma cells were 
settled by both pathologists reading the slides together and coming to an agreement. Histological 
endometritis was based on a  modification of the criteria proposed by Kiviat et al (224). 
Endometritis was defined as the presence of at least five neutrophils in the endometrial surface 
epithelium in the absence of menstrual endometrium and/or at least two plasma cells in the 
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endometrial stroma. Cervical and endometrial specimens were stored and later used to test for M. 
genitalium (8), using a microwell-plate-based PCR assay (MgPa-IMW) targeting the MgPa gene 
(225). 
A total of 205 African American women were genotyped for TLR and TLR adaptor 
molecule SNPs. For the proposed study 18 tagging SNPs (TagSNPs) including three from TLR1 
(rs5743618, rs5743817, rs4833095), three from TLR2 (rs3804099, rs11938228, rs1898830), 
three from TLR6 (rs1039559, rs5743810, rs3775073), four from TLR4 (rs4986790, rs4986791, 
rs11536889, rs5030728), two from MyD88 (rs4988457, rs7744), and three from TIRAP 
(rs3802813, rs8171374, rs7932976), were chosen from Hapmap.org. TagSNPs were chosen 
based on their reported minor allele frequencies and relative distance to one another within each 
gene.  
All SNPs were genotyped by fluorescence polarization (227). PCR conditions included 1 
X PCR 2.5µl of buffer (Invitrogen) with 1.0µl of MgCl2, 4µl of dNTPs, 1.5µl of each primer, 
0.1µl of Taq polymerase (Invitrogen), and 13.4µl of dH2O; for a total volume of 25.0µl. 
Amplification was performed using a P eltier Thermal Cycler (MJ Research). Thermal cycling 
conditions were 95oC for 3 minutes, then 35 cycles of 95oC/30 seconds for denaturing, 55oC/30 
seconds for annealing, and 72oC/30 seconds for extension, then the final extension step of 72oC/1 
minute. PCR products were visualized on a 3% agar gel by electrophoresis. To check for 
genotyping errors, allele frequencies in our cohort were compared to those reported on 
Hapmap.org from a population of African ancestry in Southwest USA and a h ealthy African 
American population from Pittsburgh, PA which was genotyped in the same lab as our samples. 
There were no significant differences in allele frequencies between the groups.  
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All analyses were conducted among 205 African American women. Demographic and 
clinical baseline characteristics including, age, education, insurance, marriage, white blood cell 
count (WBC), temperature, C-reactive protein (CRP), bilateral adnexal tenderness, cervicitis, 
erythrocyte sedimentation rate (ESR),  Neisseria gonorrhoeae, Mycoplasma genitalium, smoking 
status, and drug use were compared between chlamydial positive cases and chlamydial negative 
controls, using X2 test of proportions. Our main analyses compared genotype frequencies 
between 94 C. trachomatis positive cases and 111 C. trachomatis negative controls. In addition, 
we also compared genotype frequencies between 91 cases with confirmed endometritis and 74 
controls without histological evidence of endometritis. All SNPs were tested for Hardy-
Weinberg equilibrium (HWE), using 10,000 permutations to approximate an exact p-value. 
Additive or dominant models were analyzed for all SNPs. Dominant models were defined by the 
minor allele, where if the minor allele was A the dominant model would compare AA+AG to 
GG. Logistic regression was used to calculate odds ratios and 95% confidence intervals. Any 
model with less than 5 in any cell was excluded from logistic regression analysis (TLR1 
rs5743817, TLR4 rs11536889, TIRAP rs8171374, and TIRAP rs7932976). All models were 
adjusted for age. Permutations were used to correct for multiple comparisons. A p-value <0.004 
based on 1000 permutations, was considered significant for SNP genotype associations. 
Haplotype analyses were also conducted. The expectation-maximization algorithm was used to 
generate maximum likelihood estimates of haplotype frequencies using SAS/Genetic v9.1.3 
(228). Haplotypes were then tested for associations with each trait using chi-square test and 1000 
permutations to approximate an exact p-value based on the Monte Carlo method. For genes with 
significant and frequent haplotypes, regression analysis was used to examine associations 
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between haplotype pairs and traits. All analyses were performed using SAS/Genetics v9.1.3 
(Cary, NC).  
3.4 RESULTS 
Compared to chlamydial negative women, chlamydial positive women were more likely to be 
under the age of 25 ( p<0.001), have elevated C-reactive protein (CRP; >5mg/dL) (p=0.0003), 
and endometritis (P=0.006), but less likely to have bilateral adnexal tenderness (p=0.02) or an 
elevated temperature (p=0.02) (Table 4). All other demographic variables were similar between 
cases and controls. All SNPs were in HWE in the control group.  
Logistic regression revealed that among women with PID, the TLR4 rs1927911 CC 
genotype increased the odds of chlamydial infection (odds ratio (OR) 3.7, 95% confidence 
interval (CI) 1.6-8.8; p=0.0021) (Table 5). Results were similar for the TLR1 rs5743618 TT 
genotype (OR 2.8, 95%  CI 1.3-6.2), although this association was not statistically significant 
after adjusting for multiple comparisons (p=0.0084). No significant associations were found 
between any other TLR or adaptor molecule SNP and chlamydia. We also failed to find any 
significant associations between TLR or adaptor molecule SNPs and endometritis (Table 6). 
However, a sub-analysis among 164 women who had data on upp er genital tract infection, 
revealed that after adjustments for age and N. gonorrhoeae the TLR1 rs5743618 TT genotype 
(case:control frequency = 87:69; OR 7.2, 95% CI 1.8-27.7; p=0.004) and the TLR4 rs1927911 
CC genotype (case:control frequency = 56:27; OR 4.9, 95% CI 1.7-13.8; p=0.003) were both 
associated with upper genital tract infection.  
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Haplotype analyses revealed that women who carried the TLR1 
(rs5743618/rs5743817/rs4833095) TGA haplotype were more likely to be chlamydial positive 
(case:control frequency = 0.15:0.07; exact p=0.04) (Table 7). However, the frequency of this 
haplotype was low in the population (10%), and regression analyses could not be conducted 
because of small cell size. Women who carried the TLR4 (rs5030728/rs4986790/rs1927911) 
GAC haplotype were more likely to be chlamydial positive (0.33:0.19, exact p=0.002), while 
those who carried the GAT haplotype were less likely to be chlamydial positive (0.43:0.59, exact 
p=0.01). Regression analyses revealed similar results for the GAC/GAC haplotype pair (OR 4.3, 
95% CI 1.6-12.2) and the GAT/GAT haplotype pair (OR 0.2, 95% CI 0.1-0.6). Among women 
who carried the GAC/GAC haplotype pair, 86% (12/14) were chlamydial positive, while 39% 
(15/38) who carried the GAT/GAC haplotype pair and 35% (20/57) who carried the GAT/GAT 
haplotype pair were chlamydial positive (Figure 1). No other significant haplotype associations 
were found between TLR2, TLR6, TIRAP, or MyD88 and chlamydia.  
Women who carried the TIRAP (rs3802813/rs7932976/rs8177374) GGC haplotype were 
more likely to have histologically confirmed endometritis (0.92:0.83, exact p=0.04). Regression 
analyses revealed similar results for the GGC/GGC haplotype pair (OR 5.1, 95% CI 1.3-19.4). 
However, this haplotype was very frequent in the population (89%) and almost all women with 
data on endometritis were predicted to carry 1 or more of the GGC haplotype. Women who 
carried the TLR6 (rs1039559/rs5743810/3775073) CTA haplotype were less likely to have 
endometritis (0.04:0.11, exact p=0.04). However, the frequency of the CTA haplotype in the 
population was low (7%) and regression analyses could not be performed. Haplotype analyses 
revealed no s ignificant associations between TLR1, TLR2, TLR4, or MyD88 haplotypes and 
endometritis. However, we did find that women who were predicted to carry the TLR4 
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(rs5030728/rs4986790/rs1927911) GAC haplotype were more likely to have upper genital tract 
infection (0.35:0.21, exact p=0.02), while those with the GAT haplotype were less likely to have 
upper genital tract infection (0.59:0.42, exact p=0.01).  
3.5 DISCUSSION 
In this cohort of African American women with mild to moderate PID, TLR1 and TLR4 variants 
were associated with C. trachomatis infection. In addition, women predicted to carry haplotypes 
in the TLR1 and TLR4 genes were more likely to be C. trachomatis positive. Although these 
variants were not significantly associated with endometritis, they displayed trends towards 
increased odds of upper genital tract infection. 
TLRs initiate microbial elimination through the production of inflammatory cytokines 
and chemokines via activation of nuclear factor κ-B (NF-κB) (121-123). Although this initially 
results in a healthy immune response, variations in these genes may alter TLR signaling possibly 
playing a role in disease progression. Variations in these genes may also explain the variability 
seen in the course and outcome of C. trachomatis infection (10, 13-15). Our results show that 
TLR1 and TLR4 variants may play a role in the development of chlamydial PID. The 
involvement of innate immune receptors in chlamydial pathogenesis makes sense. Chlamydia 
ssp. can infect epithelial cells leading to the secretion of proinflammatory cytokines (135-137). 
Further, this inflammatory response may be responsible for long-term damage of the 
reproductive tract following C. trachomatis infection (146, 147). Therefore, the initial 
inflammatory response following the recognition of C. trachomatis by TLRs is likely protective. 
However, as chlamydia has a s elf-limited acute course that often resolves into a chronic low-
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grade infection (229), it is likely that TLR signaling eventually leads to chronic inflammation of 
the upper genital tract causing long-term sequelae. We did find that compared to chlamydial 
negative women, chlamydial positive women were more likely to have elevated CRP. CRP is an 
acute phase protein and is an indicator of inflammation, suggesting that these women may have 
had persistent chlamydial infections resulting in increased inflammation.  
We found that among women with PID, the CC genotype of TLR4 SNP rs1927911 was 
associated with increased odds of C. trachomatis infection. Further, women who were predicted 
to carry the TLR4 (rs5030728/rs4986790/rs1927911) GAC haplotype were more likely to be 
chlamydial positive. As those with the TLR4 GAT haplotype were significantly less likely to be 
infected with C. trachomatis, this suggests that rs1927911 is driving the haplotype associations. 
It is possible that TLR4 plays a role in C. trachomatis pathogenesis. TLR4 is expressed in the 
female reproductive tract and has been reported to be present in the endocervix, endometrium, 
and Fallopian tubes (121, 130-133). In addition, TLR4 can recognize both LPS and cHSP60 
(138).  Several retrospective studies have found cHSP60 to be linked with chlamydia-associated 
tubal infertility and PID (23-28). However, prospective data examining the relationship has been 
limited. One prospective study among 302 female sex workers in Nairobi, Kenya, found cHSP60 
antibodies to be associated with PID (OR 3.9, 95% CI 1.04-14.5; P=0.04) (29). In contrast, Ness 
et al did not find cHSP60 antibody titers to be significantly associated with sequelae following 
clinically suspected PID (18). Certain biases, such as diagnostic bias, were suggested to 
overestimate the effect size in some studies (18). For example, diagnosis of clinically suspected 
PID may have been influenced by the knowledge of a previous chlamydial exposure. If cHSP60 
is a surrogate for that prior exposure then this would have biased the results away from the null. 
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Still, it ma y be possible that cHSP60 is recognized by TLR4, resulting in persistent 
inflammation that damages the reproductive tract following C. trachomatis infection. However, 
this does not correlate with mice models which suggest that TLR4 is not involved in genital tract 
pathology following genital tract chlamydial infection (149, 150). Darville et al found that TLR2 
knockout (KO) mice had significantly lower levels of inflammatory mediators in genital tract 
secretions during the first week of chlamydial infection, as well as a significant reduction in 
oviduct and mesosalpinx pathology at late time points following challenge with C. muridarum 
(150). In contrast, after challenge with C. muridarum, TLR4 KO mice had similar pathology and 
cytokine production compared to infected controls with TLR4 genes (150). This suggests that 
there is no direct role for cHSP60-induced TLR4 mediated tissue damage in genital tract 
infection (150). Disease mechanism in mice may not always translate to human in vivo 
situations. Therefore, in humans TLR4 may indeed be involved in pathogenesis following C. 
trachomatis infection.  
However, the relationship may not be that straight forward as interactions between 
several TLRs may be involve in the balance of cytokine production. TLR2 and TLR4 have been 
reported to interact with one another altering TLR signaling (144, 230, 231). Mu et al found that 
agonist interactions between TLR2 and TLR4, in mice infected with Mycoplasma arthritidis, 
leads to differential release of IL-17 and its associated cytokines (230). Specifically the authors 
found high levels of IL-6 in TLR2+/TLR4+ mice compared to high levels of IL1β and TNF-α in 
TLR2+/TLR4- mice. When TLR4 was blocked in the TLR2+/TLR4+ mice, IL-17 and IL-6 but 
not IL-23 were decreased, while IL-17 and IL-6 were increased in TLR2 KO mice. Reiling et al, 
found that interaction between TLR2 and TLR4 resulted in increased proinflammatory cytokine 
production following infection with M. tuberculosis (231). It is clear that associations between 
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cHSP60 and TLR4, as well as interactions between TLR2 and TLR4 following C. trachomatis 
infection need to be further explored. Due to our sample size we did not examine any 
interactions, but acknowledge that our results may be masked by gene-gene or gene-environment 
interactions.  
Little is known about the functional or clinical relevance of TLR4 rs1927911. The T 
allele has been found to decrease the risk of myocardial infarction (OR 0.88, 95% CI 0.77-0.99) 
among 1,216 cases and 2,682 controls from Washington state (204). Over 90% of this population 
was Caucasian. In another Caucasian population consisting of 110 lung transplant recipients and 
422 healthy controls, the TT genotype was found to increase the odds of bronchiolitis obliterans 
(BOS) (OR 4.20, 95% CI 1.43-12.35; p=0.005) (178). Differences in the mechanisms underlying 
these diseases may explain the contrasting results. In latter study the authors noted that acute 
rejection is a risk factor for BOS and an increase in pro-inflammatory cytokines and chemokines 
may decrease acute rejection thus decreasing BOS (178). The C allele was found to decrease 
BOS in this study. In contrast, increases in inflammation may be associated with MI (204).  
Functional analyses are needed to determine the relevance of rs1927911.  As this SNP is located 
in the intron, it may be in linkage disequilibrium (LD) with another functional SNP. However, 
using Haploview, we were unable to find any SNPs in strong LD with this variant in African 
Americans. 
TLR2 has been recognized to play a role in chlamydial infections (144, 149, 150, 151) 
However, we did not find any significant associations between TLR2 variants and C. 
trachomatis. We do a cknowledge that we only had 35% gene coverage for TLR2, and other 
TLR2 variants that were not tagged by our SNPs should be further examined. TLR2 can form a 
dimer with TLR1 to recognize a r ange of pathogens and activate inflammatory responses. We 
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did find that the TLR1 rs5743618 TT genotype was associated with increased C. trachomatis 
infection. Further, the TLR1 (rs5743618/rs5743817/ rs4833095) TGA haplotype was more 
frequent among chlamydial positive women. The association between the TT genotype and 
chlamydia did not reach statistical significance after permutations. However, our sample size 
limited our power. TLR1 rs5743618 is a non-synonymous mutation and results in an amino acid 
change. The G allele has been reported to be associated with deficient TLR signaling in 
comparison to the T allele (182-185), and has been reported to reduce leprosy (182, 186, 184). 
Hawn et al, reported that the T allele expressed significantly greater NF-κB signaling in 
transfected HEK293 cells compared to the G allele (183). Among sepsis patients, the T allele 
was found to be associated with higher mortality (OR 1.79, 95% CI 1.02-3.13; P=0.042) (185). 
As rs574618 has a possible functional relevance it should be further explored in C. trachomatis 
pathogenesis. 
We found that TLR variants were associated with C. trachomatis among women with 
mild to moderate PID. However, as some women with clinically suspected PID may actually 
have ovarian cysts, pelvic adhesions, or endometriosis (81), some women in our cohort may not 
have had true upper genital tract infection and inflammation. Endometritis is an accepted 
measure of true PID. However, we found no significant associations found between any of our 
genotyped SNPs and endometritis. Endometritis is a spotty disease and may not indicate all cases 
of upper genital tract inflammation (1). Further, PID is polymicrobial and therefore women with 
endometritis could have had a variety of microorganisms. This could possibly bias our results, as 
different TLRs recognize different pathogens and have been shown to induce different sets of 
chemokines and cytokines (230-234), suggesting that immune response may be different 
depending on the pathogen present (150). Further, PID-associated pathogens may have different 
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mechanisms of disease (36). Therefore, it would have been optimal to examine upper genital 
tract inflammation specifically among women with C. trachomatis infection. We did not have 
the power to examine endometritis in a subset of women with chlamydial infection. However, we 
did find that rs1927911 and rs5743618 were associated with upper genital tract infection after 
adjusting for age and N. gonorrhoeae. This may give some suggestion that that these variants 
play a role in the progression of C. trachomatis to the upper genital tract.  
Our study has several strengths. First, data were obtained from a large, multicenter, 
prospective randomized clinical trial, with comprehensive demographic, clinical, and obstetric 
measurements. These findings are generalizable to patients treated for clinically suspected PID. 
Not all women in the PEACH study had blood samples available for analyses. However, 
important demographic and clinical characteristics between women with and without blood 
samples did not differ. This is the first study to examine the role of several TLR and adaptor 
molecule SNPs in chlamydial-PID. However, our sample size limited our power. We also had 
low SNP coverage for our genes. Therefore, other TLR variants especially in the TLR2 gene 
should continue to be explored in chlamydial pathogenesis. We also relied on an internal control 
group for comparison. Therefore women in the controls groups all had clinically suspected PID.  
Among African American women with PID, TLR1 and TLR4 variants were associated 
with C. trachomatis. These variants may increase TLR signaling leading to persistent 
inflammation which may permanently damage the reproductive tract. This study provides novel 
insight into the pathogenesis of C. trachomatis infection. However, our results need to be 
replicated. In addition, comparisons should be made between women with chlamydial PID and 
women with uncomplicated lower genital C. trachomatis infection. Further exploration into the 
role of innate immune receptors in the course and outcome of C. trachomatis is needed to 
 84 
delineate its pathogenesis. This type of research may lead to better management and control of C. 
trachomatis, possibly through vaccine development.  
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3.6 TABLES 
Table 4. Baseline demographic and clinical characteristics by chlamydial status 
 
Characteristics Chlamydia Negative 
N = 111 
n (%) 
      Chlamydia Positive 
N = 94 
n (%) 
*p-value 
Demographics    
Age 
<25 years 
25+ years 
 
53 (47.8) 
58 (52.3) 
 
81 (86.2) 
13 (13.8) 
 
 
<0.0001 
Married 8 (7.8) 5 (5.6) 0.5704 
Education 
Less than high school 
High school or greater 
 
44 (39.6) 
67(60.4) 
 
45 (47.9) 
49 (52.1) 
 
 
0.2360 
Uninsured 51 (50.0) 38 (43.7) 0.3855 
Clinical Findings    
Temperature (>100.4 F) 
WBC (> 10,000 mm3) 
C-reactive protein (>5mg/dL) 
Bilateral adnexal tenderness 
Neisseria gonorrhoeae 
Mycoplasma genitalium 
Bacterial Vaginosis 
Cervicitis 
Endometritis 
15 (14.7) 
32 (38.1) 
1 (8.3) 
92 (82.9) 
34 (35.1) 
12 (12.2) 
69 (65.7) 
60 (59.4) 
42 (45.7) 
4 (4.4) 
28 (33.3) 
16 (72.7) 
65 (69.2) 
27 (34.6) 
8 (13.3) 
58 (66.7) 
56 (65.1) 
49 (67.1) 
0.0175 
0.5195 
0.0003 
0.0207 
0.9520 
0.8417 
0.8896 
0.4226 
0.0059 
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Table 4. continued 
 
Behavioral 
Current smoker 
Drug use 
50 (45.1) 
34 (30.6) 
39 (41.5) 
31 (33.0) 
0.6088 
0.7189 
 
*Chi-square was used to derive the p-value. Fisher’s Exact was used when cell size was less than 3 
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Table 5. Association between genotypes and cervical and/or endometrial C. trachomatis 
infection among women with pelvic inflammatory disease 
 
SNPs and 
Genotypes 
Chlamydial 
Negative 
(N=111) 
Chlamydial 
Positive 
(N=94) 
*Adjusted Odds 
Ratio 
(95% CI) 
P-value 
TLR 1 
rs5743618 
GG+GT 
TT 
 
37(34.9) 
69(65.1) 
 
12(16.0) 
63(84.0) 
 
Referent 
2.8 (1.3-6.2) 
 
 
0.0084 
rs4833095 
AA+AG 
GG 
 
46(62.1) 
28(37.8) 
 
63(56.3) 
49(43.8) 
 
Referent 
1.2 (0.6-2.3) 
 
 
0.5287 
TLR 2 
rs3804099 
CC 
CT 
TT 
 
46 (41.5) 
49 (44.1) 
16(14.4) 
 
38(39.4) 
25(32.5) 
14(18.2) 
 
Referent 
0.6 (0.3-1.3) 
0.9 (0.4-2.2) 
 
    
0.1855 
0.8818 
rs11938228 
CC 
AA + AC 
 
82(73.9) 
29(26.1) 
 
54(73.0) 
20(27.0) 
 
Referent 
1.1 (0.6-2.4) 
 
 
0.6994 
rs1898830 
AA 
GG+AG 
 
84(75.7) 
27(34.3) 
 
47(77.1) 
14(22.9) 
 
Referent 
1.1 (0.5-2.6) 
 
 
0.7267 
TLR 6 
rs1039559 
TT 
CC+TC 
 
68(61.8) 
42(38.2) 
 
43(64.2) 
24(35.8) 
 
Referent 
0.8 (0.4-1.7) 
 
 
0.6263 
rs5743810 
CC 
TT + CT 
 
92(83.6) 
18(16.4) 
 
59(81.9) 
13(18.1) 
 
Referent 
1.2 (0.5-2.7) 
 
 
0.7407 
rs3775073 
GG 
AG 
AA 
 
48(43.2) 
51(46.0) 
12(10.8) 
 
25(34.3) 
39(53.4) 
9(12.3) 
 
Referent 
1.1 (0.6-2.2) 
1.0 (0.4-3.0) 
 
 
0.7504 
0.9331 
TLR 4 
rs5030728 
GG 
AA + AG 
 
75(68.8) 
34(31.2) 
 
58(75.3) 
19(24.7) 
 
Referent 
0.7 (0.4-1.5) 
 
 
0.4131 
rs4986790 
AG 
AA 
 
17(15.3) 
94(84.7) 
 
14(16.7) 
70(83.3) 
 
Referent 
0.7 (0.3-1.7) 
 
 
0.4547 
rs1927911 
TT 
 
47(42.7) 
 
30(33.7) 
 
Referent 
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* Adjusted for age 
** Significant based on an empirical P-value < 0.004 
Logistic regression was used to calculate odds ratios and 95% CI. Any model with less than 5 
observations in any cell was excluded (TLR1 rs5743817, TLR4 rs11536889, TIRAP rs8171374, and 
TIRAP rs7932976). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CT 
CC 
47(42.7) 
16(14.6) 
27(30.3) 
32(36.0) 
1.0 (0.5-2.0) 
3.7 (1.6-8.8) 
0.9675 
0.0021 
Myd88 
rs7744 
AA 
AG + GG 
 
102(91.9) 
9(8.1) 
 
86(91.5) 
8(8.5) 
 
Referent 
1.3 (0.4-3.9) 
 
 
0.6288 
rs4988457 
CG 
CC 
 
25(22.5) 
86(77.5) 
 
10(14.1) 
61(85.9) 
 
Referent 
1.9 (0.8-4.5) 
 
 
0.1429 
TIRAP 
rs3802813 
AG 
GG 
 
15(13.5) 
96(86.5) 
 
9(10.2) 
79(89.8) 
 
Referent 
1.7 (0.6-4.3) 
 
 
0.2801 
Table 5. continued 
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Table 6. Associations between genotypes and endometritis among women with pelvic 
inflammatory disease 
 
SNPs and 
Genotypes 
Endometritis 
Negative 
(N=74) 
Endometritis 
Positive 
(N=91) 
*Adjusted Odds 
Ratio 
(95% CI) 
**P-value 
TLR 1 
rs5743618 
GG+GT 
TT 
 
21(31.8) 
45(68.2) 
 
19(23.8) 
61(76.3) 
 
Referent 
1.5 (0.7-3.0) 
 
 
0.3227 
rs4833095 
AA+AG 
GG 
 
31(51.7) 
29(48.3) 
 
35(39.3) 
54(60.7) 
 
Referent 
1.7 (0.8-3.2) 
 
 
0.1391 
TLR 2 
rs3804099 
CC 
CT 
TT 
 
29(41.4) 
31(44.3) 
10(14.3) 
 
33(40.2) 
36(43.9) 
13(15.9) 
 
Referent 
1.1 (0.5-2.1) 
1.2 (0.4-3.0) 
 
 
0.8622 
0.8068 
rs11938228 
CC 
AA + AC 
 
52(76.5) 
16(23.5) 
 
58(71.6) 
23(28.4) 
 
Referent 
1.4 (0.6-2.9) 
 
 
0.4140 
rs1898830 
AA 
GG+AG 
 
48(75.0) 
16(25.0) 
 
54(72.0) 
21(28.0) 
 
Referent 
1.2 (0.6-2.7) 
 
 
0.5890 
TLR 6 
rs1039559 
TT 
CC+TC 
 
36(57.1) 
27(42.9) 
 
52(65.8) 
27(34.2) 
 
Referent 
0.7 (0.3-1.3) 
 
 
0.2467 
rs5743810 
CC 
TT + CT 
 
51(77.3) 
15(22.7) 
 
71(88.8) 
9(11.3) 
 
Referent 
0.4 (0.2-1.1) 
 
 
0.0739 
rs3775073 
GG 
AG 
AA 
 
27(40.9) 
30(45.5) 
9(13.6) 
 
33(41.3) 
39(48.8) 
8(10.0) 
 
Referent 
0.9 (0.4-1.9) 
0.5 (0.2-1.6) 
 
 
0.8226 
0.2341 
TLR 4 
rs5030728 
GG 
AA + AG 
 
51(73.9) 
18(26.1) 
 
58(71.6) 
23(28.4) 
 
Referent 
1.1 (0.5-2.4) 
 
 
0.7203 
rs4986790 
AG 
AA 
 
10(14.3) 
60(85.7) 
 
15(17.2) 
72(82.8) 
 
Referent 
0.8 (0.3-1.8) 
 
 
05334 
rs1927911 
TT 
CT 
CC 
 
29(40.9) 
27(38.0) 
15(21.1) 
 
33(37.1) 
35(39.3) 
21(23.6) 
 
Referent 
1.2 (0.6-2.4) 
1.2 (0.5-2.8) 
 
 
0.6865 
0.6367 
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Table 6. continued 
 
Myd88 
rs7744 
AA 
AG + GG 
 
69(93.2) 
5(6.8) 
 
81(89.0) 
10(11.0) 
 
Referent 
1.7 (0.6-5.4) 
 
 
0.3375 
rs4988457 
CG 
CC 
 
12(18.2) 
54(81.8) 
 
16(20.0) 
64(80.0) 
 
Referent 
0.9 (0.4-2.1) 
 
 
0.8042 
TIRAP     
rs3802813 
AG 
GG 
 
11(15.7) 
59(84.3) 
 
10(11.2) 
79(88.8) 
 
Referent 
1.6(0.6-4.1) 
 
 
0.3243 
 
* Adjusted for age 
**Significance is based on an empirical P-value of 0.004 
Logistic regression was used to calculate odds ratios and 95% CI. Any model with less than 5 
observations in any cell was excluded (TLR1 rs5743817, TLR4 rs11536889, TIRAP rs8171374, and 
TIRAP rs7932976). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 91 
Table 7. Associations between TLR haplotypes and C. trachomatis 
 
Haplotype Chlamydia 
negative 
frequencies 
Chlamydial 
positive 
frequencies 
*Exact P-value 
**TLR1 haplotype 
TGA 0.07 0.15 0.0440 
§TLR 4 haplotypes 
GAC 0.19 0.33 0.006 
GAT 0.59 0.43 0.0120 
*Based on 1000 permutations 
** TLR1 rs5743618/rs5743817/rs4833095 haplotype 
§TLR 4 rs5030728/rs4896790/rs1927911 haplotypes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
3.7 FIGURES 
 
Figure 1. Percentage of chlamydial positive women by predicted TLR4 diplotype 
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4.1 ABSTRACT 
 
Background: Toll-like receptors (TLR) are expressed throughout the female reproductive tract 
and are responsible for microbial recognition. Genetic variations in TLR genes may alter 
inflammatory responses possibly influencing the development of sequelae following pelvic 
inflammatory disease (PID).  
Methods: We explored the role of TLR single nucleotide polymorphisms (SNPs) in pregnancy 
and infertility among 205 African American women with clinically suspected PID from the PID 
Evaluation and Clinical Health Study. Outcomes were assessed over a median of 84 months. To 
determine associations with pregnancy, Cox regression methods were used to calculate hazard 
ratios (HR) and 95% confidence intervals (CI) for a total of 18 tagSNPs in 6 TLR genes (TLR1, 
TLR2, TLR4, TLR6, TIRAP, and MyD88). For infertility odds ratios (OR) and 95% CI were 
calculated using logistic regression. Significance was based on an empirical P-value of <0.003. 
All models were adjusted for age and history of infertility.  
Results: Women with PID who carried the GG genotype for TLR1 rs4833095 had a non-
significant trend towards decreased pregnancy rates (HR 0.7, 95% CI 0.5-1.1). Although power 
was limited, we found similar results among a subset of women with C. trachomatis (HR 0.5, 
95% CI 0.3-0.9, p=0.04). Further, women predicted to carry the TLR1 (rs5743618/ 
rs5743817/rs4833095) TGG haplotype were less likely to achieve pregnancy (0.80:0.71, 
p=0.04), although this was non-significant (empirical p=0.2860). 
Conclusions: Among African American women with PID, TLR and adaptor molecule variants 
did not appear to significantly alter the risk of infertility or pregnancy. As PID is polymicrobial 
these associations should be examined in cohorts defined by PID-associated pathogen.  
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4.2 INTRODUCTION 
Pelvic inflammatory disease (PID) is the infection and inflammation of the female upper genital 
tract. PID is a multimicrobial condition and is associated with several pathogens including 
Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, and anaerobic and 
aerobic bacteria commonly associated with bacterial vaginosis (BV) (5-8). Complications 
following PID can result from damage to the cilia lining of the Fallopian tubes, Fallopian tube 
blockage, or adhesion formation among pelvic organs (5). A landmark Scandinavian cohort 
study among 2500 w omen with clinically suspected PID, found that 16% of women with 
laparoscopically verified salpingitis versus 2.7% of controls became infertile (3). In addition, 
20% and 25% developed recurrent PID and chronic pelvic pain respectively (2).  Tubal factor 
infertility was also found to double with each PID episode and reached an estimated 40% after 
three or more episodes (3).  
Obstruction of the Fallopian tubes following PID is a preventable cause of infertility and 
ectopic pregnancy. There is a need for biomarkers to predict morbidity risk following an episode 
of PID. However, the role of individual microbes in the development of sequelae following PID 
is not well understood and although C. trachomatis and N. gonorrhoeae have been studied more 
extensively, the etiology and pathogenesis of PID has not been fully delineated (5). It is 
suggested that the presence of C. trachomatis or N. gonorrhoeae on the genital mucosal surface, 
invokes inflammatory responses which may clear infection and/or elicit tissue damage (36). As 
innate immune receptors results in expression of proinflammatory cytokine and chemokines, host 
genetic variations in innate immune receptor genes may play a role in the pathogenesis of PID, 
possibly through overt inflammatory responses.  
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Interaction between the immune system and the reproductive tract is important for 
fertility and reproductive health. The innate immune system serves as the first line of defense 
after exposure to pathogens and depends on pattern recognition receptors (PRRs) for microbial 
recognition (121-123). A conserved family of PRRs called the Toll-like receptor (TLR) family 
(122) is responsible for microbial elimination through induction of inflammatory cytokine and 
chemokine genes. Ten different TLRs (TLRs 1-10) have been identified in humans and the 
overlap between them allows identification of a diverse range of pathogens through ligand 
binding (121-123). Adaptor molecules including myeloid differentiation primary response 
protein 88 (MyD88) and TIR domain-containing adaptor protein (TIRAP) help to mediate TLR 
signaling (123, 127). Polymorphisms in TLR and adaptor molecule SNPs may alter TLR 
signaling and have been found to be associated with several inflammatory and infectious 
diseases (163, 173, 176, 186, 199). 
TLRs are expressed throughout the female reproductive tract (121,125,126) and could 
play a role in gynecologic disease. To our knowledge no studies have examined the role of TLRs 
in PID. One group of researchers conducted several limited studies among Dutch Caucasian 
populations and has been unable to show any significant associations between innate immune 
receptor functional single nucleotide polymorphisms (SNPs) and tubal factor infertility (154, 
156). For example, Morre et al examined 35 Dutch women with tubal pathology and 49 Dutch 
women without tubal pathology and found that the TLR4 Asp299Gyl polymorphism was not 
associated with tubal infertility (P>0.5) (Allele frequency: 7.1% vs. 10.2%) (154). In a cohort of 
227 subfertile women, among those who were C. trachomatis positive women, there was an 
increasing risk for tubal pathology (64% risk for normal genotype vs. 83% risk for heterozygous 
SNP carrier), although this did not reach statistical significance (154). Outburg et al, compared 
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253 Dutch women with subfertility to 170 f ertile women to examine the CD14 functional 
polymorphism -260C>T, and found no association between this polymorphism and subfertility 
(156). den Hartog et al reported that women with tubal pathology who were C. trachomatis Ig 
positive were twice as likely to be carriers of the TLR4 +896 G allele compared to women 
without tubal pathology, although this was not statistically significant (157).  
As no s tudies have examined TLRs in PID, our objective was to explore the role of 
TLR1, TLR2, TLR4, TLR6, MyD88, and TIRAP gene polymorphisms in infertility and 
pregnancy among African American women with clinically suspected PID. This may provide 
novel information regarding the pathogenesis of PID.  
4.3 METHODS 
This study utilized data from the PID Evaluation and Clinical Health (PEACH) study. This was 
the first randomized clinical trial to compare inpatient and outpatient treatment in preventing 
long-term complications among 831 women with mild to moderate PID. The methods of subject 
recruitment, data collection, and follow-up have been reported elsewhere (87). Briefly, between 
March 1996 a nd February 1999 w omen aged 14-37 years were recruited from emergency 
departments, obstetrics and gynecology clinics, sexually transmitted disease clinics, and private 
practices at 7 primary and 6 secondary sites throughout the eastern, southern, and central regions 
of the United States. Women who had suspected PID and gave informed consent were eligible 
for the PEACH study. Eligible women had a history of pelvic discomfort for less than 30 days, 
findings of pelvic organ tenderness (uterine or adnexal) on b imanual examination, and 
leukorrhea and/or mucopurulent cervicitis and/or untreated but documented gonococcal or 
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chlamydial cervicitis. The University of Pittsburgh Institutional Review Board approved the 
study. 
A total of 2941 women were screened for study entry, of those 346 (11.8%) did not meet 
the clinical inclusion criteria for randomization. Women were additionally excluded if they were 
pregnant (n = 141, 4.8%); had taken antimicrobials within the past 7 days (n = 248, 8.4%); had a 
history of hysterectomy or bilateral salpingectomy (n = 248, 8.4%); had an abortion, delivery, or 
gynecologic surgery within the past 14 da ys (n = 51, 1.7% ); had a suspected tubo-ovarian 
abscess or other condition requiring surgery (n = 191, 6.5%); had an allergy to the study 
medications (n = 163, 5.5%); were homeless (n = 29, 1% ); or had vomiting after a trial of 
antiemetic treatment (n = 11, 0.4%).  A total of 290 women (205 non-Hispanic black race, 51 
non-Hispanic white race, 34 ot her race) with previously stored buffy coats (n=237) or serum 
samples (n=50) were genotyped for TLR and adaptor molecule SNPs in this study. There were 
no differences in the genotype frequencies between women genotyped with buffy coats or serum 
samples. Because of small sample sizes, women of white race and other races were excluded. A 
total of 205 African American women were included in this analysis.   
Women were randomized to either inpatient treatment of intravenous cefoxitin every 6 
hours and doxycycline orally twice a day for 14 days; or outpatient treatment consisting of a 
single intramuscular injection of cefoxitin and oral doxycycline twice a day for 14 days. Because 
the treatment modality was not associated with reproductive morbidities in the PEACH study 
(87), we do not include them as a covariate in this analysis. Participants were followed-up with 
in-person visits at 5 and 30 days after treatment. At the 30-day follow-up the gynecological exam 
was repeated. Telephone follow-ups were conducted by the study nurses every 3 months during 
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the first year after enrollment and then every 4 months until June 2004. At that point information 
was obtained by self-report for 69.1% of the cohort, with a mean follow-up of 84 months.  
A pelvic examination and interview were conducted at the baseline visit. The interview 
collected information on r eason for visit, brief pain history, demographics, history of 
PID/sexually transmitted diseases (STDs), sexual and contraceptive history, reproductive 
decisions, douching history, pregnancy history, medical and gynecological history and lifestyle 
habits. Follow-up interviews collected self-reported information on pelvic pain, pregnancy and 
births, signs and symptoms of PID, STDs, contraceptive use, pattern of sexual intercourse, and 
health care utilization.   
Gynecological examinations were performed at baseline and 5 and 30 days post 
treatment. Vaginal smears were gram stained for bacterial vaginosis in a cen tral laboratory by 
standardized methods described by Nugent et al (223). Endometrial biopsy specimens were 
obtained for histological examination including, chlamydial polymerase chain reaction (PCR) 
and gonococcal culture. PCR and cultures were performed at a central reference laboratory. For 
the patients with endometrial biopsies, two reference pathologists separately evaluated at least 
one section stained with hematoxylin and eosin and at least one stained with methyl green 
pyronine. Disagreements about the presence or absences of neutrophils and plasma cells were 
settled by both pathologists reading the slides together and coming to an agreement. Histological 
endometritis was based on a  modification of the criteria proposed by Kiviat et al (224). 
Endometritis was defined as the presence of at least five neutrophils in the endometrial surface 
epithelium in the absence of menstrual endometrium and/or at least two plasma cells in the 
endometrial stroma. Cervical and endometrial specimens were stored and later used to test for M. 
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genitalium (8), using a microwell-plate-based PCR assay (MgPa-IMW) targeting the MgPa gene 
(225). 
Reproductive outcomes were assessed over a mean of 84 months and included infertility, 
pregnancy, live birth, recurrent PID, and chronic pelvic pain.  Infertility was defined by lack of 
conception despite sexual activity with rare or never use of methods of contraception considered 
reliable during 12 or  more months of follow-up. Self-reported pregnancy was determined by a 
positive urine/blood test or physician’s diagnosis. Live birth was determined by self-report, and 
recurrent PID was self-reported and verified whenever medical records were available (45% of 
cohort). Recurrent PID was confirmed in 76% of medical records. Chronic pelvic pain was 
defined by two or more consecutive reports of pelvic pain during follow-up. Data from at least 2 
follow-up visits were required to determine chronic pelvic pain. 
A total of 205 African American women were genotyped for TLR and TLR adaptor 
molecule SNPs. For the proposed study 18 tagging SNPs (TagSNPs) including three from TLR1 
(rs5743618, rs5743817, rs4833095), three from TLR2 (rs3804099, rs11938228, rs1898830), 
three from TLR6 (rs1039559, rs5743810, rs3775073), four from TLR4 (rs4986790, rs4986791, 
rs11536889, rs5030728), two from MyD88 (rs4988457, rs7744), and three from TIRAP 
(rs3802813, rs8171374, rs7932976), were chosen from Hapmap.org. TagSNPs were chosen 
based on their reported minor allele frequencies and relative distance to one another within each 
gene.  
All SNPs were genotyped by fluorescence polarization (227). PCR conditions included 1 
X PCR 2.5µl of buffer (Invitrogen) with 1.0µl of MgCl2, 4µl of dNTPs, 1.5µl of each primer, 
0.1µl of Taq polymerase (Invitrogen), and 13.4µl of dH2O; for a total volume of 25.0µl. 
Amplification was performed using a P eltier Thermal Cycler (MJ Research). Thermal cycling 
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conditions were 95oC for 3 minutes, then 35 cycles of 95oC/30 seconds for denaturing, 55oC/30 
seconds for annealing, and 72oC/30 seconds for extension, then the final extension step of 72oC/1 
minute. PCR products were visualized on a  3% agar gel by electrophoresis. To check for 
genotyping errors, allele frequencies in our cohort were compared to those reported on 
Hapmap.org from a population of African ancestry in Southwest USA and a h ealthy African 
American population from Pittsburgh, PA which was genotyped in the same lab as our samples. 
No significant differences in the frequencies were found. Therefore, we do not believe that there 
were any genotyping errors.  
All analyses were conducted among 205 African American women. Demographic and 
clinical baseline characteristics including, age, education, insurance, marriage, white blood cell 
count (WBC), temperature, C-reactive protein (CRP), bilateral adnexal tenderness, cervicitis, 
endometritis, erythrocyte sedimentation rate (ESR),  Chlamydia trachomatis, Neisseria 
gonorrhoeae, Mycoplasma genitalium, smoking status, and drug use were compared between 
pregnant women and women who did not achieve pregnancy, using X2 test of proportions. Our 
main analyses compared genotype frequencies between 77 cases who did not achieve pregnancy 
and 128 pregnant controls. In addition, we also compared genotype frequencies between 39 
infertile cases and 166 fertile controls. All SNPs were tested for Hardy-Weinberg equilibrium 
(HWE), using 10,000 permutations to approximate an exact p-value. Additive or dominant 
models were analyzed for all SNPs. Dominant models were defined by the minor allele, where if 
the minor allele was A the dominant model would compare AA+AG to GG. For the pregnancy 
models, Cox regression was used to calculate hazard ratios and 95% confidence intervals. For 
infertility, logistic regression was used to calculate odds ratios and 95% confidence intervals. 
Any model with less than 5 in any cell was excluded from regression analysis, this included 
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TLR1 rs5743817, TLR4 rs11536889, TIRAP rs8171374, and TIRAP rs7932976. In addition, 
TIRAP rs3802813 was also excluded for infertility. All models were adjusted for age and history 
of infertility. Permutations were used to correct for multiple comparisons. An empirical p-value 
<0.003 was considered significant for SNP genotype associations. Haplotype analyses were also 
conducted. The expectation-maximization algorithm was used to generate maximum likelihood 
estimates of haplotype frequencies using SAS/Genetic v9.1.3 (228). Haplotypes were then tested 
for associations with each trait using chi-square test and 1000 permutations to calculate exact p-
values. For genes with significant haplotypes, regression analysis was used to examine 
associations between haplotype pairs and traits. All analyses were performed using 
SAS/Genetics v9.1.3 (Cary, NC).  
4.4 RESULTS 
Baseline demographic, clinical, and behavioral characteristics between cases and controls were 
similar (Table 8). However, pregnant women were more likely to be less than 25 years of age 
(78% vs 44%, p<0.001) compared to women who did not achieve pregnancy. No SNPs were out 
of HWE among controls. 
Among women with PID, those who carried the TIRAP rs3802813 GG genotype had 
decreased odds of achieving pregnancy (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3-
0.9). However, this was not significant after correction for multiple comparisions (p=0.02) 
(Table 9). No other TLR or adaptor molecule SNP was significantly associated with pregnancy, 
although several non-significant trends were observed. Women who carried the TLR6 rs5743810 
TT or CT genotype had increased pregnancy rates (HR 1.6, 95% CI 1.0-2.5, p=0.0599). Among 
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women who carried the TLR1 rs5743618 TT genotype, a non-significant trend towards 
decreased pregnancy rates (HR 0.7, 95% CI 0.4-1.1) was also observed. Although our power was 
limited, in a subset of 94 women with C. trachomatis, we found that the TT genotype was more 
frequent in women who did not achieve pregnancy (93% vs. 78%) compared to pregnant women. 
However, because of small cell size we were unable to perform logistic regression. Women who 
carried the GG genotype for TLR1 rs4833095 had a non-significant trend towards decreased 
pregnancy rates (HR 0.7, 95%  CI 0.5-1.1). Results were similar among a subset of C. 
trachomatis positive women (HR 0.5, 95% CI 0.3-0.9, p=0.04). We did not find any significant 
associations between TLR and adaptor molecule SNPs and infertility (Table 10).  
Women who carried the TLR1 (rs5743618/rs5743817/rs4833095) TGG haplotype were 
less likely to achieve pregnancy (0.80:0.71, p=0.04). However, this was no l onger significant 
after correction for multiple comparisons (p=0.2860). Still, among women who carried the 
TGG/TGG haplotype pair 53% achieved pregnancy, compared to a 60% pregnancy rate among 
women who were predicted to carry only 1 TGG haplotype, and a 77% pregnancy rate among 
carriers of all other haplotypes (Figure 2). Cox regression analyses revealed decreased pregnancy 
rates among carriers of the TGG/TGG haplotype pair (HR 0.5, 95% CI 0.3-0.8, p=0.007) 
compared to all other haplotype pairs. However, this was not significant after correction for 
multiple comparisons. No other haplotype was significantly associated with pregnancy. 
Similarly, TLR or adaptor molecule haplotypes were not significantly associated with infertility. 
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4.5 DISCUSSION 
In this cohort of African American women with clinically suspected PID, TLR and adaptor 
molecule variants did not appear to significantly alter the risk of pregnancy or infertility. 
However, women predicted to carry the TLR1 TGG/TGG haplotype pair had decreased 
pregnancy rates. Although our power was limited, we found that TLR1 variants were 
significantly associated with decreased pregnancy among a subset of women with chlamydial-
PID. As PID is polymicrobial, TLR variants could play a role in PID pathogenesis in specific 
subsets of pathogens. 
The exact mechanism of activity and function of TLRs in relation to fertility and 
reproductive health are unknown. However, as TLRs are expressed throughout the female 
reproductive tract (121,125,126) and are responsible for microbial elimination through 
inflammatory responses, there is a possible role for TLRs in reproductive health. TLRs 1-3, 5 
and 6 are expressed in the vaginal and cervical epithelial cells, further TLRs 1-3, and 6 are 
expressed by primary endocervical epithelial cells (121, 130-133). TLR4 has been reported to be 
present in the endocervix, endometrium, and uterine tubes (121, 130-133). TLRs 7-10 have been 
identified in the endometrial epithelia and stroma (134). Studies have also shown that TLRs can 
bind to several PID-associated pathogens. TLR4 may recognize LPS and HSP60 (138). TLR2 
can respond to a variety of ligands such as lipoproteins and lipopeptides, lipoarabinomannan, 
lipoteichoic acid, and bacterial prion (139-143). Further, TLR2 can dimerize with TLRs 1 and 6, 
possibly to recognize a more diverse range of pathogens (144). TLRs 2 and 4 have also been 
found to bind to N. gonorrhoeae ligands (161, 162), while TLR2 may bind to M. genitalium 
(167). Thus, during an upper genital tract infection TLR or adaptor molecule SNPs could alter 
TLR signaling, possibly leading to an overt inflammatory response and long-term sequelae.  
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We were unable to find any significant associations between TLR or adaptor molecule 
SNPs and pregnancy or infertility. There several explanations for these findings. First, due to our 
sample size our power to detect significant associations was limited. We did find two 
associations with borderline significance. Carrying T allele for TLR6 SNP rs5743810 appeared 
to increase pregnancy rates (HR 1.6, 95%  CI 1.0-2.5). TLR6 SNP rs5743810, also known as 
Ser249Pro, is a non-synonymous polymorphism and results in an amino acid change. Sales et al 
found that monocytes from hypertensive women with the TT genotype had reduced IL-6 and 
TNF-α release compared to sex matched cells carrying the C allele (P<0.05). Similarly in a study 
among 100 subjects from South Africa, the T allele of Ser249Pro was associated with decreased 
NF-κB signaling activity (197). We also found that the TIRAP rs3802813 GG genotype was 
associated with decreased pregnancy rates (HR 0.6, 95% CI 0.3-0.9), but not after correction for 
multiple comparisons (p=0.02). However, the functional and clinical relevance of this SNP is 
unknown. Second, our gene coverage for the TLRs and adaptor molecules was low (ranged 15-
35%). Variants in TLR genes may be responsible for infertility following an episode of PID, and 
our SNPs simply may not have tagged those disease variants if they exist. Therefore, larger 
studies with better gene coverage should examine the role of TLRs and their adaptor molecules 
in PID.  
Lastly, the polymicrobial nature of PID complicates analyses. Although, PID-associated 
pathogens are recognized by several TLRs, their mechanisms of disease may differ. For example, 
N. gonorrhoeae causes a severe acute neutrophilic inflammatory response and tissue damage 
possibly through an endotoxic effect, while C. trachomatis causes a l ess severe, cell-mediated 
lymphocytic response that often resolves into a chronic infection (36). Although our power was 
limited, among a subset of 94 women with C. trachomatis infection, TLR1 variants rs5743618 
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and rs4833095 appear to alter the risk of pregnancy. Further, among the entire PID cohort we 
found that the TLR1 (rs5743618/rs5743817/rs4833095) TGG/TGG haplotype pair decreased 
pregnancy rates. TLR1 SNPs rs5743618 (Ser602Ile) and rs4833095 (Asn248Ser) are non-
synonymous mutations and result in amino acid changes. The G allele of Ser602Ile has been 
reported to be associated with deficient TLR signaling in comparison to the T allele (182-185). 
Hawn et al, reported that the T allele expressed significantly greater NF-κB signaling in 
transfected HEK293 cells compared to the G allele (183). Like the Ser602Ile variant, Asn248Ser 
may alter TLR signaling increasing the risk of infection. Compared to the wild-type, the A allele 
was found to impair TLR response to Pam3CSK4 (P<0.05) (189). In a population-based case-
control study among 1312 tuberculosis patients and controls, the G allele significantly increased 
risk of tuberculosis in African Americans (P=0.009) (181). Similar to our findings, Pino-Yanes 
et al reported that the 248Ser-602Ile haplotype (T and G alleles) was associated with circulatory 
dysfunction among 218 sepsis patients (P<0.022), decreased IL-10 (P<0.047), and increased 
CRP (P<0.036) (194).  
Our study has several strengths. First, data were obtained from a large, multicenter, 
prospective randomized clinical trial, with comprehensive demographic, clinical, and obstetric 
measurements. These findings are generalizable to patients treated for clinically suspected PID. 
Not all women in the PEACH study had blood samples available for analyses, but demographics 
between women with and without blood samples did not differ (185). This is the first study to 
examine the role of several TLR and adaptor molecule SNPs in PID and its subsequent sequelae. 
However, our sample size limited our power. We also had low SNP coverage for our genes. 
Further, we relied on i nternal control groups. Therefore, all controls had clinically suspected 
PID.  
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Among African American women, TLR and adaptor molecule variants did not appear to 
significantly alter the risk of pregnancy or infertility following an episode of PID. However, our 
power was limited and we did observe trends towards decreased pregnancy rates for TLR1 
variants. These TLR1 variants also appeared to decrease pregnancy among a subset of women 
with C. trachomatis infection. Further, the TLR1 TGG/TGG haplotype pair appeared to reduce 
pregnancy rates. TLR1 variants may increase TLR signaling leading to persistent inflammation 
which may permanently damage the reproductive tract following an episode of PID. As PID is 
polymicrobial future studies with larger samples sizes should examine the role of innate immune 
receptor variants in infertility among specific subsets of PID-associated pathogens. In particular, 
as chlamydia appears to be immunologically driven, the role of innate immune receptors should 
be explored in infertility and pregnancy following chlamydial-PID.  
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4.6 TABLES 
Table 8. Baseline demographic and clinical characteristics by pregnancy status 
 
Characteristics Pregnant 
N = 128 
n (%) 
Not Pregnant 
N = 77 
n (%) 
*p-value 
Demographics    
Age 
<25 years 
25+ years 
 
100 (78.1) 
28 (21.9) 
 
34 (44.2) 
43 (55.8) 
 
 
<0.0001 
Married 8 (6.8) 5 (7.0) 0.9449 
Education 
Less than high school 
High school or greater 
 
60 (46.9) 
68 (53.1) 
 
29 (37.7) 
48 (62.3) 
 
 
0.1975 
Uninsured 49 (41.5) 40 (56.3) 0.0482 
Clinical Findings    
Temperature (>100.4 F) 
WBC (> 10,000 mm3) 
C-reactive protein (>5mg/dL) 
Bilateral adnexal tenderness 
Chlamydia trachomatis 
Neisseria gonorrhoeae 
Mycoplasma genitalium 
Bacterial Vaginosis 
Cervicitis 
8 (6.7) 
37 (35.2) 
10 (50.0) 
98 (76.6) 
62 (48.4) 
39 (35.8) 
11 (11.1) 
86 (69.9) 
73 (63.5) 
11 (15.1) 
23 (36.5) 
7 (50.0) 
59 (76.6) 
32 (41.6) 
22 (33.3) 
9 (15.3) 
41 (59.4) 
43 (59.7) 
0.0601 
0.8679 
1.000 
0.9920 
0.3384 
0.7420 
0.4487 
0.1402 
0.6066 
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Endometritis 32 (53.3) 59 (56.2) 0.7226 
Behavioral 
Current smoker 
Drug use 
50 (39.1) 
38 (29.7) 
39 (50.7) 
27 (35.1) 
0.1050 
0.4230 
*Chi-square was used to derive the p-value. Fisher’s Exact was used when cell size was less than 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. continued 
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Table 9. Associations between genotypes and time-to-pregnancy among women with pelvic 
inflammatory disease 
 
SNPs and 
Genotypes 
Not 
Pregnant 
(N=77) 
Pregnant 
(N=128) 
*Adjusted Hazard 
Ratio 
(95% CI) 
**P-value 
TLR1 
rs5743618 
GG+GT 
TT 
 
15(20.8) 
57(79.2) 
 
34(31.2) 
75(68.8) 
 
Referent 
0.7 (0.4-1.1) 
 
 
0.1206 
rs4833095 
AA+AG 
GG 
 
26(35.1) 
48(64.9) 
 
50(44.6) 
62(55.4) 
 
Referent 
0.7 (0.5-1.1) 
 
 
0.1168 
TLR 2 
rs3804099 
CC 
CT 
TT 
 
32(43.2) 
31(41.9) 
11(14.9) 
 
52(45.6) 
43(37.7) 
19(16.7) 
 
Referent 
0.9 (0.6-1.4) 
1.0 (0.6-1.7) 
 
 
0.7842 
0.9034 
rs11938228 
CC 
AA + AC 
 
55(75.3) 
18(24.7) 
 
81(72.3) 
31(27.7) 
 
Referent 
1.2 (0.8-1.8) 
 
 
0.4833 
rs1898830 
AA 
GG+AG 
 
53(74.7) 
18(25.4) 
 
78(77.2) 
23(22.8) 
 
Referent 
1.1 (0.7-1.7) 
 
 
0.7200 
TLR 6 
rs1039559 
TT 
CC+TC 
 
50(69.4) 
22(30.6) 
 
61(58.1) 
44(41.9) 
 
Referent 
1.2 (0.8-1.9) 
 
 
0.2543 
rs5743810 
CC 
TT + CT 
 
67(90.5) 
7(9.5) 
 
84(77.8) 
24(22.2) 
 
Referent 
1.6 (1.0-2.5) 
 
 
0.0599 
rs3775073 
GG 
AG 
AA 
 
35(46.7) 
33(44.0) 
7(9.3) 
 
38(34.9) 
57(52.3) 
14(12.8) 
 
Referent 
1.0 (0.7-1.7) 
1.0 (0.5-2.0) 
 
 
0.9159 
0.9108 
TLR 4 
rs5030728 
GG 
AA + AG 
 
52(70.3) 
22(29.7) 
 
81(72.3) 
31(27.7) 
 
Referent 
1.0 (0.7-1.5) 
 
 
0.9773 
rs4986790 
AG 
AA 
 
15(19.7) 
61(80.3) 
 
16(13.5) 
103(86.5) 
 
Referent 
1.5 (0.9-2.5) 
 
 
0.1622 
rs1927911 
TT 
CT 
CC 
 
29(37.7) 
29(37.7) 
19(24.7) 
 
48(39.3) 
45(36.9) 
29(23.8) 
 
Referent 
1.0 (0.7-1.5) 
0.8 (0.5-1.4) 
 
 
0.9354 
0.5766 
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Myd88 
rs7744 
AA 
AG + GG 
 
71(92.2) 
6(7.8) 
 
117(91.4) 
11(8.6) 
 
Referent 
1.4 (0.7-2.6) 
 
 
0.3463 
rs4988457 
CG 
CC 
 
15(20.3) 
59(79.7) 
 
20(18.5) 
88(81.5) 
 
Referent 
1.1 (0.7-1.9) 
 
 
0.6291 
TIRAP 
rs3802813 
AG 
GG 
 
6(7.8) 
71(92.2) 
 
18(14.8) 
104(85.3) 
 
Referent 
0.6 (0.3-0.9) 
 
 
0.0235 
* Adjusted for age and history of infertility 
**Significance based on a permutated P-value of 0.004 
Cox regression was used to calculate hazard ratios and 95% CI. Any model with less than 5 observations 
in any cell was excluded (TLR1 rs5743817, TLR4 rs11536889, TIRAP rs8171374, and TIRAP 
rs7932976). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9. continued 
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Table 10. Associations between genotypes and infertility among women with pelvic 
inflammatory disease 
 
SNPs and 
Genotypes 
Fertile 
(N=166) 
Infertile 
(N=39) 
*Adjusted Odds 
Ratio 
(95% CI) 
**P-value 
TLR 1 
rs5743618 
GG+GT 
TT 
 
39(26.9) 
106(73.1) 
 
10(27.8) 
26(72.2) 
 
Referent 
1.0 (0.4-2.3) 
 
 
0.9938 
rs4833095 
AA+AG 
GG 
 
60(81.1) 
14(18.9) 
 
87(77.7) 
25(22.3) 
 
Referent 
1.3 (0.6-2.7) 
 
 
0.4916 
TLR 2     
rs5743618 
CC 
TT+TC 
 
70(46.4) 
81(53.6) 
 
14(37.8) 
23(62.2) 
 
Referent 
1.3 (0.6-2.8) 
 
 
0.4353 
rs5743817 
CC 
AA+AC 
 
107(72.3) 
41(27.7) 
 
29(78.4) 
8(21.6) 
 
Referent 
0.7 (0.3-1.6) 
 
 
0.3512 
rs4833095 
AA 
GG+AG 
 
103(75.7) 
33(24.3) 
 
28(77.8) 
8(22.2) 
 
Referent 
0.8 (0.3-2.0) 
 
 
0.6792 
TLR 6 
rs1039559 
TT 
CC+TC 
 
87(62.1) 
53(37.9) 
 
24(64.9) 
13(35.1) 
 
Referent 
0.9 (0.4-1.9) 
 
 
0.7505 
rs3775073 
GG 
AA+AG 
 
58(39.7) 
88(60.3) 
 
15(39.5) 
23(60.5) 
 
Referent 
1.1 (0.5-2.4) 
 
 
0.7920 
TLR 4 
rs5030728 
GG 
AA + AG 
 
108(72.5) 
41(27.5) 
 
25(67.6) 
12(32.4) 
 
Referent 
1.2 (0.6-2.7) 
 
 
0.6294 
rs4986790 
AG 
AA 
 
23(14.7) 
134(85.4) 
 
8(21.1) 
30(78.9) 
 
Referent 
0.7 (0.3-1.7) 
 
 
0.4359 
rs1927911 
TT 
CT 
CC 
 
61(38.1) 
59(36.9) 
40(25.0) 
 
16(41.0) 
15(38.5) 
8(20.5) 
 
Referent 
1.0 (0.4-2.2) 
0.7 (0.3-1.9) 
 
 
0.9615 
0.4871 
Myd88 
rs4988457 
CG 
CC 
 
29(20.0) 
116(80.0) 
 
6(16.2) 
31(83.8) 
 
Referent 
1.2 (0.5-3.2) 
 
 
0.7089 
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* Adjusted for age **Significance based on a permutated P-value of 0.004 
Logistic regression was used to calculate odds ratios and 95% CI. Any model with less than 5 
observations in any cell was excluded TLR1 rs5743817, TLR4 rs11536889, TIRAP rs8171374, TIRAP 
rs7932976, and TIRAP rs3802813). 
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4.7 FIGURES 
 
Figure 2. Percentage of women who achieved pregnancy by predicted TLR1 diplotype 
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5.0  CONCLUSIONS 
For this study, data was obtained from the PID Evaluation and Clinical Health (PEACH) study. 
This cohort is generalizable to women with clinically suspected PID and obtained comprehensive 
data on de mographic, clinical, and obstetric measurements. We used this data to examine 
important aspects of PID epidemiology including the microbial correlates of delayed care and the 
role of innate immune receptors in chlamydia, endometritis, and infertility. Results from this 
study suggest that women with C. trachomatis or M. genitalium monoinfection had longer times 
to care than women with N. gonorrhoeae monoinfection or co-infection with two or more 
pathogens. Furthermore, study results suggest that among women with PID variations in TLR1 
and TLR4 genes may contribute to chronic inflammation following chlamydial infection, 
possibly leading to upper genital tract pathology. 
Among women with mild to moderate PID, women waited a m ean of 7 days before 
seeking treatment for symptoms. Women with C. trachomatis monoinfection, and M. genitalium 
monoinfection displayed the longest times to care, while the shortest times were among women 
with N. gonorrhoeae monoinfection and co-infection with two or more pathogens. We found that 
time to care differed significantly between C. trachomatis monoinfection or M. genitalium 
monoinfection and N. gonorrhoeae monoinfection. However, time to care did not significantly 
differ between C. trachomatis and M. genitalium. These results suggest that M. genitalium and 
C. trachomatis may have a similar course of infection. In general, the long time to care in this 
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cohort is of concern as treatment after the first 3 days of the onset of symptoms has been shown 
to increase the risk for impaired fertility (9). Although, we did not find any significant 
associations between delayed care of more than 14 da ys and reproductive sequelae, rates of 
infertility, recurrent PID, and chronic pelvic pain were high in our cohort. As PID is difficult to 
diagnose and treatment is often delayed, this data supports a continued need for early 
identification and treatment of lower genital tract infections.  
Among African American women with mild to moderate clinically suspected PID, the 
TLR4 rs1927911 CC genotype significantly increased the odds of C. trachomatis infection. In 
addition, women who were predicted to carry the TLR4 GTC haplotype were significantly more 
likely to have C. trachomatis infection, while those predicted to carry the GTT haplotype were 
significantly less likely to have C. trachomatis infection. The exact function of TLR4 rs1927911 
is unknown. The TLR1 rs5743618 TT genotype was significantly associated with C. 
trachomatis, but not after correction for multiple comparisons. In addition, the TLR1 TGA 
haplotype was significantly more frequent in chlamydial positive women. Although our power 
was limited, among a subset of 94 w omen with C. trachomatis infection, TLR1 variants 
rs5743618 and rs4833095 appear to alter the rates of pregnancy. Further, among the entire PID 
cohort we found that the TLR1 (rs5743618/rs5743817/rs4833095) TGG/TGG diplotype 
decreased pregnancy rates. Both of these variants result in an amino acid change and may 
increase TLR signaling (181-185, 189). No other variants in TLR or adaptor molecule genes 
were significantly associated with chlamydia, endometritis, infertility, or pregnancy. TLR and 
their adaptor molecules initiate microbial elimination through induction of inflammatory 
responses. As genetic variations may alter TLR signaling, they may play a role in C. trachomatis 
pathogenesis. 
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5.1 FUTURE RESEARCH 
In the PEACH study, women with C. trachomatis or M. genitalium monoinfection had longer 
times to care compared to women with N. gonorrhoeae monoinfection. This data is consistent 
with previous research which suggests that C. trachomatis and M. genitalium symptoms are 
often mild, while N. gonorrhoeae symptoms are more overt. As this data can be translated to a 
population of women with uncomplicated sexually transmitted diseases, future studies with 
larger sample sizes, should prospectively follow women with uncomplicated lower genital tract 
infections to examine the role of delayed care in the development of PID and reproductive 
sequelae. This study may also suggest that women with C. trachomatis or M. genitalium may 
have low level chronic inflammation which may damage the reproductive tract prior to 
treatment. This reiterates the need for early identification and treatment of lower genital tract 
infections. Specifically, research should continue to delineate and compare the pathogenesis of 
asymptomatic, mildly symptomatic and symptomatic lower genital tract infections. This will 
enable public health professionals to determine the best approach for the prevention of sexually 
transmitted diseases. Currently, in the United States young women under the age of 26 are 
recommended to be screened for C. trachomatis (6). However, the evidence examining the 
effectiveness of chlamydia screening is limited, as few high quality randomized clinical trials 
have been conducted (234). Therefore, future research is needed to determine the best approach 
for chlamydia management. This can be achieved through research focused on host immunology, 
bacterial antigens, duration, and the role of pathogen load in the course and outcome of 
chlamydial infections. These factors should also be examined in M. genitalium as its symptoms 
consistently appear to be similar to C. trachomatis and little is known about its pathogenesis. 
Furthermore, as M. genitalium has also been found to be associated with PID, studies should also 
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examine the cost effectiveness of screening high risk women for M. genitalium in order to 
prevent fertility reducing sequelae. 
Chlamydia has been suggested to be a disease of immunopathology (229). Our study 
suggests that polymorphisms in innate immune receptor genes may play a role in C. trachomatis 
pathogenesis. Further studies with larger sample sizes and appropriate control groups are needed 
to reproduce these findings. It is very important that future studies compare innate immune 
receptor SNPs between women with uncomplicated C. trachomatis infection and women with 
chlamydial-PID. Adverse reproductive outcomes should also be explored in a larger subset of 
women with C. trachomatis infection. In addition, larger studies should examine a broader range 
of innate immune receptor SNPs in the course and outcome of C. trachomatis. Larger cohorts 
would also enable researchers to examine gene-gene and gene-environment interactions, as well 
as examine haplotypes with greater power. As the function and clinical relevance of many TLR 
and adaptor molecule SNPs is unknown, it is imperative that research continue to delineate their 
function. In future studies it would be optimal to examine cytokine expression in women with C. 
trachomatis and PID. As disparities exist in gynecological disease, these innate immune receptor 
variants should also be examined in other racial groups. Lastly, although it is important to further 
examine innate immune receptors in PID, it is a polymicrobial condition. Therefore, the role of 
innate immune receptors in the course and outcome of other lower genital tract infections should 
be explored. In particular, the role of innate immune receptors in M. genitalium should be 
examined as it appears to be similar to C. trachomatis.    
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5.2 APPLICATION TO PUBLIC HEALTH 
Sexually transmitted diseases are a serious public health concern and can cause major 
reproductive morbidity. The anatomy and physiology of the female reproductive tract puts 
women at greater risk of complications following many lower genital tract infections (235). 
Women who have lower genital infections can develop PID and its sequelae including infertility, 
ectopic pregnancy, and recurrent PID (5-8). An estimated 8% of American women will develop 
PID at some time in their reproductive lives (4). Further, the estimated average per person life 
time cost of PID is $1060-$3180, suggesting that PID prevention would have substantial savings 
to the health care system (36). Various organisms have been implicated in the etiology of PID 
including Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, and 
anaerobic and aerobic bacteria commonly associated with bacterial vaginosis (BV) (5-8). 
However, the pathogenesis of PID has not been completely elucidated (5) and the role of 
individual microbes in the etiology of PID is not well understood. Further, treatment of PID may 
not effectively reduce reproductive sequelae (36).  
Prevention of PID and its morbidities is of great public health importance (36). It has 
been suggested that prompt treatment of PID is an important strategy for infertility prevention 
(36, 9). Compared to women with C. trachomatis, women with N. gonorrhoeae have a quicker 
onset of severe symptoms, possibly through an endotoxic effect, which may lead to earlier care 
and less tubal damage (36). However, only one study has actually examined the role of prompt 
care seeking in fertility preservation among women with PID (9). Hillis et al, in a cohort of 
women recruited in the 1960-1980’s, found that delaying care for 3 or more days significantly 
increased the risk of impaired fertility, with the strongest associations being found among 
women infected with C. trachomatis (9). Our study was the first study to examine these 
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associations in a contemporary cohort of women with clinically suspected PID. Our study shows 
that women with clinically suspected PID waited a m ean of 7 days before seeking treatment. 
Similar to Hillis et al, we were also able to show that women with C. trachomatis monoinfection 
waited longer to receive treatment compared to women with N. gonorrhoeae monoinfection. In 
addition, this is the first study to show that women with M. genitalium had significantly longer 
time to care compared to women with N. gonorrhoeae, while M. genitalium and C. trachomatis 
has similar times to care. This result may suggest women infected with M. genitalium or C. 
trachomatis have low levels of chronic inflammation that can lead to serious reproductive 
damage before treatment is sought. Therefore, continued efforts should be made at early 
identification and treatment of lower genital tract infections to prevent the progression to PID 
and its long term morbidities. Inflammatory processes are suggested to play a role in C. 
trachomatis pathogenesis (36, 229). If inflammation tends to peak within one to two weeks after 
infection, it makes sense that women with C. trachomatis would delay care (9). We are adding 
the observation that M. genitalium pathogenesis may also be driven by inflammatory processes, 
as these women were also likely to delay treatment.  
Although screening for chlamydia is considered a cost effective way to prevent PID, cost-
effectiveness is influenced by the rate of complications (236-238), which may be lower than 
previously estimated (237, 238). More recent studies using dynamic simulation models reported 
that chlamydia screening may not be as cost-effective as previously thought. (239, 240) Further, 
of the efficacy of chlamydia screening to reduce PID is limited (234). Aggressive screening and 
treatment has also been suggested to blunt the natural immunity to C. trachomatis, essentially 
increasing reinfection in the population (241). Reinfection rates are high in both men and women 
(242, 243) and may further increase the risks of reproductive sequelae (18, 29). The 
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asymptomatic nature of C. trachomatis and our incomplete understanding of its natural history 
further complicate control efforts. Therefore, the management and control of C. trachomatis may 
ideally be through a safe and effective vaccine (144), which can generate an immune response, 
better than what occurs naturally (229). However, epidemiologic research examining the role of 
host immunity and bacterial virulence factors in the pathogenesis of C. trachomatis is limited. 
Our study provided a novel exploration into the role of innate immune receptor variants in PID. 
We found that TLR1 and TLR4 SNPs increased the odds of C. trachomatis infection among 
women with clinically suspected PID. Further, TLR1 variants may decrease pregnancy rates 
among women with PID and among a subset of women with chlamydial-PID. Although these 
findings need to be reproduced, this study provides insight into the pathogenesis of C. 
trachomatis. This is significant as this type of research could aid in vaccine development. If 
researchers can delineate the role of TLRs in chlamydial pathogenesis, they may be able to be 
selectively target or manipulate TLR genes to induce an optimal immune response, thus 
enhancing host resistance to chlamydial infection (144). In addition, our study may help to better 
understand the etiology of PID and post-PID sequelae. This is particularly important as there is a 
great need for markers to predict sequelae following an episode of PID. Lastly, this research is of 
importance as the future may hold a place for SNPs in personalized medicine. Physicians one 
day may be able to use innate immune receptor SNPs in individual level risk estimation and 
prediction of sexually transmitted diseases, PID, and post-PID sequelae. This would enable 
doctors to identify patients who are the greatest risk for developing upper genital tract infection 
and infertility, thus ensuring that they are frequently tested for lower genital tract infections so 
that prompt and proper treatment can be initiated.  
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APPENDIX A: SUPPLEMENTARY FIGURES AND TABLE TO MANUSCRIPT 1 
 
Figure 3. Microbial correlates for delayed care among women with clinically suspected PID 
(n=774) 
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Figure 4. Microbial correlates for prompt care among women with clinically suspected PID 
(n=774) 
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Figure 5. Ratio of sequelae among women with histologically confirmed endometritis 
(n=298) 
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Table 11. Effect of delayed care on time-to-pregnancy and time-to-recurrent PID 
 
Subgroup Pregnancy Recurrent PID 
Crude HR  
(95% CI) 
*Adjusted HR  
(95% CI) 
Crude HR  
(95% CI) 
*Adjusted HR  
(95% CI) 
Entire cohort 
(n=298) 
0.79 (0.55 – 1.26) 0.79 (0.55 – 1.13) 1.49 (0.84 – 2.63) 1.46 (0.83 – 2.58) 
C. trachomatis  
only (n = 23) 
1.08 (0.39 – 2.99) 1.07 (0.32 – 3.61) 3.06 (0.28 – 33.86) 6.11 (0.21 – 184.41) 
M. genitalium 
only  (n = 7) 
0.91 (0.12 – 6.64) 1.05 (0.06 – 19.93) 3.94 (0.04 – 358.5) 1.59 (0.02 – 125.52) 
N. gonorrhoeae 
only (n = 45) 
1.13 (0.34 – 3.77) 1.17 (0.34 – 4.03) 1.44 (0.18 – 11.71) 1.23 (0.15 – 10.05) 
Co-infection 
(n=50) 
0.78 (0.27 - 2.22) 0.79 (0.26 – 2.39) 1.56 (0.34 – 7.22) 2.38 (0.47 – 12.05) 
Risk estimate is presented in Hazard Ratios (HR) with 95% confidence intervals (CI) 
* Pregnancy and recurrent PID were both adjusted for age and race. Additionally pregnancy was adjusted 
for self-reported history of infertility at baseline. 
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APPENDIX B: SUPPLEMENTARY TABLES TO MANUSCRIPT 2 
 
Table 12. Allele and genotype frequencies, only of SNPs included in regression analyses, 
among the entire cohort, chlamydial cases and controls, and outside control groups 
 
 
SNPs and 
Genotypes 
Entire PID 
cohort  
Chlamydial 
positive 
cases 
Chlamydial 
negative 
controls 
*Healthy African 
American 
control group 
Hapmap.org 
rs5743618 
Alleles 
G 
T 
 
0.141 
0.859 
 
0.093 
0.907 
 
0.174 
0.825 
 
0.120 
0.880 
 
0.250 
0.750 
Genotypes 
GG 
GT 
TT 
n=181 
2   (0.01) 
47 (0.26) 
132 (0.73) 
n=75 
2   (0.03) 
10 (0.13) 
63 (0.84) 
n=106 
0  (0.00) 
37 (0.35) 
69 (0.65) 
n=187 
5   (0.03) 
35   (0.19) 
147 (0.79) 
n=48 
4  (0.08) 
16 (0.33) 
28 (0.58) 
rs4833095  
Alleles 
G 
A 
 
0.763 
0.237 
 
0.753 
0.247 
 
0.771 
0.229 
 
0.755 
0.244 
 
0.792 
0.208 
Genotypes 
GG 
AG 
AA 
n=186 
112 (0.60) 
60  (0.32) 
14  (0.08) 
n=77 
49 (0.64) 
18 (0.23) 
10 (0.13) 
n=109 
63 (0.58) 
42 (0.39) 
4 (0.04) 
n=192 
112 (0.58) 
66   (0.34) 
14   (0.07) 
n=53 
32 ( 0.60) 
20 ( 0.38) 
1   ( 0.02) 
rs3804099 
Alleles 
C 
T 
 
0.644 
0.356 
 
0.656 
0.344 
 
0.635 
0.364 
 
0.630 
0.370 
 
0.615 
0.385 
Genotypes 
CC 
CT 
TT 
n=188 
84 (0.45) 
74 (0.39) 
30 (0.16) 
n=77 
38 (0.49) 
25 (0.32) 
14 (0.18) 
n=111 
46 (0.41) 
49 (0.44) 
16 (0.14) 
n=177 
71 (0.40) 
81 (0.46) 
25 (0.14) 
n=52 
20 (0.39) 
24 (0.46) 
8   (0.15) 
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Table 12. continued  
 
SNPs and 
Genotypes 
Entire PID 
cohort  
Chlamydial 
positive 
cases 
Chlamydial 
negative 
controls 
*Healthy African 
American 
control group 
Hapmap.org 
rs11938228 
Alleles 
A 
C 
 
0.148 
0.851 
 
0.169 
0.831 
 
0.135 
0.865 
 
0.171 
0.830 
** 
Genotypes 
 
AA 
AC 
CC 
n=185 
 
6  (0.03) 
43  (0.23) 
136 (0.74) 
n=74 
 
5 (0.07) 
15 (0.20) 
54 (0.73) 
n=111 
 
1 (0.01) 
28 (0.25) 
82 (0.74) 
n=173 
 
8  (0.05) 
43 (0.25) 
122 (0.71) 
** 
rs1898830 
Alleles 
A 
G 
 
0.845 
0.125 
 
0.869 
0.131 
 
0.878 
0.122 
 
0.859 
0.141 
 
0.774 
0.226 
Genotypes 
AA 
AG 
GG 
n=172 
131 (0.76) 
39   (0.23) 
2     (0.01) 
n=61 
47 (0.77) 
12 (0.20) 
2 (0.03) 
n=111 
84 (0.76) 
27 (0.24) 
0 (0.00) 
n=174 
131 (0.75) 
37   (0.21) 
6     (0.03) 
n=53 
34 (0.64) 
14 (0.26) 
5   (0.09) 
rs1039559 
Alleles 
C 
T 
 
0.201 
0.799 
 
0.202 
0.799 
 
0.200 
0.800 
**  
0.173 
0.827 
Genotypes 
CC 
CT 
TT 
n=177 
5     (0.03) 
61   (0.34) 
111 (0.63) 
n=67 
3 (0.04) 
21 (0.31) 
43 (0.64) 
n=110 
2 (0.02) 
40 (0.36) 
68 (0.62) 
** n=98 
2   (0.02) 
30 (0.31) 
66 (0.67) 
rs5743810 
Alleles 
C 
T 
 
0.912 
0.088 
 
0.903 
0.097 
 
0.918 
0.081 
 
0.848 
0.152 
 
0.915 
0.085 
Genotypes 
CC 
CT 
TT 
n=182 
151 (0.83) 
30   (0.16) 
1     (0.01) 
n=72 
59 (0.82) 
12 (0.17) 
1 (0.01) 
n=110 
92 (0.84) 
18 (0.16) 
0 (0.00) 
n=178 
129 (0.72) 
44   (0.25) 
5     (0.03) 
n=53 
44 (0.83) 
9   (0.17) 
0   (0.00) 
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Table 12. continued 
 
SNPs and 
Genotypes 
Entire PID 
cohort  
Chlamydial 
positive 
cases 
Chlamydial 
negative 
controls 
*Healthy African 
American 
control group 
Hapmap.org 
rs3775073 
Alleles 
A 
G 
 
0.359 
0.641 
 
0.390 
0.609 
 
0.337 
0.662 
 
0.088 
0.911 
 
0.321 
0.679 
Genotypes 
AA 
AG 
GG 
n=184 
21 (0.11) 
90 (0.49) 
73 (0.40) 
n=73 
9 (0.12) 
39 (0.53) 
25 (0.34) 
n=111 
12 (0.11) 
51 (0.46) 
48 (0.43) 
n=180 
1   (0.005) 
30   (0.17) 
149 (0.83) 
n=53 
4   (0.08) 
26 (0.49)  
23 (0.43) 
rs5030728 
Alleles 
A 
G 
 
0.156 
0.844 
 
0.149 
0.851 
 
0.161 
0.839 
**  
0.113 
0.887 
Genotypes 
AA 
AG 
GG 
n=186 
5  (0.03) 
48   (0.26) 
133 (0.72) 
n=77 
4 (0.05) 
15 (0.19) 
58 (0.75) 
n=109 
1 (0.01) 
33 (0.30) 
75 (0.69) 
** n=53 
0 (0.00) 
12 (0.23) 
41 (0.77) 
rs4986790 
Alleles 
T 
C 
 
0.921 
0.080 
 
0.916 
0.083 
 
0.923 
0.077 
**  
0.943 
0.057 
Genotypes 
TT 
TC 
CC 
n=195 
164 (0.84) 
31 (0.16) 
0   (0.00) 
n=84 
70 (0.83) 
14 (0.17) 
0 (0.00) 
n=111 
94 (0.85) 
17 (0.15) 
0 (0.00) 
** n=53 
48 (0.91) 
4  (0.08) 
1  (0.01) 
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Table 12. continued 
 
 
 
SNPs and 
Genotypes 
Entire PID 
cohort  
Chlamydial 
positive 
cases 
Chlamydial 
negative 
controls 
*Healthy 
African 
American 
control group 
Hapmap.org 
rs1927911 
Alleles 
C 
T 
 
0.427 
0.573 
 
0.511 
0.489 
 
0.359 
0.641 
**  
0.425 
0.575 
Genotypes 
CC 
CT 
TT 
n=199 
48 (0.24) 
74 (0.37) 
77 (0.39) 
n=89 
32 (0.36) 
27 (0.30) 
30 (0.34) 
n=110 
16 (0.15) 
47(0.43) 
47 (0.43) 
** n=53 
9   (0.17) 
27 (0.51) 
17 (0.32) 
rs7744 
Alleles 
A 
G 
 
0.956 
0.043 
 
0.952 
0.048 
 
0.959 
0.041 
**  
0.925 
0.075 
Genotypes 
AA 
AG 
GG 
n=205 
188 (0.92) 
16   (0.08) 
1    (0.004) 
n=94 
86 (0.91) 
7 (0.07) 
1 (0.01) 
n=111 
102 (0.92) 
9 (0.08) 
0 (0.00) 
** n=53 
45 (0.85) 
8  (0.15) 
0  (0.00) 
rs4988457 
Alleles 
C 
G 
 
0.903 
0.096 
 
0.930 
0.070 
 
0.887 
0.113 
**  
0.925 
0.075 
Genotypes 
CC 
CG 
GG 
n=182 
147 (0.81) 
35  (0.19) 
0   (0.00) 
n=71 
61 (0.86) 
10 (0.14) 
0 (0.00) 
n=111 
86 (0.77) 
25 (0.23) 
0 (0.00) 
** n=53 
45 (0.85) 
8  (0.15) 
0  (0.00) 
rs3802813 
Alleles 
A 
G 
 
0.060 
0.940 
 
0.051 
0.948 
 
0.068 
0.934 
**  
0.028 
0.972 
Genotypes 
AA 
AG 
GG 
n=199 
0 (0.00) 
24 (0.12) 
175 (0.88) 
n=88 
0 (0.00) 
9 (0.10) 
79 (0.90) 
n=111 
0 (0.00) 
15 (0.14) 
96 (0.86) 
** n=53 
0  (0.00) 
3  (0.06) 
50 (0.94) 
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* Group of healthy African American controls from Pittsburgh, PA 
** Allele or genotype frequencies were not available 
All frequencies taken from Hapmap.org were for African American ancestry, from the Southwest, USA 
This table only displays frequencies of SNPs that were used in the regression analyses (SNPs not used in 
regression analyses included: TLR1 rs5743817, TLR4 rs11536889, TIRAP rs8171374, and TIRAP 
rs7932976). 
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Table 13. Allele frequencies, only of SNPs included in regression analyses, among patients 
genotyped with buffy coats vs. serum samples 
 
SNPs & Alleles Buffy Coats (n=157) Serum Samples (n=48) 
rs5743618 
G 
T 
 
0.1565 
0.8435 
 
0.0735 
0.9265 
rs4833095 
G 
A 
 
0.7810 
0.2190 
 
0.6818 
0.3182 
rs3804099 
C 
T 
 
0.6401 
0.3599 
 
0.6613 
0.3387 
rs11938228 
A 
C 
 
0.1401 
0.8599 
 
0.1964 
0.8036 
rs1898830 
A 
G 
 
0.8710 
0.1290 
 
0.9118 
0.0882 
rs1039559 
C 
T 
 
0.2000 
0.8000 
 
0.2045 
0.7955 
rs5743810 
C 
T 
 
0.9231 
0.0789 
 
0.8462 
0.1538 
rs3775073 
A 
G 
 
0.3408 
0.6592 
 
0.4630 
0.5370 
rs5030728 
A 
G 
 
0.1516 
0.8484 
 
0.1774 
0.8226 
rs4986790 
C 
T 
 
0.0828 
0.9172 
 
0.0658 
0.9342 
rs1927911 
C 
T 
 
0.3942 
0.6058 
 
0.5465 
0.4335 
rs7744 
A 
G 
 
0.9554 
0.0446 
 
0.9583 
0.0417 
rs4988457 
C 
G 
 
0.8942 
0.1058 
 
0.9615 
0.0385 
rs3802813 
A 
G 
 
0.0732 
0.9268 
 
0.0119 
0.9881 
This table only displays frequencies of SNPs that were used in the regression analyses (SNPs not used in 
regression analyses included: TLR1 rs5743817, TLR4 rs11536889, TIRAP rs8171374, and TIRAP 
rs7932976). 
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Table 14. Associations between selected SNPs and upper genital tract infection 
 
SNPs and 
Genotypes 
*UGTI 
Negative 
(N=101) 
*UGTI 
Positive 
(N=64) 
**Adjusted Odds 
Ratio 
(95% CI) 
P-value 
TLR 1 
rs5743618 
GG+GT 
TT 
 
29(30.9) 
65(69.2) 
 
6(12.2) 
43(87.8) 
 
Referent 
7.2 (1.8-27.7) 
 
 
0.0043 
rs4833095 
AA+AG 
GG 
 
41(44.1) 
52(55.9) 
 
17(31.5) 
37(68.5) 
 
Referent 
2.0 (0.8-5.0) 
 
 
0.1368 
TLR 4 
rs1927911 
TT 
CT 
CC 
 
43(43.4) 
40(40.4) 
16(16.2) 
 
18(30.0) 
19(31.7) 
23(38.3) 
 
Referent 
1.5 (0.5-4.2) 
4.9 (1.7-13.8) 
 
 
0.4568 
0.0026 
*Upper genital tract infection (UGTI) 
** Adjusted for age and N. gonorrhoeae 
Logistic regression was used to calculate odds ratios and 95% CI. 
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Table 15. Haplotype associations with endometritis 
 
Haplotype Endometritis 
negative 
frequencies 
Endometritis 
positive 
frequencies 
*Exact P-value 
**TIRAP haplotype 
GGC 0.83 0.92 0.0420 
§TLR 6 haplotypes 
CTA 0.11 0.03 0.0410 
*Exact p-value based on 1000 permutations 
**TIRAP haplotype (rs3802813/rs7932976/rs8177374) 
§ TLR6 haplotype (rs109559/rs5743810/rs3775073) 
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APPENDIX C: SUPPLEMENTARY TABLES TO MANUSCRIPT 3 
Table 16. Associations between selected SNPs and pregnancy among a subset of women 
with C. trachomatis infection 
 
SNPs and 
Genotypes 
 Pregnant 
(N=62) 
Not 
Pregnant 
(N=32) 
*Adjusted Hazard 
Ratios 
(95% CI) 
P-value 
TLR 1 
rs5743618 
GG+GT 
TT 
 
10(21.2) 
37(78.7) 
 
2(7.1) 
26(92.9) 
 
** 
 
** 
rs4833095 
AA+AG 
GG 
 
19(41.3) 
27(58.7) 
 
9(29.0) 
22(71.0) 
 
Referent 
0.5 (0.3-0.9) 
 
 
0.0412 
TLR 4 
rs1927911 
TT 
CT 
CC 
 
18(31.6) 
17(29.8) 
22(38.6) 
 
12(37.5) 
10(31.3) 
10(31.3) 
 
Referent 
1.2 (0.4-3.9) 
1.0 (0.6-2.1) 
 
 
0.7823 
0.7796 
*Adjusted for age and history of infertility 
**Cell size too small for logistic regression 
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Table 17. TLR1 haplotypes and pregnancy 
 
Haplotype Pregnancy 
frequencies 
No Pregnancy 
frequencies 
P-value *Exact P-value 
**TLR1 haplotypes 
TGC 0.72 0.80 0.0494 0.2860 
TGT 0.12 0.08 0.2626 0.3490 
*Based on 1000 permutations 
** TLR1 rs5743618/rs5743817/rs4833095 haplotype 
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